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The γ-secretase protease complexes and associated regulated intramembrane 
proteolysis play an important role in controlling receptor-mediated intracellular 
signalling events, which have a central role in Alzheimer’s disease, cancer progression 
and immune surveillance. It has previously been reported that the Interleukin-1 
receptor, type 1, (IL-1R1) is a substrate for regulated intramembrane proteolysis, 
mediated by presenilin (PS)-dependent γ-secretase activity. The aims of this project 
were twofold. Firstly, to determine the conservation of regulated intramembrane 
proteolysis as a physiological occurrence amongst other cytokine receptors. In this 
regard, similar to IL-1R1, we identified the Tumour necrosis factor receptor type 1 
(TNFR1) and the Toll like receptor 4 (TLR4) as novel γ-secretase substrates. Secondly, 
given that the diversity of signalling events mediated by the IL-1R1, TLR4 and TNFR1 
are spatially segregated, we investigated the spatial distribution, subcellular trafficking 
and subcellular occurrence of regulated intramembrane proteolysis of IL-1R1, TLR4 and 
TNFR1. Using dynasore an inhibitor of clathrin-dependent receptor endocytosis, both 
ectodomain shedding and γ-secretase-mediated cleavage of IL-1R1 were observed 
post-internalization. In contrast, TNFR-1 underwent ectodomain shedding at the cell 
surface followed by endosomal γ-secretase-mediated cleavage. Furthermore, 
immortalised fibroblasts from PS1-deficient mice showed impaired γ-secretase-
mediated cleavage of IL-1R1 and TNFR1, indicating that both are cleaved by PS1-and 
not PS2-containing γ-secretase complexes. Subcellular fractionation and 
immunofluorescence studies revealed that the γ-secretase generated IL-1R1 ICD 
translocates to the nucleus on IL-1β stimulation. These observations further 
demonstrate the novel PS-dependent means of modulating IL-1β, LPS and TNFα-







AD   Alzheimer’s disease 
ADAM  A disintegrin and metalloprotease 
AICD   APP intracellular domain 
Aph   Anterior pharynx defective 
APP   Amyloid precursor protein 
ApoE   Apolipoprotein E 
Aβ   Amyloid β 
BACE   β-secretase converting enzyme 
CCL   CC-chemokine ligand 
cDKO   Conditional knock-out 
CRD   Cysteine rich domain 
CSF-1   Colony-stimulating factor-1 
CTF   C-terminal fragment 
CXCL   CXC-chemokine ligand 8 
DAP   DYIGS and peptidase 
DD   Death domain 
DR   Death receptor 
DISC   Death inducing signalling complex 
ER   Endoplasmic reticulum 





FAD   Familial Alzheimer disease 
FADD   Fas-Associated protein with Death Domain 
GSK-3β  Glycogen synthase-3-β 
GnT-V  β 1,6 N-acetylglucosaminyltransferase V 
GPCR   G-protein coupled receptor 
GSK-3β  Glycogen synthase kinase-3β 
HMW   High molecular weight 
ICAM   Intercellular Adhesion Molecule 1 
ICD   Intracellular domain 
I-CLiPs  Intramembrane-cleaving proteases 
ID   Intermediate domain 
IKK   IκB Kinase 
IFN   Interferon 
IL-1   Interleukin-1 
IL-1R   Interleukin-1 receptor 
IL-1Ra  Interleukin-1 receptor antagonist 
IL-1RAcP  Interleukin-1 receptor accessory protein 
IRAK   Interleukin-1 receptor-associated kinase 
JNK   c-Jun N-terminal Kinase 
KD   Kinase domain 
LAR   Leukocyte-common antigen-related 





LRP   Lipoprotein-related protein 
LT-α   Lymphotoxin-α 
MAPK  Mitogen-activated protein kinase 
MEKK  Mitogen-activated protein kinase kinase3 
MMP   Matrix metalloproteinase  
NaVβ2  Voltage-gated sodium channel β2 
NCT   Nicastrin 
NFT   Neurofibrillary tangles 
NF-κB  Nuclear factor κ-beta 
NTF   N-terminal fragment 
PARL   PSEN associated rhomboid-like membrane protease 
PBMC  Peripheral blood mononuclear cells 
p75 NTR  p75 neurotrophin receptor 
Pen   PS enhancer 
PI3K   Phosphoinositide-3 kinase 
PLAD   Pre-ligand binding assembly domain 
PKA   Protein kinase A 
PKC   Protein kinase C 
PS   Presenilin 
Psen   Presenilin 
PTM   Post translational modifications 





RIP1   Receptor interacting protein 
SDP   Soluble neurotrophil-derived serine proteases 
SLE   Systemic lupus erythematosus 
SP   Senile plaques 
SPP   Signal peptide peptidase 
TAB   TAK binding protein 
TAK   Transforming growth factor β-activated protein kinase 
TCR   T-cell receptor 
TGN   Trans-golgi network 
TLN   Telencephalin 
TLR4   Toll like receptor-4 
TNF   Tumor necrosis factor 
TNF-R  Tumor necrosis factor receptor 
TNFSR  Tumor necrosis factor superfamily receptor 
TRADD  TNF receptor 1-associated protein 
TRAF   TNFR-associated factor 











1.1 Alzheimer’s disease and Regulated Intramembrane Proteolysis 
1.1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a slow progressing, heterogeneous neurodegenerative 
disorder. On November 3, 1906, Dr. Alyosius Alzheimer, for the first time discussed the 
pathology and clinical symptoms of AD, which at the time was termed presenile 
dementia (Alzheimer et al., 1995). Since its discovery, several proposals have been put 
forward, in which researchers have speculated that the primary pathologies of AD may 
be the causative events in the onset of this disease (Armstrong, 2013). The two 
principal proposals are the amyloid cascade and the Tau hypothesis. Although the 
primary cause of AD has been the subject of much debate, the amyloid cascade 
hypothesis has dominated the field of AD research (Piplikar, 2009; Selkoe, 1991). The 
amyloid cascade hypothesis proposes that the deposition of amyloid-β (Aβ) leads to 
the formation of senile plaques (SPs) and neurofibrillary tangles (NFTs), which in turn 
are responsible for neuronal cell death, and ultimately dementia (Hardy et al., 1992). 
However, this hypothesis has been refuted since deposition of Aβ in senile plaques has 
been reported to be a late event which occurs as a result of other more important 
pathological changes which have been divided into “positive” changes including lesions 
such as amyloid plaques, NFTs, glial responses, and “negative” lesions such as neuronal 
and synaptic loss (Lee et al., 2004; Nalivaeva et al., 2013; Serrano-Pozo et al., 2011). 
Additionally, Aβ accumulation and deposition has also been shown to induce 
hyperphosphorylation of tau (Chesser et al., 2013). The tau protein is important for 
neurite outgrowth and microtubule stabilization. Furthermore, redistribution of tau 
from the axon to the soma and dendrites followed by its phosphorylation, and 
deposition within the NFTs has been shown to trigger the AD pathology (Morris et al., 
2011).  Following these observations, a new “dual pathway’’ model of causality has 





upstream driver including Apolipoprotein E  (ApoE) mediated increase in plaque and 
NFTs load, mutations within the Presenilin (Psen1) and Presenilin (Psen2) and others 
like glycogen synthase kinase-3β (GSK-3β)-mediated tau phosphorylation etc. 
(Ramachandran et al., 2013; Small et al., 2008).  
To date four loci have been associated with early-onset AD; amyloid precursor protein 
(APP), Psen1, Psen2 and ApoE (Bekris et al., 2010). The first gene to be identified was 
the APP gene on chromosome number 21 (Goate et al., 1991). The Psen1 and Psen2 
genes associated with the early-onset AD encode highly homologous integral 
membrane proteins with eight putative transmembrane domains and till date over 150 
Psen1 and 40 Psen2 mutations have been identified (Bart De Strooper et al., 2012). 
These are discussed with relevance to the PS-mediated γ-secretase dependent and 
independent activity in the later sections. Furthermore, the E4 allele of the ApoE on 
chromosome 19 was identified as a genetic risk factor for both early-onset and late-
onset AD and was found to be involved in increased Aβ deposition and shown to 
promote Aβ fibril formation in vitro (Bekris et al., 2010). 
APP is a type I transmembrane protein which was found to undergo sequential 
proteolytic cleavage by combination of different enzymes in two different pathways: 
the non-amyloidogenic or the amyloidogenic pathway (Hui Zheng et al., 2006) Figure 1. 
Irrespective of the pathway involved, the removal of the extracellular domain of APP 
was found to be a pre-requisite for subsequent cleavage events (Brown et al., 2000). In 
the non-amyloidogenic pathway or α-pathway, APP is cleaved between lysine-16 and 
leucine-17 of the Aβ domain by α-secretase, a member of the “a disintegrin and 
metalloprotease” (ADAM) family generating a soluble extracellular domain: APP-α 
(sAPPα) and the membrane bound C-terminal fragment (CTF) 83 (C83) (Anderson et 
al., 1991). While in the case of amyloidogenic pathway, APP is first cleaved by the 
aspartyl protease, a β-secretase enzyme (BACE1), releasing the extracellular domain- 





(C99) (Kang et al., 1987; Sinha et al., 1999; Vassar, 1999; Yan et al., 1999). The APP 
CTFs C99 and C83 are then further processed by a transmembrane enzyme complex, 
known as γ-secretase (Hass et al., 1993). While the γ-secretase-mediated cleavage of 
C83 gives rise to the hydrophobic peptide p3 and the cytosolic APP intracellular 
domain (AICD), the C99 cleavage by γ-secretase results in the generation of Aβ 
peptides and AICD.  
The aberrant accumulation or defective clearance of Aβ peptides is hypothesized to be 
critical in the pathogenesis AD (Hardy et al., 1992). These series of sequential 
proteolytic cleavage events of APP by ADAMs, or BACE and γ-secretase are termed 







Figure 1. Proteolytic processing of the amyloid precursor protein (APP).  
APP is processed by either of the two pathways: the non-amyloidogenic or the 
amyloidogenic pathway. The right panel shows the non-amyloidogenic pathway, 
where an initial cleavage by α-secretase generates sAPPα and C83. On the left panel, in 
amyloidogenic pathway APP is first cleaved by β-secretase to generate sAPPβ and C99. 
C83 and C99 from both pathways are subsequently processed by the γ-secretase 
enzyme complex. Proteolysis by γ-secretase at the ε-site generates the APP 






1.1.2 Regulated Intramembrane Proteolysis 
The conventional view of receptor-mediated cell signalling holds that plasma 
membrane receptors upon binding of their ligand relay signals across membranes, and 
intracellular enzymes or changes in second messengers facilitate the propagation of 
ligand-receptor initiated signal. Following ligand binding, most receptors either 
undergo ectodomain shedding or internalization, thereby negatively regulating or 
terminating the ligand-receptor generated signal. Once internalized a receptor can be 
either degraded or recycled back to the plasma membrane. Additionally, in a few 
cases, like G-protein coupled receptors (GPCR), binding of an inhibitory protein acts to 
terminate the signalling (Madshus et al., 2009).  
Recently, a new signalling pathway has emerged, whereby cell surface receptor 
signalling events are regulated by sequential proteolysis. Regulated intramembrane 
proteolysis influences a diverse range of processes such as lipid metabolism, cellular 
differentiation, gene transactivation and the response to unfolded proteins (Hass et 
al., 2009). The functional significance of regulated intramembrane proteolysis, 
particularly γ-secretase-mediated processing, has gained much attention lately owing 
to its involvement in many vital processes in the cell and in some diseases. Regulated 
intramembrane proteolysis describes a novel regulated proteolytic cleavage event in 
which specific receptors that first undergo ectodomain shedding, are subsequently 
cleaved within the lipid bilayer to liberate an intracellular domain (ICD) (Brown et al., 
2000). Regulated intramembrane proteolysis is a two step process. First, multiple 
proteases in a highly regulated proteolytic cleavage event at the cell surface, cleave 
transmembrane proteins forming soluble extracellular domain (Lichtenthaler et al., 
2007; Weber et al., 2012). These proteases collectively termed sheddases belong to 
one of the following families of proteases: ADAMs (Edwards et al., 2008), matrix 





serine proteases (SDPs) (Lin et al., 2008). Following ectodomain shedding, the 
membrane-bound carboxyl terminal fragment (CTF) is cleaved by Intramembrane-
cleaving proteases (I-CLiPs), which results in the release of the membrane bound or 
soluble ICD Figure 2. It has also been suggested that the main function of iCLiP family 
members was to regulate degradation of integral membrane proteins, but with time 
the released fragments have acquired signalling properties allowing regulated 
signalling by some substrates (Kopan et al., 2004). 
I-CLiPs are multispanning, integral membrane proteins containing classic protease 
motifs within their transmembrane domains (Wolfe, 2009). I-CLiPs family members 
include S2P metalloproteases, rhomboid serine proteases and GxGD aspartyl proteases 
which consist of γ-secretase and signal peptide peptidase (SPP) Table 1.1. The 
substrates for the I-CLiP members undergo a prior cleavage in the extracellular 
domain, except rhomboid proteases which have the ability to process full length 
substrates with large ectodomain (Strisovsky, 2013). The S2P catalytic activity is 
dependent on its conserved HEXXH motif, which contributes two histidines and one 
glutamate, and a distally located conserved aspartate residue found within the LDG 
motif (Wolfe, 2009). SPP and γ-secretase protease complex share the highly conserved 
GxGD and YD motifs containing the two critical catalytic aspartate residues necessary 
for their enzymatic activity and located within the transmembrane domain (Tomita et 
al., 2013). Rhomboids on the other hand contain transmembrane serine, histidine, and 
asparagine catalytic triad and a serine-histidine dyad (Strisovsky, 2013). Among the 
iCLiP family members, γ-secretase has been most widely studied owing to its role in 







Figure 2. Regulated Intramembrane Proteolysis involves the sequential proteolytic 
cleavage of select transmembrane receptors 
Step1: An initial cut at a site outside the membrane by sheddases such as ADAMs, 
MMPs and SDPs shortens the protein to less than 30 amino acids in the extracellular 
domain, generating a soluble extracellular domain and CTF. Step 2: The second cut is 
performed on CTF by I-CLiP family members within the transmembrane domain 






Table 1.1 The iCLiP family members and their substrates 






1.2 The γ-secretase protease complexes: The protein quartet 
Christian Hass and Denis J. Selkoe gave the name γ-secretase to a proteolytic enzyme 
which, in combination with BACE1 cleaved APP resulting in the generation of Aβ 
peptides associated with AD pathologies (Christian Hass et al., 1993). In 1995, Peter St 
George Hyslop and co-workers identified pathogenic mutations in the encoding gene 
Psen1 in several families with early-onset AD, which subsequently led to the discovery 
of the multipass membrane proteins-PS1 and PS2 (Sherrington et al., 1995; Tanzi et al., 
1996). Mutations in the homologous Psen1 and Psen2 genes were found to cause the 
most common and aggressive form of familial AD (FAD). In an attempt to purify the PS-
dependent γ-secretase activity, PS proteins (PS1 and PS2) were consistently pulled 
down as part of a high molecular weight multi-protein complex. Later, with the help of 
high-grade biochemical purification studies and genetic screens, γ-secretase was 
discovered to be an oligomeric complex consisting of at least four integral membrane 
proteins: PS, nicastrin (NCT), anterior pharynx defective-1 or-2 (Aph-1/Aph-2) and PS 
enhancer-2 (Pen-2) (Francis et al., 2002; Goutte et al., 2002; Strooper, 2003a) Figure 3. 
Further the genetic ablation or RNAi knockdown of either of the components, and 
reconstitution of these four elements in S. cervisiae, a cell type devoid of intrinsic γ-
secretase, demonstrated that these components were sufficient for complete γ-







Figure 3 The molecular components of γ-secretase complex. 
The active γ-secretase complex is composed of four distinct integral membrane 
proteins: presenilin, nicastrin, APH-1/2 and Pen-2. Two conserved aspartates within 
the presenilin transmembrane domain 6 and 7 are required for both presenilin 





1.2.1 Presenilin proteins and γ-secretase protease 
Structurally, PS proteins are polytopic transmembrane domain proteins with nine 
membrane-spanning regions (transmembrane domains 1-9) (Laudon et al., 2005; 
Steiner et al., 2008) located in the ER, the intermediate compartment, the cis-Golgi 
region and plasma membrane (Annaert et al., 1999; Culvenor et al., 1997; Kim et al., 
2000; Ray et al., 1999; Walter et al., 1996). Following translation, the endoproteolysis 
of the PS holoproteins is triggered by the assembly of active γ-secretase complexes 
which generate stable, non-covalently associated N-terminal fragment/C-terminal 
fragment (NTF/CTF) heterodimers (Dries et al., 2008; Podlisny et al., 1997; Thinakaran 
et al., 1996; Ward et al., 1996). An unidentified protease named presenilinase is known 
to mediate the endoproteolytic cleavage of PS proteins. It has been suggested that 
presenilinase is either PS or γ-secretase, since catalytic defunct PS mutants cannot be 
endoproteolysed (Xia et al., 2008).  
A wealth of biochemical evidence supports the theory that PS proteins facilitate γ-
secretase activity. Firstly, mutations in either of the two PS homologues (PS1 or PS2) 
alter Aβ production, and genetic ablation of PS1 dramatically impairs γ-secretase 
cleavage of APP for example, PS1Δ9, T291-S319del, PS1-L166P, PS1-G384A, PS1-A246E 
and PS2 N141I (Bentahir et al., 2006); secondly, the types of compounds that inhibit γ-
secretase contain moieties typically found in aspartyl protease inhibitors; thirdly, 
studies aimed at purifying γ-secretase concluded that involvement of the PS proteins in 
γ-secretase activity requires incorporation of the PS-NTF/CTF heterodimer into HMW-
protein complexes (250-1000-kDa in size), which contain at least three additional PS-
binding molecules: NCT, Aph-1/2 and Pen-1/2 (Marjaux & Hartmann, 2004; Gu et al., 
2003; Strooper, 2003b). It is the assembly of these functionally conserved proteins that 
results in the formation of catalytically active PS-dependent γ-secretase complexes 






NCT is a type I transmembrane glycoprotein. After PS proteins, NCT was the next 
component of γ-secretase complex to be detected via PS1 immunoprecipitation in 
conjunction with mass spectrometry (Dries et al., 2008). The N-terminal region of NCT 
transmembrane domain interacts with the C-terminus of PS, facilitating the assembly 
of NCT into γ-secretase complex (Capell et al., 2003). The interaction of NCT with 
substrates is considered to be critical for them to be cleaved and for this reason NCT 
has always been considered as the “gatekeeper” of γ-secretase complex (Wakabayashi 
et al., 2008). The extracellular domain of NCT was reported to be a docking site for the 
incoming γ-secretase substrate (Shah et al., 2005). This interaction was found to be 
mediated by the carboxylate side chain of a glutamate residue (E333) present in the 
DYIGS and peptidase (DAP) domain of NCT, the site of binding to α-amino group of the 
available N-terminus of ectodomain-shed substrates (Dries et al., 2008). However, it 
was indicated that E333 was essential for the maturation of γ-secretase but 
dispensable for its catalytic activity (Chávez-Gutiérrez et al., 2008).  
1.2.3 Aph-1 
A seven transmembrane domain-containing protein, Aph-1, was identified as γ-
secretase complex member through the discovery of an Aph-1 deficiency in C.elegans 
(Yu et al., 2000). This deficiency was found to exhibit a similar phenotype to the PS 
(sel-12 and hop-1 in C. elegans) and NCT (aph-2 in C. elegans) mutants of the same 
species (Francis et al., 2002). Further to this, Aph-1 mutant embryos were found to be 
aberrant in NCT trafficking as seen in PS defective embryos (Francis et al., 2002) and 
the absence of Aph-1 was associated with decreased processing of PS proteins 
(Takasugi et al., 2003). Further studies demonstrated that Aph-1 interacts and 
stabilizes the immature form of NCT (pre-complex) in the ER or cis-Golgi which then 





stable transfection of cells with Aph-1 no differences in Aβ secretion were observed. 
This was later attributed to the role played in maturation of γ-secretase complex by 
another limiting factor-Pen-2 (Seong Hun Kim et al., 2003). 
1.2.4 Pen-2 
Pen-2 was identified using a genetic screen in C. elegans for loci that interact with 
Notch, PS and NCT (Francis et al., 2002). Furthermore, the incorporation of Pen-2 into 
γ-secretase complex was shown to trigger endoproteolysis of the PS holoprotein into 
its stable heterodimer (Dries et al., 2008). Binding of Pen-2 is mediated through the 
fourth transmembrane domain of PS proteins and this event subsequently prompts the 
final steps of the γ-secretase maturation process with the concomitant final 
glycosylation of NCT and release of the γ-secretase enzyme complex from ER to the 






Figure 4 A schematic representation of the formation of γ-secretase complex. 
Evidence shows that PS, NCT, Aph-1, and Pen-2 are the only components of γ-
secretase complex. NCT and Aph-1 are involved in the early formation of the complex, 
interacting with each other and forming a dimeric sub-complex. The PS holoprotein is 
incorporated into the Aph-1: NCT sub-complex, NCT undergoes post-translational 
modifications and the complex is transported to the cell surface (or other Aβ 
generating compartments, i.e. TGN) as a trimeric complex. Pen-2 is incorporated into 
the complex and PS is cleaved, thus  forming the active γ-secretase complex (Adapted 





1.3 γ-secretase dependent and independent functions of PS proteins 
1.3.1 γ-secretase dependent functions of PS proteins 
After their discovery as the catalytic components of the γ-secretase enzyme complex 
responsible for processing APP, PS proteins were a major target for anti-amyloidogenic 
therapy (Hui Wang et al., 2012). However, PS knock-out mice models which were 
generated to study and define the essential roles of PS proteins in AD pathology 
highlighted the severe side effects posed by the therapeutic use of γ-secretase 
inhibitors (Yan et al., 2010). Additionally, the discovery of over 91 substrates with 
varied functions pointed out a more general role of PS-dependent γ-secretase-
mediated cleavage (Haapasaloa et al., 2012). PS/γ-secretase-mediated cleavage of 
proteins was shown to affect biological processes in several ways, 1) by removing the 
membrane bound CTF’s responsible for signalling, thus inhibiting key signalling events, 
2) processing of proteins by γ-secretase enzyme complex acting to enhance or inhibit 
its interaction with the cytosolic adaptor proteins, hence directing the output of the 
signalling event, or 3) the product of the γ-secretase-mediated cleavage in most cases 
was a transcriptionally active ICD, which regulated gene transcription (Haapasaloa et 
al., 2012). Table 1.2 lists the known γ-secretase cleavage products which translocate to 





Table 1.2 Type-I γ-secretase substrates and suggested roles of their γ-secretase-
mediated cleavage products 
 
As highlighted in Table 1.2, PS/γ-secretase is involved in the proteolytic processing of a 
diversity of receptors with varied functions. This diversity emphasized the need to 
generate PS knock-out mouse models to further study the effect of loss of PS/γ-
secretase. In the attempt to create these mouse models, deletion of Psen1 was shown 
to be embryonically lethal (Donoviel et al., 1999), while in contrast Psen2 deficiency 
was associated with no major pathologies, apart from an age-associated mild 
pulmonary phenotype, but Psen2-deficiency enhanced the embryonic lethal 





has also been highlighted, where loss of PS2 activity has revealed significant deficits in 
proteolytic processing of APP indicating a defect in γ-secretase activity (Steiner et al., 
1999; Toda et al., 2011). In this context it was interesting to note that the PS1+/-PS2+/- 
mice remained healthy, clearly indicating a critical minimum threshold, below which 
the drop of Psen gene dosage and function result in serious risks (Tournoy et al., 2004). 
In the following years, this limitation which was hindering further studies aimed at 
determining the functions of PS proteins was overcome by the development of tissue-
specific Psen-knock-out models. Selective disruption of Psen1 in the mouse forebrain 
during post-natal life enabled the tissue-specific deletion of Psen1 (Feng et al., 2002; 
Guo & Fu et al., 1999; Wang et al., 2004; Xia et al., 2001). In addition, the selective 
knock-out of one or more alleles of Psen1 genes, with the retention of at least one 
functional copy was used (Tournoy et al., 2004). Additionally, both PS1 and PS2 FAD 
mutant transgenic lines were generated using heterologous promoters exhibiting 
transgene expression patterns varying from neuron-specific to ubiquitous (Wang et al., 
2004; Wen et al., 2004, 2002). In this regard the PS1+/-PS2-/- ‘partial deficient’ mice had 
the most severe reduction in PS alleles, still permitting post-natal survival allowing the 
analysis of long-term partial inhibition of γ-secretase in vivo (Donoviel et al., 1999). 
Furthermore, deficiency in PS proteins in lymphoid T and B cells antagonized T cell 
homeostasis and signalling (Maraver et al., 2007), while B cells presented with a deficit 
in both lipopolysaccharide (LPS) and B-cell antigen receptor-induced proliferation and 
signal transduction events (Yagi et al., 2008). The phenotype of various PS knock-out 





Table 1.3 Phenotypes of presenilin transgenic animals  
 
Interestingly, the study of the various Psen KO mouse models and transgenic animals 
has highlighted the role of PS/γ-secretase in the immune system. The importance of γ-
secretase-mediated proteolysis in neuroinflammatory responses was first highlighted 
when several groups demonstrated the association of activated microglia and reactive 
astrocytes with amyloid plaques, along with upregulated expression of cell-surface 
proteins (MHC class II molecules, CD11b and scavenger receptors), cytokines (tumor-
necrosis factor (TNF)), interleukin-6 (IL-6 and IL-1) and chemokines (CXC-chemokine 
ligand 8 (CXCL8) and CC-chemokine ligand-3 (CCL3)) (Weiner et al., 2006). Interestingly, 
studies in PScDKO mice models led to a new perspective, where at 3 months of age 
inflammatory changes including small inducible cytokine A27, complement component 
C1qα-β, cathepsins D and S, CD antigens and MHC histocompatibility proteins were 





which were followed by activated microglia and reactive astrocytes associated with 
amyloid plaques in addition to synaptic loss, tau hyperphosphorylation and 
subsequent neurodegenration (Saura et al., 2004). The involvement of PS proteins/γ-
secretase in immune system was further strengthened by in vivo Psen1 -/+ Psen2 -/- 
‘partial knock-out’ mouse models which had a severe autoimmune phenotype 
characterized by glomerulonephritis, keratitis, dermatitis and vasculitis, furthermore, 
with age these mice developed skin hyperplasia, increased CD4+/CD8+ T cell ratio and B 
cell infiltrates in several tissues (Tournoy et al., 2004). In addition to the brain 
inflammation, FAD-linked PS1 M146L and PS1 M5 transgenic mice models showed 
defective T-cell activation and higher susceptibility of lymphocytes to cell death 
compared to their wild-type counterparts (Eckert et al., 2001). Further studies led to 
the hypothesis that PS/γ-secretase-dependent Notch signalling positively influenced 
selection and development of T cells by modifying TCR signalling and these mice 
models being defective in γ-secretase cleavage-mediated Notch signalling 
demonstrated decreased CD8+ T cells (Germain, 2002). Additionally, a role of PS 
proteins in B cell function was also reported, where loss of PS function resulted in 
reduced LPS and B cell antigen receptor-induced proliferation and signalling events 
(Yagi et al., 2008). This has also been credited to processing of CD46 by PS/γ-secretase 
in response to pathogens which in turn stimulates CD46-dependent T cell responses 
(Weyand et al., 2010). Jayadev and co-workers have also reported a γ-secretase-
dependent PS2 role in microglia activation by suppressing the proinflammatory 
responses, with IFNγ up-regulating PS2 expression and PS2 deficiency resulting in 
enhanced cytokine expression possibly by targeting various immune receptors 
(Jayadev et al., 2010). 
Along with neurodegeneration and immune system a role of PS/γ-secretase-mediated 
cleavage on cancer has also been demonstrated. For example, γ-secretase-mediated 





in human carcinoma cells (Riedle et al., 2009), Notch ICD is oncogenic (Takebe et al., 
2013), p75NTR ICD has been reported to have a role in glioma invasion (Johnston et al., 
2007; Wang et al., 2008), and CD-44 ICD has been shown to promote neoplastic 
transformation of rat fibroblastic cells (Nagano et al., 2004; Pelletier et al., 2006). 
Recently a number of γ-secretase-independent role of PS proteins have also emerged 
discussed in the next section Figure 5. 
1.3.2 γ-secretase independent functions of PS proteins 
Apart from the involvement in γ-secretase-mediated cleavage events, independent 
research reports have demonstrated that the PS proteins are involved in numerous 
other cell-signalling pathways independent of their γ-secretase activity (Koo, 2004). 
Using yeast-two-hybrid or co-immunoprecipitation approaches the PS proteins have 
been shown to interact with over 30 proteins ( Chen et al., 2002; McCarthy et al., 
2009). In some cases, while the biological significance of the association with the PS 
proteins is not apparently obvious, these associated proteins can be subdivided into 
functional groups, including those involved in γ-secretase protein complex, Wnt 
signalling, cell-cell adhesion, vesicular transport, calcium signalling and apoptosis 








Figure 5 Presenilin: γ-secretase dependent and independent functions 
The left panel shows the role played by PS proteins in RIP of proteins and subsequent 
signalling events. The right panel highlights the emerging functions of PS proteins in 
various pathways-cell adhesion, Wnt signalling, apoptosis and calcium regulation 





1.3.2.1 PS proteins and β-catenin 
Among the PS interacting proteins, β-catenin has been most widely studied. The 
membrane bound β-catenin interacts with cadherin family members like E (epithelial) 
and N (neural) cadherin, which are γ-secretase substrates linking them to α-catenin 
and enabling the formation of a linkage between adherence junctions and the 
cytoskeleton (Parisiadou et al., 2004). In contrast as a cytoplasmic protein, β-catenin 
translocates to the nucleus to initiate canonical Wnt signalling  (Killick et al., 2001). 
Studies have linked β-catenin with PS proteins, where β-catenin interacts with the 
cytoplasmic domain of PS1, which then targets β-catenin for protein kinase A (PKA) 
and GSK-3β-mediated degradation, requiring the formation of a scaffold complex 
comprising of Axin and APC  (Cox et al., 2000; Huang and Xi He, 2009; Murayama et al., 
1998, 1999; Noll et al., 2000). Furthermore, the expression of wild-type PS1 as well as 
PS1 with FAD-linked mutations stabilizes the E-cadherin/β-catenin/α-catenin complex 
demonstrating that it is γ-secretase independent function of PS1 (Baki et al., 2001). 
PS1 has also been shown to function in phosphoinositide-3 kinase/ Akt (PI3K) signalling 
pathway and regulate the association of PI3K regulatory subunit p85 with N-or E-
cadherin, resulting in inactivation of GSK3-β, thereby preventing GSK3-β mediated 
degradation of β-catenin (Baki et al., 2008a). The hypothesis that PS1/β-
catenin/cadherin interactions are PS dependent but γ-secretase independent has been 
challenged by the impaired γ-secretase activity and exacerbated amyloid pathology 
seen in PS1 hydrophilic loop deleted mice models (Zhu et al., 2011a) and the emerging 
evidence suggesting that PS1 regulates β-catenin-mediated cell adhesion and signalling 
through γ-secretase-mediated cleavage of leukocyte-common antigen-related (LAR) 





1.3.2.2 PS proteins and calcium signalling 
PS proteins have also been implicated in calcium signalling (Wu et al., 2013). Evidence 
shows that PS proteins localize predominantly in the ER and have been suggested to 
function as ER Ca2+ leak channels (Area-Gomez et al., 2009; J. Walter et al., 1996). This 
is supported by the studies with fibroblasts from FAD patients containing PS1-A246E 
mutation (Ito et al., 1994), cultured neural cells expressing PS1 L286V (Guo et al., 1996; 
Guo et al., 1997), Xenopus oocytes injected with cRNA encoding PS1-M146V and PS2-
N141I FAD mutants (Leissring et al., 1999), synaptosomes and cortical neurons from 
PS1-M146V mutant mice (Guo et al., 1997; Stutzmann et al., 2004)and in hippocampal 
neurons from PS2-N141I transgenic mice (Guo and Sebastian, et al., 1999; Schneider et 
al., 2001). Additionally, the γ-secretase independent interaction between PS and 
proteins involved in calcium signalling, including IP3 receptor, ryanodine receptor, 
sarco-/endoplasmic reticulum Ca2+ ATPase (SERCA) further strengthens this hypothesis 
(Zhang et al., 2013). On the contrary, the observation that a large proportion of AD 
family members show altered Ca2+ release prior to the development of AD, have led to 
studies which depict the defect in ER Ca2+ signalling is caused by the many FAD-linked 
PS mutations (Das et al., 2012; Etcheberrigaray et al., 1998). Thus suggesting that the 
long-term Ca2+ signalling dysregulation is the early diagnostic change occurring long 
before histopathological features for AD, which in turn further increase Ca2+ levels, 
leading to a feed-forward loop. Supporting this view, increased Ca2+ levels have been 
functionally linked to the major features and risk factors of AD: ApoE4 expression, PS 
and APP mutations, amyloid β plaques, apoptosis, hyperphosphorylation of tau and 





1.3.2.3 PS proteins and apoptosis 
The role of PS proteins in apoptosis was highlighted when FAD-linked PS variants, or 
the conditional deletion of Psen1/Psen2 in adult mouse brains led to progressive loss 
of synapses, dendrites, and neurons, suggesting that loss of Psen function, caused 
neuronal degeneration which was credited to increased apoptosis (Saura et al., 2004).  
This was further established when the expression of PS2 CTF rescued mouse T-cell 
hybridomas from T-cell receptor and Fas-induced apoptosis (Vito et al., 1996), 
additionally,  conditional deletion of Psen1/Psen2 in thymocytes increased their 
resistance to anti-CD3-induced apoptosis in vivo (Maraver et al., 2007) and PS1-
deficient neurons with increased caspase-3 activation and apoptosis, were rescued by 
expression of wild-type PS1 but not by FAD-linked PS1 mutants (Baki et al., 2008b) 
while the primary hippocampal neurons from PS1 M146V knock-in mice displayed 
increased apoptosis and also increased neuronal vulnerability to focal ischemia as 
compared to their wild-type controls (Guo and Sebastian, et al., 1999; Mattson et al., 
2000). On the contrary a γ-secretase independent function of PS proteins in apoptosis 
was highlighted when the primary cortical neurons from Psen1 P264L knock-in mice 
did not exhibit increased degeneration, (Siman et al., 2001, 2000).  
PS proteins have also been suggested to alter apoptosis directly through their 
interactions with mitochondrial associated proteins like Bcl-2 and Bcl-XL (Alberici, 
1999; Passer, 1999), the two major anti-apoptotic members of the Bcl-2 family and 
other apoptosis related proteins such as FKBP38 (an immunophilin family member 
residing in the mitochondrial membrane), Omi/HtrA2 and PARL (PSEN-associated 
rhomboid-like inner mitochondrial membrane protease) (Gupta et al., 2004; Pellegrini 
et al., 2001; Wang et al., 2005). The pro-apoptotic effect of Psen2 over-expression is 
associated with down-regulation of Bcl-2, whereas the anti-apoptotic effect of Psen 
deficiency in thymocytes is linked to the elevation of Bcl-XL expression (Maraver et al., 





mediated cleavage of PS proteins (Kim, 1997; Walter et al., 1998), where inhibition of 
caspase-mediated cleavage of PS1 in cells makes them more susceptible to apoptosis, 
while caspases-mediated cleavage of PS2 generates the Met298-Ile448 intracellular 
PS2 fragment with an anti-apoptotic function (Vito, 1997). Furthermore, as previously 
discussed an indirect effect of PS proteins on apoptosis has also been suggested owing 
to their role in both calcium signalling and Aβ generation. 
1.3.2.4 PS proteins and protein trafficking 
Another γ-secretase-independent PS function which has been reported is its role in 
protein trafficking. PS proteins interact with a number of vesicle transport proteins like 
syntaxins, or Rab family members’ (Dumanchin et al., 1999; Kametani et al., 2004; 
Scheper et al., 2004; Smith et al., 2000; Suga et al., 2004). Additionally, PS1 is known to 
regulate the glycosylation and intracellular trafficking of components of γ-secretase 
complex (Wang et al., 2004). This is supported by the studies showing that the loss of 
PS1 function leads to increased maturation and cell surface accumulation of AβPP, a γ-
secretase substrate (Cai et al., 2003) and also non γ-secretase substrates like 
transferrin, again highlighting a γ-secretase independent function of PS proteins in 
protein trafficking (Zhang et al., 2006). PS proteins also function at the lysosomal levels 
to degrade proteins through the autophagosome–lysosome system, where PS1 
interacts with and affects the trafficking of telencephalin (TLN or ICAM-5) to affect 
autophagic vacuole maturation (Neely et al., 2011). Loss of PS1 function leads to 
abnormal accumulation of TLN in autopgahic vacuoles and is rescued by over-
expression of either the wild type PS1 or γ-secretase inactive PS1 D257A mutant and is 
not mimicked by the use of γ-secretase inhibitors, thus highlighting that it is a γ-
secretase independent function of PS1 (Esselens et al., 2004). Furthermore, PS1-
deficient neurons accumulate degradative organelles containing α and β-synuclein 
consistent with a physiological role for PS1 in the regulation of neuronal organelle 





are chaperone/trafficking proteins, which bring the substrate and protease together 
and/or assemble γ-secretase complex.  
1.4 The many substrates of γ-secretase 
Since the identification of APP, 91 new γ-secretase substrates have been identified 
using proteomic, genetic and biochemical methods (Hemming et al., 2008), with 
distinct functions like regulating cell fate, adhesion, migration, neurite outgrowth, or 
synaptogenesis (Haapasaloa et al., 2012). Despite the increasing number of reported γ-
secretase substrates, there has been no consensus regarding the characteristic 
features amongst the substrates facilitating their recognition by the γ-secretase 
enzyme complex. However, from the rigorous characterisation of some known γ-
secretase substrates like Notch, APP, IL-1R1 and ErB4, some common features and 
regulatory mechanisms have emerged. 
Firstly, most known γ-secretase substrates are found to be type-I integral membrane 
proteins. However, there are exceptions and substrates of other topologies like β 1,6 
N-acetylglucosaminyltransferase V (GnT-V) and Glutamate Receptor Subunit 3 have 
been reported (Haapasaloa et al., 2012; Meyer et al., 2003; Nakahara et al., 2006). 
Secondly, most of these substrates undergo ectodomain shedding, a pre-requisite to γ-
secretase-mediated cleavage of the remaining membrane bound CTF (Haapasaloa et 
al., 2012; Selkoe et al., 2007; Yan et al., 2010). The ectodomain shedding is generally 
mediated by ADAM family members and in most cases is constitutive, but it can also 
be induced by several stimuli, such as ligand binding, protein kinase C (PKC) activation 
by phorbol esters, or Ca2+ influx (Edwards et al., 2008). Some of the currently 
characterized γ-secretase substrates, such as lipoprotein-related protein-1 (LRP) or 
voltage-gated sodium channel β2 subunit (Navβ2), have been shown to undergo an 
alternative N-terminal cleavage by BACE1 in a similar manner to APPβ (Haapasaloa et 





substrate specificity by reducing ectodomain size. While not all receptors that undergo 
ectodomain shedding are cleaved by γ-secretase like tumor necrosis factor (TNF) 
receptor type 2 (TNF-R2) and the transferrin receptor (Hemming et al., 2008), a general 
pre-requisite for ectodomain shedding is considered to be the defining characteristic 
of potential γ-secretase substrates. Additionally, the identification of γ-secretase 
substrates with diverse topologies also makes it difficult to predict consensus 
structural sequences and the fact that a single substrate is cleaved at multiple sites for 
example for APP, CD44, Notch1-4 (Kopan et al., 2004) makes it even harder. For 
example, mutagenesis studies of PS1 showed that single amino acid substitutions can 
alter the preference for Notch cleavage over APP. Despite such varied characteristics, 
there are some common features shared by most of these substrates listed in Table 
1.4.  
Table 1.4 Characteristic features of the known γ-secretase substrates 






1.5 Post translational modifications and spatiotemporal regulation of γ-secretase 
substrates 
Apart from the characteristic features of known γ-secretase substrates, it is likely that 
there are other types of substrate recognition that are required to facilitate γ-
secretase-mediated cleavage of the membrane-bound stub, including post-
translational modifications (PTMs) and spatiotemporal regulation.  
The reversible PTM of a large number of proteins has a ubiquitous role in the 
regulation of protein functions and activities in a diverse range of cellular functions. It 
is therefore not surprising that PTMs are important in directly or indirectly modulating 
the activity of the γ-secretase enzyme complex itself, for example PS proteins undergo 
proteolysis, phosphorylation and ubiquitination; additionally glycosylation of NCT is 
also essential for the trafficking of PS proteins (Herreman, 2003). PTMs also affect the 
processing of γ-secretase substrates. In this context, 1) palmitoylation of p75 
neurotrophin receptor (p75NTR)-CTF (Underwood et al., 2008), 2) ubiquitination of the 
human Notch-CTF (Gupta-Rossi et al., 2004), 3) increased phosphorylation of APP-CTFs 
(Vingtdeux et al., 2005) and 4) palmitoylation and phosphorylation of CD44-CTFs 
(Thorne et al., 2004) have been shown to facilitate their processing by γ-secretase. 
PTMs also tend to regulate γ-secretase-mediated cleavage of substrates in an indirect 
manner. For example, (1) hypoglycosylation of LRP1 has been reported to facilitate 
extracellular cleavage resulting in increased production of LRP1 CTF, a substrate 
precursor for γ-secretase-mediated cleavage (May et al., 2003); (2) palmitoylation of 
betacellulin is not required for ADAM10-dependent cleavage in its extracellular 
domain, but is necessary for the stability of betacellulin-CTF to generate betacellulin-
ICD (Stoeck et al., 2010). Interestingly, there have been reports where PTMs prevent 
the substrates from being targeted for γ-secretase-dependent processing as in the 





by sheddases to generate MUC1 CTF thus preventing their cleavage by γ-secretase 
enzyme complex (Julian et al., 2011).  
Apart from regulating stability of γ-secretase substrates or enhancing their processing 
by the γ-secretase enzyme complex, PTMs also regulate trafficking of substrates and 
their γ-secretase generated cleavage products between distinct subcellular membrane 
compartments. For example, 1) palmitoylation of betacellulin is not only required for 
the synthesis of betacellulin-ICD but is also crucial for its localization to the nuclear-
membrane (Stoeck et al., 2010). The importance of PTM in regulating trafficking of 
substrates is further highlighted by the evidence that regulation of proteolysis can also 
be co-ordinated at a higher resolution within the plane of the organelle’s membrane 
(Grbovic et al., 2003; Gupta-Rossi et al., 2004; Hass et al., 2009; Urra et al., 2007).  
The role of PS proteins in trafficking of γ-secretase substrates and their cleavage 
products has recently been highlighted, where  1) PS1 deficient cells or cells expressing 
γ-secretase inactive PS Asp mutants demonstrate increased cell surface accumulation 
of APP and APP CTFs (Cai et al., 2003; Leem et al., 2002). Additionally, a delay in 
internalization of APP is seen in PS1 deficient cells, supported by the observation that 
FAD mutations in PS1 lead to decreased release of APP-containing vesicles and reduce 
cell surface APP (Kaether et al., 2002; Kim et al., 2005; Leem et al., 2002; Réchards et 
al., 2006). 2) PS1 deficiency in vivo or the use of γ-secretase inhibitors also leads to 
aberrant accumulation of tyrosinase and its CTFs in post-Golgi vesicles (Wang et al., 
2006).  One explanation for the role of PS proteins in γ-secretase-dependent protein 
trafficking is that some γ-secretase substrates mediate protein transport. For example 
SorLA, Sortilin and SorCS1b are members of the mammalian Vps10p sorting receptor 
family that bind to various cargo proteins and regulate the sorting and trafficking of a 
diverse array of protein (Andersen et al., 2005; Böhm et al., 2006; Nyborg et al., 2006). 
Therefore, some trafficking deficits in PS deficient models may be attributed to altered 





1.6 Regulated intramembrane proteolysis of immune receptors 
Ectodomain shedding is a pre-requisite to γ-secretase-mediated proteolysis. A role for 
ectodomain shedding in the regulation of cytokine signalling has been elucidated for 
several receptors, including TNFR1/TNFR2 and IL-1R1/IL-1R2 generating soluble 
receptor ectodomain. As previously discussed PS/γ-secretase play an important role in 
regulating immune system (Section 1.3.1). Further to this, a growing list of immune 
receptors undergoing regulated intramembrane proteolysis highlight the importance 
of these cleavage events in cytokine signalling Table 1.5. Relevant to the current study 
we will focus on the IL-1, TLR and TNF superfamily members, discussing their role in 
Aβ/AD, neuroinflammation and highlighting the current knowledge about their 
interplay with PS/γ-secretase. 







The inheritance of certain IL-1 gene variants have been associated with AD (Nicoll et 
al., 2000). For instance, a polymorphism in the promoter region of IL-1α (-899) or IL-1β 
(exon 5) has been shown to triple the risk for AD, even a greater risk is associated with 
a composite IL-1α (-899) and IL-1β exon 5 polymorphism (Grimaldi et al., 2000). In 
1989, Griffin and co-workers for the first time highlighted the importance of IL-1β-
mediated signalling in AD pathology, reporting a thirty-fold increase in IL-1β expression 
by glial cells associated with amyloid-plaques (Alvarez et al., 1996; Griffin et al., 1989; 
Sheng et al., 1998),  later increased plasma and blood levels of IL-1β were also seen in 
patients with AD (Licastro et al., 2000). In an attempt to better understand the 
mechanism and effect of increased IL-1β in AD patients, a cell type specific, IL-1β-
mediated positive regulation of  the γ-secretase mediated proteolytic processing of 
APP and the secretion of the Aβ-peptides (Buxbaum et al., 1992),  through a c-Jun N-
terminal Kinase (JNK)-dependent mitogen-activated protein kinase (MAPK) pathway 
was observed (Liao et al., 2004). Furthermore, IL-1β was also shown to directly impair 
microglial phagocytosis of Aβ in in vitro cell cultures thus negatively regulating the 
clearance of Aβ (Koenigsknecht-Talboo et al., 2005). However, studies carried out in 
mouse models have suggested that elevated IL-1 levels and resulting 
neuroinflammatory response might not be completely detrimental in the case of AD 
(Shaftel et al., 2008). On the contrary, more recent studies have highlighted a 
neuroprotective role of IL-1β. For instance, inhibition of IL-1β signalling in the brain has 
been shown to be associated with brain atrophy, and modified levels of APP and PS1 
(Oprica et al., 2007), further APPswe/PS1dE9 transgenic animals over-expressing IL-1β 
in the hippocampus show a reduction in Aβ peptide levels and plaque burden, with no 
effect on Aβ processing or APP expression at transcription level (Matousek et al., 2012; 





IL-1Ra, sIL-1R1 and sIL-1R2 bind to IL-1β with a higher affinity than IL-1R1, and thereby 
negatively modulate the IL-1R1 signalling cascade. In this context, increased levels of 
sIL-1R2 was also found in the cerebrospinal fluid (Garlind et al., 1999). The observed 
elevation of sIL-1R2 in AD fitted with the finding that IL-1R2 undergoes α- and β-
secretase-mediated ectodomain shedding followed by γ-secretase-mediated cleavage 
(Kuhn et al., 2007). Additionally, upregulated levels of IL-1Ra was found in peripheral 
blood mononuclear cells (PBMCs) of AD patients (Mizwicki et al., 2013) while the IL-
1Ra knock-out mice exhibited increased microglial activation and neuronal damage 
induced by intracerebroventricular infusion of human Aβ peptide (Craft et al., 2005). 
Additionally, IL-1R1 is the major mediator of IL-1β-induced signalling. However, an IL-
1R1 independent role in AD is indicated by the observation that IL-1R1 knock-out  does 
not affect Aβ deposition in Tg2576 mice and does not alter efficiency following Aβ 
immunotherapy (Das et al., 2006). Activation of protein kinase C (PKC) can increase the 
processing and secretion of APP (Yang et al., 2007). Similarly, IL-1R1 ectodomain 
shedding is inducible by PKC activation (Elzinga et al., 2009).  Interestingly, our group 
reported IL-1R1 to undergo similar sequential cleavage first by sheddases followed by 
γ-secretase enzyme complex. Importantly, we demonstrated that inhibition of γ-
secretase activity antagonised IL-1-induced cytokine secretion, suggesting that PS/γ-
secretase regulate IL-1-induced cytokine responsiveness (Elzinga et al., 2009).  In 
addition to IL-1R1 and IL-1R2, IL6R has also been reported as a γ-secretase substrate 
(Chalaris et al., 2010; Kuhn et al., 2007).  
The importance of IL-1-induced cytokine responsiveness in AD and the regulated 
intramembrane proteolysis of IL-1 receptors is further highlighted by upregulated 
transcription/secretion of cytokines IL-1, IL-6 and chemokines CCLs and CXCLs  by Aβ 
(Mizwicki et al., 2013). These observations clearly implicate an important role for IL-






Despite contrary results, a role of IL-1β-induced signalling has been suggested in 
microglial activation and clearance of Aβ in AD brain. TLR family members have also 
been linked with AD and neuroinflammation, where ligands for TLR2, TLR4 and TLR9 
show enhanced phagocytic uptake of Aβ peptides and play a role in the activation of 
microglial cells (Chen et al., 2006; Iribarren et al., 2005; Jin et al., 2008; Tahara et al., 
2008; Trudler et al., 2010).  Further to this, Aβ peptides activate typical TLR signalling 
pathways via MyD88 and NF-κB (Jana et al., 2009). This has been validated by the 
knock down of MyD88 expression in AD mouse model, which shows reduced 
inflammation and accelerated cognitive deficits, indicating a protective role of TLR-
mediated signalling via MyD88 (Michaud et al., 2011), and up-regulation of NF-κB-
regulated microRNA (miRNA-146a) in response to Aβ (Cui et al., 2010).  
Studies in tlr2-/- mice have demonstrated that TLR2 is required for activation of 
microglial cells and the clearance of Aβ peptides, as tlr2-/- mice are unresponsive to 
Aβ42 and show accelerated cognitive decline  (Frank et al., 2009; Jana et al., 2009; 
Richard et al., 2008).  In addition to TLR2 a role for TLR4 has been demonstrated, as 
the administration of an acute injection of the TLR4 ligand, lipopolysaccharide (LPS), in 
AD transgenic mice models reduces Aβ plaque burden, suggesting that TLR4 activation 
also facilitates Aβ uptake (DiCarlo et al., 2001; Herber et al., 2007). Additionally, 
spontaneous loss-of-function mutation in the tlr4 gene strongly inhibits microglial and 
monocytic activation by aggregated Aβ resulting in a significantly lower release of the 
inflammatory products IL-6, TNF-α and nitric oxide (Walter et al., 2007). This has been 
further supported by research in the AD mouse model (Hu APPswe PS1dE9) 
homozygous for a destructive mutation of tlr4 which demonstrates increased levels of 
diffuse and fibrillar Aβ deposits as well as soluble and insoluble Aβ in the brain, along 
with TLR4-dependent down-regulation of IL-1β, IL-10, IL-17 and TNF-α cytokines (Jin et 





regulation of tlr4 mRNA in APP transgenic mice and increased expression of TLR4 in AD 
brain tissue associated with amyloid plaque deposition (Walter et al., 2007). There are 
also studies correlating TLRs with the PS/γ-secretase. For instance, a role of TLRs in 
monocyte/macrophage differentiation by regulating the γ-secretase-mediated 
regulated intramembrane proteolysis of the colony-stimulating factor 1 (CSF-1) 
receptor has been demonstrated (Trudler et al., 2010). Additionally, integrative 
computational analysis of whole-genome datasets has led to the discovery of defective 
TLR4-mediated signalling in PS-deficient B cells (Yagi et al., 2008). The benefits of TLR4-
mediated signalling are further supported by their neuroprotective benefits of TLR4-
mediated signalling in stroke (Marsh et al., 2010). The study carried out with the TLR4 
agonist called monophosphoryl lipid A (MPL) which significantly reduces Aβ levels in 
brain, mitigates AD-related pathology, and improves cognitive function with negligible 
side effects in the APPswe/PS1 mouse model of AD (Buchanan et al., 2010; Michaud et 
al., 2013; Wang, 2013). These observations highlight a neuroprotective role of TLR4-
mediated signalling in inflammatory etiologies of the nervous system. 
1.6.3 TNF 
Apart from increased levels of sIL-1R2, a 25-fold increase in TNFα levels was observed 
in cerebrospinal fluid of AD patients. Following which AD associated region in TNF gene 
was verified by studies correlating AD and TNF halotype via sibling pair families (Perry 
et al., 2001). Interestingly, the genes for TNF receptors, Tnfr1 (chromosome 1p) and 
Tnfr2 (chromosome 12p) also showed genetic linkage to late-onset AD, while only 
Tnfr2 (exon6) polymorphism was found to be associated with late-onset AD (Perry et 
al., 2001). On the contrary, increased expression of TNFR1 in the AD brain was 
observed (Li et al., 2004). These observations were supported by the studies in PS and 
AD transgenic mouse models, whereby TNF-α and interferon (IFN)-γ induced Aβ 
production (Klegeris et al., 1997), and deletion of either of these cytokine receptors- 





inflammation, as well as learning and memory deficits (Yamamoto et al., 2007). TNFα-
mediated stimulation of γ-secretase activity by JNK-dependent phosphorylation of PS1 
and NCT (Kuo et al., 2008) could be one mechanism via which TNFα induces Aβ 
production. Thus the inhibition of inflammatory cytokine TNF-α is seen as a potential 
approach to AD (Tobinick et al., 2008). 
This is further highlighted by the functions mediated by this cytokine and its receptors. 
For instance the increased generation of TNFα by monocytes and macrophages in AD 
brain is generally accompanied by the induction of iNOS and shown to mediate 
neurotoxicity (Combs et al., 2001). Also, Aβ interacts with TNFα to induce neuronal 
damage via reactive oxygen species (ROS) and NO-dependent pathways with the 
involvement of JNK/c-Jun and NF-кB with the involvement of JNK/c-Jun and NF-кB 
(Combs et al., 2001; Eberhardt et al., 1996; Goodwin et al., 1995).  The neuronal loss in 
AD brain has also been attributed to apoptosis. In this context Aβ binding to TNFR1 has 
been suggested to induce neuronal apoptosis (Li et al., 2004). Additionally, TNF binding 
to neuronal Cd120a/b receptors is suggested to trigger caspase activation via increased 
release of TNF by the microglia and caspase-3 activation (Pickering et al., 2005). 
Interestingly, the TACE enzyme responsible for cleaving the membrane bound TNFα, 
TNFR1 and TNFR2 is also upregulated in some neuroinflammatory conditions.  
1.7 Interleukin-1 superfamily 
The discovery of interleukin-1 (IL-1) cytokines and further insight into their mechanism 
of action has led to a better understanding of the host-immune response to injuries, 
infections and several diseases. Since its discovery, the IL-1 superfamily has expanded 
and as of now consists of 11 cytokines, 13 receptors, including a subgroup of decoy 
and adaptor receptors (Garlanda et al., 2013; Smith, 2000) These are briefly described 







Figure 6 Members of the IL-1 superfamily 
The IL-1R family includes the receptors (IL-1R1, IL-18R, T1/ST2, and IL-1Rrp2) and the 
accessory proteins (IL-1RAcP) for IL-1, IL-18, IL-33, and other IL-1 family members (IL-
36a, IL-36b, and IL-36g). IL-1Ra, soluble IL-1R1, IL-36Ra, IL-37, IL-18 binding protein (IL-
18BP), IL-1R2, and TIR8/SIGIRR are negative regulators acting at different levels, as 
receptor antagonists, decoy receptors, scavengers, or dominant negative. Single 
immunoglobulin IL-1R related receptor (SIGIRR), three Ig IL-1R related molecule-1 and 






1.7.1 IL-1 cytokines 
IL-1α and IL-1β are ubiquitously expressed and are synthesized as precursor proteins, 
pro IL-1α and pro IL-1β which are cleaved by calpain and interleukin converting 
enzyme (ICE) respectively forming the mature IL-1α and IL-1β  Figure 7 (Dinarello et al., 
1995). Pro IL-1α and mature IL-1α are biologically active; whereas pro IL-1β is 
biologically inactive and requires cleavage (Dinarello, 2006). A third member of the IL-1 
cytokine family which inhibits the binding and biological activities of both IL-1α and IL-
1β, is called interleukin-1 receptor (IL-1R) antagonist (IL-1Ra) (Arend, 1991). IL-1R1a 
binds to IL-1R1 with a similar affinity but fails to transduce a signal (Eisenberg et al., 
1990). Thus, acting to regulate the IL-1 α/ β mediated signalling through the IL-1R1. 
Studies of mice deficient in IL-1R1, IL-1α, IL-1β or double deficient in IL-1α and IL-1β, 
show no particular phenotype and exhibit normal homeostasis, but are distinctly 
different from IL-1Ra deficient mice (Horai et al., 1998; Zheng et al., 1995). IL-1Ra 
deficient mice exhibit abnormal reproduction, stunted growth and develop 
spontaneous diseases such as rheumatoid arthritis (Hirsch et al., 1996). However, in 
case of externally induced diseases, these mouse models highlight the role played by 
these three IL-1 members in disease severity. For example- mice lacking IL-1R1 fail to 
develop proliferative lesions of vascular smooth muscle cells in mechanically injured 
arteries (Rectenwald et al., 2000). Also IL-1β deficient mice do not develop destructive 
joint processes following injection of streptococcal wall components (Van Den Berg, 
2001).  IL-1α deficient mice have brisk inflammatory response to turpentine-induced 
inflammation while the IL-1β deficient mice have no response (Horai et al., 1998). 
These differences can be attributed to the fact that IL-1β has an important role in the 
positive regulation of immune responses, while IL-1α acts to down-regulate the effect 
of IL-1β (Boraschi et al., 2005). Due to their ability to induce a broad spectrum of 
systemic changes in neurological, endocrinologic, hematologic and metabolic systems, 





diseases (Barrie et al., 2005; Navarro-González et al., 2008; Numerof et al., 2005). The 
strategies used so far include  targeting the enzymes responsible for activating IL-1α 
and IL-1β cytokines post cleavage from their precursor proteins (Miller et al., 1993), 
blocking IL-1α/β cytokines using the receptor or ligand antagonists and targeted gene 
disruption (Luheshi et al., 2009). However, the clinical administration of these 
antagonists, IL-1Ra and antibodies to IL-1 receptors is limited due to the complexity of 
delivering these proteins, thus reducing their usefulness (Dinarello, 2011). 
Furthermore, it is critical to develop a better understanding of the signalling pathways 
regulated or affected by these cytokines before targeting them and developing 







Figure 7 Proteolytic processing of IL-1α and IL-1β. 
Precursor of IL-1α and IL-1β (pro-IL-1α and IL-1β) are translated and translocated to 
the cytosol. These are then transported to the cell surface, where they are cleaved by 
the intracellular IL-1β converting enzyme (ICE), generating mature IL-1α and IL-1β 







IL-1R1, indispensible for IL-1α and IL-1β mediated effects, is a type-1 transmembrane 
protein with an extracellular N-terminus, an intracellular C-terminus, and a single 
transmembrane domain (Sims et al., 1988). Studies showed that, antibodies to IL-1R1 
blocked IL-1-mediated responses in most cell types (Campbell, 2012; Schäfers et al., 
2001; Sommer et al., 1999). Additionally, in IL-1R1-deficient mice, IL-1 responses such 
as increased IL-6 production, fever, acute-phase response, delayed type 
hypersensitivity, and the ability to combat infection by Listeria were impaired 
(Glaccum et al., 1997), highlighting its importance in various signalling pathways.  
IL-1R1 extracellular fragment consists of three immunoglobulin (Ig) domains. Two of 
these Ig domains are required for effective binding to the ligand and one is essential 
for binding to the IL-1R1 accessory protein (IL-1R1 AcP) which is essential for IL-1 
mediated signalling and only binds to the IL-1R1-ligand complex (Greenfeder et al., 
1995; Lu et al., 2008). The ICD of both these receptors contains a region known as the 
Toll/Interleukin-1 receptor (TIR) domain which is conserved among the members of 
the IL-1R family and can be subdivided into three regions of high similarity 
(Subramaniam et al., 2004). The mutation in the first two regions prevents signalling 
from IL-1R1; the mutation in the third region is known to alter the subcellular 
localization of the protein, preventing its translocation to the cell surface (Slack et al., 
2000) Figure 8. IL-1R1 and IL-1RAcP have splice variants which function differently and 
potentiate as well as negatively regulate the IL-1 mediated signalling. IL-1R1 has three 
reported isoforms, two of which ST2L and sST2 are membrane bound and can 
transduce IL-1 mediated signals (Li et al., 2000). Additionally, there is a soluble IL-1R1 
isoform-vST2, which sequesters IL-1 ligands and attenuates the IL-1 mediated 
signalling pathway (Tago et al., 2001). There are two IL-1RAcP variants, a membrane 





surface, which then can no longer interact with IL-1RAcP with full functional capability 
(Greenfeder et al., 1995; Jensen et al., 2000).  
The C-terminal domain of both IL-1R1 and IL-1R1 AcP is required for effective signalling 
(Huang et al., 1997; Leung et al., 1994). Interestingly, the truncated IL-1R1 lacking the 
C-terminal domain still binds to IL-1 ligands and IL-1RAcP with the same affinity as the 
full length IL-1R1. Though this receptor complex undergoes internalization and nuclear 
localization, it is incapable of undergoing IL-1 mediated signalling (Heguy et al., 1991). 
This has highlighted the importance of the IL-1R1 C-terminus domain in IL-1 induced 
signalling pathways. On the other hand, the lack of the N-terminal domain reduces the 
binding of IL-1 to the receptor by 50% (Heguy et al., 1992). Both IL-1R1 and IL-1RAcP 
are glycosylated in their N-terminal domain, which is essential for their interaction and 
the interaction with the ligand (Mancilla et al., 1992). Thus, these data indicate the 
importance of the N-terminal domain in ligand binding and signalling.  
Further investigation into the function of the C-terminal domain of IL-1R1 has revealed 
that it does not contain any intrinsic protein kinase activity or homology to catalytic 
subunit of protein kinases (Madge et al., 2000). However, following ligand binding IL-
1R1 was shown to undergo phophorylation and PKC/PKA acceptor sites fitting the 
consensus KKSRR or R-X-S-T were identified in the C-terminus domain of the receptor; 
these sites were later shown to be disposable for IL-1 mediated signal transduction 
(Heguy et al., 1992; Kunos et al., 1993). Furthermore, residues 28-42 in the CTF of the 
receptor were shown to be necessary for the induction of IL-8 and IL-2 gene expression 
(Kunos et al., 1993). Extensive mutagenesis studies have been performed and highlight 
the importance of specific IL-1R1 residues in receptor trafficking and ligand induced 







Figure 8 Three-dimensional representation of the Ig and the TIR domains of IL-1R1 
(a) Ribbon diagram of Ig domains of IL-1R1 showing the regions interacting with the IL-
1 ligand and the IL-1R1AcP. (b) Ribbon diagram of IL-1R1 TIR domain, with two regions 
important for signalling and the third responsible for proper trafficking of the receptor. 











1.7.3 IL-1R1 mediated signalling 
IL-1α and IL-1β induced signalling through IL-1R1 is responsible for the activation of the 
nuclear factor к-beta (NF-κB), and mitogen activated protein kinase (MAPK) signalling 
pathways (O’Neill et al., 1990; O’Neill, 2008). The MAPK signalling pathways involve 
three distinct pathways; p42 and p44 [p42/p44; also known as the extracellular signal-
regulated kinase (ERK) 1 and ERK 2 (ERK1/2)], Janus N-terminal kinase (JNK) and p38. 
While ERK1/2 MAPK also appears to regulate transcription, p38 and JNK promote the 
stabilization of induced mRNA (Chang et al., 2001). These signalling pathways have 
been extensively studied due to the role played by IL-1 cytokines in inflammatory 
diseases, including neurodegenerative diseases, atherosclerosis, pulmonary diseases, 
ischemia induced inflammation, type-2 diabetes, joint and bone diseases, and multiple 
sclerosis (Lukens and Gross, et al., 2012). Furthermore, IL-1 signalling induces the 
production of secondary inflammatory cytokines and chemokines such as IL-6, TNFα, 
KC, and G-CSF (Di Paolo et al., 2009; Orjalo et al., 2009). IL-1 cytokines also lead to 
inflammatory diseases by promoting the induction of pathogenic cytokines (IFN-γ, IL-
17, and GM-CSF) by T cells and innate effector cell (Lukens and Barr, et al., 2012; 
Sutton et al., 2009). 
Despite of the critical role played by IL-1 mediated signalling pathways; there are fewer 
than 100 IL-1R1 proteins on most cell surfaces at any one time and occupancy of as 
little as 5% is sufficient for IL-1 signal transduction (Arend et al., 1990). Several 
contradictory outcomes have been reported regarding IL-1R1 signalling pathways. This 
reflects cell type- and species specific responses to IL-1. NF-кB activation can be 
mediated through two separate pathways- transforming growth factor-β-activated 
protein kinase 1 (TAK1)-independent or TAK1-dependent pathway (Yao et al., 2007). 
Each of these pathways is distinct from the other based on the subcellular site for the 





pathway is initiated from the cell surface and does not require internalization of IL-1R1 
ligand complex (Takaesu et al., 2001). 
1.7.3.1 TAK1-independent pathways-mediated at the cell surface 
It is well established that IL-1 stimulation leads to the recruitment of IL-1RAcP forming 
the IL-1/IL-1R1/IL-1RAcP complex (Greenfeder et al., 1995; Huang et al., 1997). The TIR 
domains of these two receptors act as a scaffolding platform for further recruitment of 
MyD88. The MyD88 recruitment leads to the recruitment of interleukin-1 receptor-
associated kinase (IRAK)1 and IRAK4, via their death domains (DD) (Zhaodan Cao et al., 
1994; Loiarro et al., 2009; Wesche et al., 1997). IRAK4 then activates IRAK1, which 
undergoes autophosphorylation which in turn interact with TRAF6, an E3 ubiquitin 
ligase (Kollewe et al., 2004; Li et al., 1999).  
At this stage two different signalling pathways are initiated leading to NF-кB activation. 
The first pathway involves the recruitment of mitogen-activated protein kinase kinase 
3(MEKK-3) (Yao et al., 2007). On the other hand, the second pathway requires the 
interaction of ubiquitinated TNFR-associated factor-6 (TRAF6) with p62 leading to 
activation of atypical PKC (aPKC) (Geetha et al., 2002; Sanz et al., 2000). Both these 
events are followed by phosphorylation of IKKβ leading to the activation of IKKα. Upon 
activation IKKα phosphorylates IκBα such that it is not recognized by SCF-bTrCP, thus 
preventing its proteasome-dependent degradation while it is associated with NF-кB, 
following which the phosphorylated IkBα dissociates from NF-кB, thus allowing NF-кB 







Figure 9 TAK-1-independent pathways 
IL-1 binds to IL-1RI forming a complex with IL-R1AcP, leading to recruitment of MyD88, 
Tollip, IRAK-1, IRAK-4 and TRAF6 to form complex I. TRAF6 then interacts with p62, 
leading to activation of atypical PKCs and phosphorylation of IKKβ leading to activation 
of IKKα which subsequently phosphorylates IkBα in a way that does not trigger its 
recognition by SCF-bTrCP and proteasome- dependent degradation. Phosphorylated 
IkBα dissociates from NF-кB, thus allowing NF-кB to translocate to the nucleus. 
Alternatively, TRAF6 can also interact with MEKK3, leading to activation of IKKα, and 





1.7.3.2 TAK1-dependent pathway 
The formation of the IL-1/IL-1R1/IL-1RAcP complex leads to the recruitment of MyD88, 
Tollip, IRAK-1, IRAK-4 and TRAF6 to form complex I (Jiang et al., 2002). Formation of 
complex I leads to the activation and autophosphorylation of IRAK-1, making it 
avaialble as an adaptor protein in IL-1 signalling pathway (Kollewe et al., 2004). MyD88 
binding induces endocytosis of IL-1R1 following ligand binding (Li et al., 2006), which is 
followed by endosomal dissociation of MyD88 and Tollip, but not TRAF6. After 
dissociation from the complex I, IRAK-1/TRAF6/IRAK-4 complex interacts with the pre-
existing membrane bound Transforming growth factor β-activated protein kinase 1 
(TAK1)-binding protein (TAB) (TAK1-TAB1-TAB2/3) complex, forming complex I. IRAK-1 
undergoes K-63 linked poly-ubiquitination by Pellino, which is itself phosphorylated by 
IRAK-1 (Ordureau et al., 2008). Following which both IRAK-1 and Pellino undergo K-48 
linked polyubiquitination and are degraded (Ordureau et al., 2008; Yamin, 1997). The 
TRAF6-TAK1-TAB1-TAB2/TAB3 complex then leaves the membrane and is referred to 
as complex III (Jiang et al., 2002). While in the cytoplasm TRAF6 undergoes 
autoubiquitnation and activates TAK1/TAB2 (Walsh et al., 2008). These events are 
followed by phosphorylation of IKKβ which then lead to the activation of IKKα. IKKα 
upon activation phosphorylates IкBα such that it is not recognized by SCF-bTrCP, thus 
preventing its proteasome-dependent degradation (Cui et al., 2012). Following this, 
the phosphorylated IκBα dissociates from NF-κB, thus allowing NF-κB to translocate to 






Figure 10 TAK-1-dependent pathways 
The formation of IL-1R complex leads to the recruitment of MyD88, Tollip, IRAK-1, 
IRAK-4 and TRAF6 to form complex I. This then triggers IRAK-4 autophosphorylation 
and the phosphorylation of IRAK-1. Subsequently, IRAK-1 leaves the receptor complex 
together with TRAF6 and associates with the pre-formed TAK1-TAB1-TAB2/TAB3 
complex (complex II). A series of events lead to the release of TRAF6-TAK1-TAB1-
TAB2/TAB3 from the membrane (complex III). In the cytoplasm, TRAF6 undergoes 
auto-ubiquitination which triggers the binding of TAB2 and activation of TAK1, which 
subsequently phosphorylates IKKβ. IKKβ phosphorylates IkBα followed by proteasome-
dependent degradation. In this way, NF-кB (shown as p65/p50 dimers) is set free and 
translocates to the nucleus to bind the promoters of responsive genes (Adapted from 





1.7.4 Regulation of IL-1R1 signalling 
IL-1R1 signalling is regulated at several steps, beginning from the controlled expression 
of IL-1R1 on the cell surface, to the existence of the IL-1Ra which has a high affinity to 
IL-1R1 but fails to recruit IL-1RAcP and induce a signal. Additionally, another receptor, 
IL-1R2 is referred to as the decoy receptor since ligand binding to IL-1R2 does not 
result in cytokine production (Garlanda et al., 2013). While IL-1R2 shares sequence 
homology to IL-1R1, it lacks the C-terminal domain, making it incapable of IL-1 induced 
signal transduction (Mcmahan et al., 1991). Thus, IL-1R2 acts by sequestering IL-1 
ligands and dampening the IL-1R1 signalling cascade. Certain viruses such as Vaccinia 
virus or cowpox have been shown to encode genes for proteins with 30% homology to 
IL-1R2. These viral mimics of IL-1R2 diminish the host’s ability to mount an 
inflammatory response, allowing the viruses to replicate at a higher rate (Alcamí et al., 
1992; Spriggs et al., 1992).   
The co-ordinated regulation of IL-1R1, IL-1R2 and IL-1Ra represents a principal 
mechanism involved in controlling IL-1 local effects (Bellehumeur et al., 2009). 
Furthermore, sIL-1R1 has higher affinity towards the IL-1R1a than the sIL-1R2 (Svenson 
et al., 1993). Furthermore, the inhibitory activity of IL-1Ra is enhanced by sIL-1R1 and 
diminished by sIL-1R2 (Burger et al., 1995). Thus it is feasible that the extracellular 
domain of IL-1R1 functions to sequester the IL-1Ra which allows the IL-1 ligands to 
bind to IL-1R1 efficiently and transduce a signal across the membrane. Also reports 
indicating the presence of a soluble splice variant of the IL-1R2 encoding its 
extracellular domain functions to sequester ligands from the extracellular matrix, 
causing a negative effect on IL-1 signalling (Cui et al., 2003; Hart, 1996).  
Apart from triggering the formation of IL-1R1/IL-1RAcP complex, IL-1β, also induces 
endocytosis of IL-1R1. Upon internalization activated receptor complexes are often 





the IL-1R1 receptor complex has been reported to stay in cells without getting 
processed or degraded for up to 6 hours, after which it translocates to the nucleus 
(Curtis et al., 1990). Interestingly, nuclear localization signal sequences within the 
intracellular fragment of IL-1R1 are dispensable for IL-1β induced signal transduction 
and translocation of the IL-1R1-IL-1β complex to the nucleus. Also Heguy and co-
workers constructed a series of deletion mutants of the cytoplasmic domain of the IL-
1R1 and showed that these mutants internalized and trafficked to the nucleus, but 
failed to induce IL-2 (Heguy et al., 1992). Furthermore, they showed that the amino 
acids 527-477 were required to transduce signals mediating activation of IL-2 or SV40 
promoter activation (Heguy et al., 1991). Furthermore, Brissoni and co-workers 
showed that IL-1R1 interacted with Tom1, an ubiquitin-, clathrin, and Tollip-binding 
protein; knockdown of Tom1 resulted in IL-1R1 accumulation in the late endosome. 
This group also suggested that Tollip is an endosomal adaptor protein linking IL-1R1, 
via Tom1, to the endosomal degradation pathway (Brissoni et al., 2006). Furthermore, 
Tollip deficient mice produce less TNFα and IL-6 after IL-1β administration, despite the 
absence of any defects in IкB, JNK, p38 and ERK signalling pathways (Didierlaure et al., 
2006). Thus, these data clearly indicate an important role of trafficking of IL-1R1 
trafficking and the signalling pathways activated. 
Our group previously showed that IL-1R1 undergoes ectodomain shedding on 
stimulation with IL-1β or the PKC activator- PMA. IL-1R1 was shown to undergo 
ectodomain shedding by an unidentified metalloprotease, releasing the sIL-1R1 
fragment into the extracellular matrix. The IL-1R1 CTF generated was subsequently 
shown to be cleaved by γ-secretase enzyme complex. Additionally, the inhibition of γ-
secretase-mediated cleavage of IL-1R1 was found to negatively regulate IL-1β 
responsiveness (Elzinga et al., 2009), however, the mechanism underlying this 
regulation remains unclear. Taking a closer look at the mutagenesis studies carried out 





of IL-1R1, it is possible that the ectodomain shedding and subsequent γ-secretase-
mediated cleavage of IL-1R1 functions to regulate IL-1-mediated-signalling at a 
completely different level.  
1.8 Tumor necrosis factor superfamily 
In 1891, Dr. William Coley performed an experiment with an intention to treat cancer 
in a terminally ill patient. He injected the man with a solution of infectious bacteria 
known to cause a skin disease called erysipelas. He expected that the patients while 
recovering from the skin disease would also recover from cancer. It was an experiment 
and he was successful in treating cancer in terminally ill patient (Coley., 1893).  The 
toxin injected by William Coley was called Coley’s toxin for a long time. In 1984 in an 
attempt to isolate Coley’s toxin, Aggarwal and co-workers discovered two cytotoxic 
factors, one from macrophages and the other from lymphocytes with 50% sequence 
homology. These toxins came to be known as Tumor Necrosis Factor-α (TNFα) and 
lymphotoxin-α (LTα), which was later renamed TNF-β (Aggarwals et al., 1985). They 
were the first discovered members of the TNF superfamily. Over the past three 
decades, the TNF superfamily has expanded and now consists of over 19 different 
cytokines, 29 interacting receptors (three additional TNF superfamily receptors have 
been identified and found only in mice) and several adaptor proteins. The main TNF 
superfamily death ligands and their receptors are shown in Figure 11. The TNF 
receptors are oligomeric, type I or type III transmembrane proteins which can be 
divided into two groups, based on the presence or absence of the intracellular death 
domain (DD). The DD consists of 45 amino acids and is essential for the interaction and 
recruitment of caspase-interacting proteins following ligand binding to initiate the 
extrinsic pathway of caspase activation, thereby transducing cell death signals 
(Feinstein et al., 1995; Tartaglia et al., 1993). TNF receptors lacking the DD bind TNF 
receptor-associated factors (TRAFs) and activate intracellular signalling pathways that 





et al., 1995). The extracellular domain of these receptors contains multiple cysteine-
rich domains. 
1.8.1 Tumor necrosis factor receptor-1 (TNFR1) 
In 1990 TNFR1 was first isolated and characterised (Loetscher et al., 1990). TNFR1, also 
known as CD120a, p55/p60 and death receptor 1 (DR1), is a type I transmembrane 
protein. The extracellular domain of TNFR1 includes four-40 amino acids long cysteine-
rich domains (CRDs) (CRD1 or the pre-ligand binding assembly domain (PLAD), CRD2, 
CRD3 and CRD4) involved in ligand binding (Marsters et al., 1992). The cytoplasmic 
domain of TNFR1 has the characteristic DD which acts as a scaffolding site for 
recruitment of the adaptor proteins and the subsequent formation of the death 
inducing signalling complex (DISC) (Tartaglia et al., 1993). The importance of TNFR1-
mediated signalling is highlighted by the TNFR1 knock out animals. These animals show 
a defective immune phenotype with abnormal microglial cell morphology, decreased 
inflammatory response, decreased susceptibility to endotoxin shock, increased 
circulating TNF levels, decreased IL-6, increased susceptibility to bacterial infection and 
lung inflammation (Iosif et al., 2006; Kanehiro et al., 2002; Peschon et al., 2013). Apart 
from this, these animals also show decreased tumor incidence (Arnott et al., 2004). 









Figure 11 Death ligands and their receptors 
The figure shows the known TNF superfamily death ligands and their receptors 






1.8.2 TNFR1 compartmentalization and signalling 
TNFR1 binds to the TNF ligand, which leads to the trimerization of the receptor-ligand 
complex. This is followed by cleaved in its extracellular domain by a family of 
sheddases, namely ADAM10 or ADAM17, releasing the extracellular domain of the 
receptor into the extracellular milieu (Edwards et al., 2008). The TNFR1 DD then 
provides a platform for the recruitment of the adaptor protein TNF receptor 1-
associated protein (TRADD) via the homotypic DD interactions. TRADD then recruits 
TRAF2, RIP1 and other associated proteins-UBC13, cIAP1/2 (Zarnegar et al., 2008). The 
complex thus formed at the cell surface is referred to as the Complex I which signals 
for NF-кB activation. There is a lot of discrepancy regarding the adaptor proteins 
recruited to the Complex I, and the order in which they are recruited. This has been 
attributed to the cell type and species specific differences. A general consensus about 
the adaptor proteins recruited to form the two complexes is highlighted in Figure 12.  
The TNFR1 complex I then undergoes internalization and gets dissociated. This event 
leads to the formation of endosomal complex II. It has been reported by several groups 
that two different types of complex II referred to as complex IIA and complex IIB can 
be formed depending upon the adaptor proteins recruited (Gyrd-Hansen et al., 2010). 
Though there has been a lot of discrepancy about the spatial segregation of these 
complexes, the subcellular fractionation studies and studies reporting that the 
formation of complex II is enhanced upon knock-out or knockdown of components of 
complex I, has validated the compartmentalization of TNFR1 mediated signalling (Hsu 






Figure 12 Compartmentalization of TNFR1 signalling pathways 
Upon TNF stimulation, TNFR1 trimerizes and recruits TRADD via its DD. TRADD in turn 
binds to TRAF2 and RIP1. In absence of NF-кB signalling following TNFR1 endocytosis, 
TRADD dissociates from TNFR1 and associates with FADD and Caspase-8 activating the 
pro-apoptotic pathway. Alternatively in absence of cIAPs, RIP1 dissociates from TNFR1 
following endocytosis. RIP1 then recruits  FADD and Caspase 8, leading to the 
activation of pro-apoptotic pathways (Adapted from Verstrepen et al., 2008; Gyrd-





Complex IIA is formed in the absence of NF-кB signalling. In Complex IIA, upon 
endocytosis TRADD dissociates from TNFR1 and associates with Fas-Associated protein 
with Death Domain (FADD) which then recruits Caspase 8, thereby initiating the pro-
apoptotic signalling. Interestingly, in the absence of cIAPs it is RIP which dissociates 
from the TNFR1 complex I, recruiting FADD and Caspase 8 forming Complex IIB. This 
complex initiates the pro-apoptotic signalling pathways. Thus, TNFR1 can initiate both 
pro-survival and pro-apoptotic signalling pathways. 
1.8.3 TNFR1 mutational studies 
To characterize TNFR1 and better understand the role of the intracellular and 
extracellular domains in terms of ligand binding and the signalling pathways mediated, 
several TNFR1 deletion mutants and point mutants have been made Table 1.7.  
Table 1.7 Residues mutated and studied for the TNFR1  
 
Deletion mutagenesis of the cytoplasmic domain identified an ∼80 amino acid domain 
(Δ218) responsible for signalling cytotoxicity (Tartaglia et al., 1992). Following which 
attempts were made to map the region responsible for downstream signalling. Several 
of the residues within this deleted region were conserved with the Fas antigen. 
Mutation in any of these residues was shown to inhibit cytotoxic signals (Tartaglia et 
al., 1993). Further mutagenesis studies showed that the lysine residue numbered 351 
was critical for induction of necrosis (Boone et al., 2000). Following this discovery, 





spatial signal segregation. The domain corresponding to amino acids 405-413 were 
shown to be important for the localization of TNFR1 to lipid rafts (Cottin et al., 2002). 
In this context, C.A. Fielding and co-workers pointed out that residues 218-324 
negatively regulated cell surface expression of TNFR1 (Fielding et al., 2004). This 
domain was referred to as TNFR1 internalization domain (TRID). This internalization 
site was then mapped to tryptophan residue 239, which was responsible for clathrin 
mediated internalization of the receptor (Schneider-Brachert et al., 2004). This group 
thus established the spatially segregated TNF signalling pathways by 
compartmentalization of plasma membrane-derived endocytic vesicles harbouring the 





1.9 Research Objective 
Regulated intramembrane proteolysis is a two-step sequential process where 
ectodomain shedding has been regarded as the key regulatory event for the further 
processing of proteins by the γ-secretase protease complex. The importance of 
ectodomain shedding and γ-secretase-mediated cleavage is highlighted by the 
increasing list of their substrates. Studies carried out to determine the expression 
pattern, substrates and the subsequent direct or indirect involvement of these 
enzymes in various signalling pathways has allowed future progress to target these 
enzymes for various diseases. The subcellular location for the activity of sheddases 
varies from Golgi vesicles to the plasma membrane and shed microvesicles. 
Furthermore, ectodomain shedding is regulated by several factors including signalling 
pathways and post-translational modifications. Apart from direct regulation of the 
sheddases, spatial segregation of its substrates is another mode of regulation.  Also, 
the γ-secretase enzyme complex is active on cell surface, endosomes, ER, and trans-
Golgi. Thus, it is important to study the subcellular location and trafficking of γ-
secretase substrates and the fragments generated post cleavage to define the role 
they might play in the signalling events mediated and their regulation.  
We previously reported IL-1R1 to undergo ectodomain shedding followed by γ-
secretase-mediated regulated intramembrane proteolysis. Additionally, we also 
highlighted a role for TRAF6 in regulated intramembrane proteolysis of IL-1R1, where 
TRAF6-mediated ubiquitnation was shown to positively modulate regulated 
intramembrane proteolysis of IL-1R1 (Twomey et al., 2009). Recent studies reflect the 
importance of trafficking and degradation of γ-secretase cleavage products in the 
regulation of cell signalling, and also emphasize the role played by ubiquitination in 
mediating subcellular trafficking of proteins. However nothing is yet known about the 
subcellular location for ectodomain shedding and regulated intramembrane 





we focused on the subcellular occurrence of IL-1R1 cleavage events and studied the 
role played by TRAF6 in mediating IL-1R1 proteolysis and determined the fate of the IL-
1R1 ICD. The second main aim of this work is to determine the conservation of 
regulated intramembrane proteolysis as a physiological occurrence amongst other 
immune receptors. In this regard, similar to Interleukin 1, receptor, type 1, (IL-1R1), we 
examined the Toll like receptor 4 (TLR4) as a potential γ-secretase substrate. 
Furthermore we determined the role of PS proteins in apoptosis by screening cell 
death receptors as potential γ-secretase substrates. The role of PS proteins in 
apoptosis was highlighted when conditional deletion of Psen1/Psen2 in adult mouse 
brains led to progressive loss of synapses, dendrites, and neurons, suggesting that loss 
of Psen function, caused neuronal degeneration which was credited to increased 
apoptosis. This phenotype has always been attributed to defective Notch signalling 
following inhibition of γ-secretase activity (Curry et al., 2005; Rosati et al., 2013). 
However, the involvement of specific cell death receptors as potential γ-secretase 
substrates has not been studied, highlighting the need to find potential γ-secretase 
substrates in the cell death receptor family. In this context TNFR1 was investigated as a 
potential γ-secrtease substrate. We also studied the subcellular occurrence of the 














2.1.1 General Chemicals and Reagents 
All salts and reagents were purchased from Sigma-Aldrich (Dublin, Ireland) unless 
otherwise stated. Protein G-sepharose beads and DNA ladder were procured from 
Invitrogen (Paisley, Scotland). Prestained molecular weight protein marker was 
purchased from BioRad Laboratories (GmbH, Munich, Germany). Bicinchoninic acid 
(BCA) protein concentration reagents were purchased from Pierce Biotechnology 
(Rockford, Illinois) through Medical Supply Company (MSC) Ltd. (Dublin, Ireland). 
Nitrocellulose membrane and western blotting filter paper were purchased from 
Schleicher and Schuell (GambH, Dassel, Germany). The chemiluminescent detection kit 
ECL was purchased from GE Healthcare (Buckinghamshire, UK). Complete protease 
inhibitor tablets were purchased from Roche (Boehringer-Mannheim, Indianapolis, 
USA). Recombinant murine IL-β and TNFα was purchased from Peprotech (Dublin, 
Ireland). Phorbol 12-myristate 13-acetate (PMA), recombinant human TNFα, 
recombinant human IL-1β and LPS was procured from Calbiochem (Nottingham, 
England) Appendix Table 1. 
2.1.2 Molecular Biology Reagents 
Primers were ordered and synthesised by Sigma-Aldrich (Dublin, Ireland) or Integrated 
DNA Technologies (Leuven, Belgium). DNA polymerase and KOD hot start DNA 
polymerase were purchased from Calbiochem (Nottingham, England). High-fidelity Pfu 
polymerase was bought from Stratagene (Edinburgh, Scotland). T4 DNA ligase and all 
restriction enzymes were purchased from New England Biolabs through ISIS (Co. 
Wicklow, Ireland). PCR and DNA Gel purification kits were obtained from Qiagen Ltd. 
(West Sussex, UK). DNA midiprep kit and Opti-MEM or Turbofect transfection medium 





phenylindole (DAPI) and Prolong gold antifade mouting media were purchased from 
Invitrogen, Ireland. Glass coverslips were purchased from Reagecon, UK. Appendix 
Table 1  
2.1.3 Plasmid Sources  
FLAG-tagged TNFR1 was a gift from Dr. Martin S. Kluger (Yale University School of 
Medicine, Connecticut). IL-1R1 and FLAG-tagged TRAFs constructs were kindly 
provided by Dr. Vishva Dixit (Genetnech, South San Francisco, CA). HA-tagged Ubiquitin 
constructs were obtained from Dr. Ruaidhri Carmody (University of Glasgow). HA-
tagged Ubiquitin K48 only and K63 only were provided by Dr. Mathijis Baens 
(University of Leuven, Leuven, Belgium). Dr. Aymelt Itzen (Max-Planck-Institute for 
Molecular Physiology, Dortmund, Germany) kindly provided the GFP-tagged Rab5 
constructs and GFP-tagged Rab7 constructs were a gift from Dr. Cecilia Bucci 
(Department of Science and Technology, University of Salento, Italy). The wild-type 
Dynamin and Dynamin-K44A mutant was procured from Dr. Pietro De Camilli (Addgene 
22163 and Addgene 22197). All the other constructs were generated in-house. 
Appendix Table 2 
2.1.4 Vector Maps 
Vector maps for the constructs are listed in the Appendix Table 3. These include 
pcDNA3, pBabepuro, pRK5, pEGFP-C1, pEGFP-N1, pEYFP-C1, and pEYFP-N1. 
2.1.5 Primers 














The following antibodies were used in the study: anti-TNFR1 (S-20), anti-TNFR1 (N-20), 
anti-TNFR1 (H-80), anti-IL-1R1 (C-20), anti-IL-1R1 (N-20), anti-TLR4 (C18), anti-YFP, anti-
TRAF6 , anti-TRADD, anti-IκBα and anti-JNK were purchased from Santa Cruz, CA, USA. 
Anti-human PS1-NTF and anti-human PS1-CTF were purchased from Chemicon 
(Hamphshire, UK); PS1 antibody (3.6.1) was previously described (Kirschenbaum et al., 
2001). Anti-TNFR1 (C25C1), anti-RIP1, anti-PS2, anti-phospho IκBα and anti-phospho 
JNK were obtained from Cell Signalling Technology (Danvers, Massachusetts, USA). 
Anti-HA antibody was purchased from Covance (Berkely, California, USA). Antibodies 
purchased from Abcam (Cambridge, UK) included anti-Histone 2b, anti-Na+/K+ ATPase, 
anti- Rab5, anti-GFP and anti-EEA1 antibody was from BD Biosciences (Oxford, UK). 
Anti-β-actin, anti-β-tubulin, anti-FLAG and anti-FLAG FITC antibody were from Sigma 
(Wicklow, Ireland).  
Isotype Antibodies 
Anti-mouse IgG, anti-rabbit IgG and anti-goat IgG were purchased from Santa Cruz (CA, 
USA).  
Secondary Antibodies 
Peroxidase-conjugated secondary anti-rabbit, anti-mouse and anti-goat antibodies 
were purchased from DAKO (Denmark). Infrared secondary antibodies- IRDye 680 Goat 
Anti-Rabbit IgG and IRDye 800CW Goat Anti-Mouse IgG were procured from LI-COR 
(Dublin, Ireland). Alexa Fluor® anti-rabbit 488, Alexa Flour® anti-rabbit 546, Alexa 
Fluor® anti-mouse 488, Alexa Fluor® anti-mouse 546, Alexa Fluor® anti-goat 488 and 





catalogue number and the dilution used for the antibodies are listed in the Appendix 
Table-4. 
2.1.7 Pharmacological modulators of protease activities 
Sodium orthovanadate, dithiothreitol (DTT), leupeptin, ethylene glycol bis (2-
aminoethyl ether) tetra acetic Acid (EGTA) and ethylene diamine triacetic acid  (EDTA) 
were purchased from Sigma-Aldrich (Dublin, Ireland). Phorbol 12-myristate 13-acetate 
(PMA), in solution™ γ-Secretase Inhibitor (XIX), in solution™ TAPI, DAPT, epoxomicin 
and concanamicin were purchased from Calbiochem (Nottingham, England). Appendix 
Table 1 
2.1.8 Cell lines 
Human embryonic kidney 293T (HEK293T) cells originally purchased from ATCC 
(Middlesex, UK) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% (v/v) fetal bovine serum (FBS), 1% (v/v) L-glutamine, 50 units/ml 
penicillin and 50 g/ml streptomycin. Immortalized fibroblasts derived from PS1-
deficient, PS2-deficient or both PS1-and PS2-deficient or wild-type mouse embryos 
were generously provided by Bart De Strooper (KU Leuven, Belgium) and previously 
described (B De Strooper et al., 1998). All murine embryonic fibroblast (MEF) cell lines 
were grown in DMEM, 10% (v/v) FBS, 1% (v/v) glutamine, 1% (v/v) non-essential amino 
acids, 1% (v/v) sodium pyruvate, penicillin (50units/ml) and streptomycin 5g/ml. All cell 
lines were grown in a humidified incubator at 37°C and 5% CO2. 
2.1.9 Bacterial Strains and Media used 
E. coli DH5α was purchased from Invitrogen (Dublin, Ireland). Lab stocks of the E. coli 







2.2.1 Computer software used in Bioinformatics analysis 
DNA sequence analysis and alignments were performed using Vector NTI. 
Bioinformatics analysis was carried out using the online tools PredictNLS and NetNES 
to detect NLS and NES respectively. NetNES is available online at 
http://www.cbs.dtu.dk/services/NetNES/ and PredictNLS at 
http://cubic.bioc.columbia.edu/cgi/var/nair/resonline.pl. 
2.2.2 Competent cell preparation and transformation 
DH5-α strain of E.coli grown to log or exponential phase was streaked for single 
colonies on LB agar plate and grown overnight at 37°C. A single colony was picked and 
inoculated in 5ml of LB broth medium overnight at 37°C, 250rpm/min. Then 3ml of 
overnight grown culture was inoculated into 100-200ml of LB broth solution and grown 
for 2-3h. Once cell density reached a value of 0.6 to 1.0 at OD595, cells were harvested 
by centrifugation at 3000x g for 15min at 4°C. The supernatant was discarded and the 
pellet resuspended in pre-cooled 0.1 M MgSO4 at one third of the bacterial culture 
volume. Cells were then harvested as above and the pellet resuspended in 0.1M CaCl2 
containing 15% (v/v) of glycerol with 1/25 of bacterial culture volume. Aliquots were 
put in pre-cooled tubes, frozen on dry ice and then stored at -80°C. 
2.2.3 Transformation of DH5α competent cells 
Competent cells were thawed on ice for 15-20min. Approximately 1ng of a plasmid 
DNA or 2-18μl of a ligation mixture was mixed with 100μl of competent cells and 
incubated on ice for 30min. Cells were heat-shocked at 42°C for 45sec and 
immediately cooled on ice. Then 900μl of LB broth was added and the culture was 





was spread on a pre-warmed LB agar plate containing an appropriate antibiotic 
(50μg/ml ampicillin or 50 μg/ml kanamycin) and incubated at 37°C overnight. A single 
colony was picked and inoculated in 5ml LB broth medium, shaking at 37˚C for 6-8h. 
Then 1ml of the inoculated media was incubated shaking at 37˚C overnight in 200ml LB 
broth medium with appropriate antibiotic. Plasmid isolation was performed using 
Promega midiprep kit per the manufacturer’s instructions. 
2.2.4 Site-directed mutagenesis of plasmids 
All molecular biology procedures complied with those outlined in Sambrook and 
Maniatis (Sambrook., 1989). Site-directed mutagenesis was performed as directed by 
the two-primer pair method QuickChange™ Site-Directed Mutagenesis Kit by 
Stratagene (Edinburgh, Scotland). The fidelity of the PCR reaction and subcloning were 
confirmed by DNA sequencing by Macrogen Inc. (Seoul, Korea).  
2.2.5 Plasmid DNA restriction digest and DNA gel electrophoresis 
Following NEB guildlines (http://www.neb.com/nebecomm/default.asp) the following 
reagents were added to an Eppendorf tube: 500ng plasmid DNA, 2μl 10x NEBuffer, 
0.5μl 100x BSA (if required), 0.5μl restriction enzyme and deionized H2O to make the 
final volume 20μl. Mixed and incubated at 37°C for 3h. Samples were then mixed with 
5μl DNA running dye (10mM EDTA, 0.25% Bromophenol Blue, 50% Glycerol). Samples 
were loaded onto a 1% Agarose gel containing gold stain sampler at 1:10,000 dilution 
so that DNA could be visualised. DNA was separated with an applied potential 
difference of 100V for about 1h. Gel was observed by illuminating on a 302 nm UV 






2.2.6 Cell line Culture  
All the cell lines were cultured in class II biohazard safety cabinet at 37oC under 5% CO2 
atmosphere. Cells were maintained in the appropriate size tissue culture treated flasks 
with specific media and growth supplements under adherent conditions. For 
passaging, cells were washed twice with incomplete media and detached from the 
tissue culture flask by incubating at 37oC for 1min in 0.25% trypsin/EDTA solution. 
Trypsinisation was followed by, neutralisation of trypsin with an equal volume of 
serum supplemented medium. Cells were then recovered by centrifugation at 500rpm 
for 2min at room temperature. Cell pellet was washed with incomplete media and 
centrifuged again at 500rpm for 2min at 4oC before re-suspending in appropriate 
volume of cell growth specific medium. 
2.2.7 Cell Viability 
Trypan blue is a diazo dye with negatively charged chromophore, which does not 
interact with the cell until its membrane is damaged. Dead cells thus acquire the dye 
and appear blue under the microscope while the live cells are excluded from the dye. 
Cells were detached from tissue culture flask using 0.25% trypsin/EDTA solution 
followed by neutralisation of trypsin using equal volume of serum containing media. 
Cell suspension was then mixed with trypan blue solution in 1:9 ratio. Then 10μl of the 
cell/trypan blue mix was placed on the hemocytometer (Hausser Scientific, PA, USA) to 
perform cell count under the microscope. 
Fluorescent chemical compound propidium iodide (PI) was used to check the cell 
viability using flow cytometry. Cells were detached from the tissue culture flask using 
0.25% trypsin/EDTA solution, followed by neutralisation of trypsin using equal volume 
of serum containing media. Cell suspension was then washed with PBS, followed by 





PBS supplemented with 0.25μg of PI per million cells, for 5min at 4oC, in dark. Cells 
were analysed for viability using Accuri C6 flow cytometer (BD Biosciences, Franklin 
Lakes, NJ), and Accuri C6 software. 
2.2.8 Calcium phosphate transfection of HEK293T cells 
Transfection was carried out on sub confluent HEK293T cell cultures using the calcium 
phosphate precipitation method. For a 10cm dish with 10ml of culture media, 2.5µg of 
each plasmid was added to 62μl 2M CaCl2 with up to 438µl of sterile water. This 
solution was added drop-wise over the course of two minutes to 500μl hanks buffered 
salt solution (HBSS) and the resulting cloudy mixture was allowed to stand for three 
minutes. The 1ml precipitate solution was then added to the cell culture. Essentially 
the same procedure was performed for each well of a 6-well plate except 200µl of the 
precipitate solution containing 2µg of total DNA was added per well. In all instances 
the total amount of DNA in each culture was kept constant by addition of empty vector 
pcDNA3 (Invitrogen). Media was changed 8-16h post-transfection and cells were 
harvested 24-48h post-transfection. 
2.2.9 Transfection of mouse embryonic fibroblasts (MEFs) 
Transfection was carried out on subconfluent MEF cell cultures using the TurboFect™ 
in vitro tansfection reagent from BioRad Laboratories (GmbH, Munich, Germany). 
Plasmid and TurboFect™ were added in 1:3 ratio and incubated for 5min. 200μl of 
serum-free DMEM was then added to the above mixture and incubated for 15min at 
room temperature. Then the combined solution was added drop-wise to the cell 






2.2.10 Preparation of cellular protein extracts 
HEK293T cell cultures were washed with ice-cold phosphate-buffered saline (PBS) and 
lysed in 200μl/ml of lysis buffer (50 mM HEPES, 150mM NaCl, 1 mM EDTA, 0.1% (v/v) 
Nonidet P-40, 1mM sodium orthovanadate and protease inhibitor mixture) for 6 well 
plates or 10 cm dishes respectively. Cells were lysed on ice for one hour, spun at 
13000rpm at 4°C for 10min and supernatants were collected. Lysates were normalised 
using the bicinchoninic acid (BCA) method by Pierce.  
MEF cell cultures were transferred on ice and cell cultures were washed with ice-cold 
PBS. Cells were scraped in PBS and pellet at 1000rpm at 4°C for 10min. Removing any 
excess PBS, cells were lysed in cell lysis buffer containing 1X complete protease 
inhibitor, for 1h. Cells were then syringe and needle lysed to be broken up into viscous 
lysate. Lysate was spun down at 13000rpm at 4°C for 10min and supernatants were 
collected. Lysate was normalised to ensure an equal amount of protein loaded to each 
sample using the bicinchoninic acid (BCA) method by Pierce biotechnology. 
2.2.11 Preparation of poly-l-lysine coated plates 
Coverslips were washed with 1XPBS and etched with 50% HCl (v/v) for 1h at 60˚C. Post 
etching coverslips were washed three times with 1X PBS and placed in tissue culture 
plates. Then Poly-l-lysine (Sigma) 1mg/ml stock (1000μg/ml) was diluted down (with 
sterile-filtered water) to either 100μg/ml (1/10 dilution) or 200μg/ml (1/5 dilution). 
Next 2ml of diluted poly-l-lysine was added to cover the coverslips for 1h at room 
temperature. Excess poly-l-lysine was collected and was re-used up to 3 times. Plates 
were washed three times with sterile-filtered water. Finally plates were allowed to dry 





2.2.12 Immunoprecipitation of proteins from cellular extracts 
Equivalent concentrations of lysates (for exogenously expressed proteins 200-500μg of 
protein lysate and for endogenously expressed proteins 1000μg of protein lysate) were 
pre-cleared for 1h at 4°C with 25μl Protein-G sepharose beads. Pre-cleared lysates 
were immunoprecipitated for 2h at 4°C with 2-5μg of the indicated antibody followed 
by incubation with 25μl Protein-G sepharose beads overnight. Immunoprecipitates 
were then washed three times in 500mM NaCl lysis buffer followed by two washes in 
150mM NaCl lysis buffer. Samples were resolved by 10% or 12% SDS-PAGE, transferred 
to nitrocellulose membrane and visualised as outlined in 2.2.13. 
2.2.13 Immunoprecipitation of proteins from cellular extracts for 
ubiquitination assay 
Cell cultures were washed twice in ice-cold PBS and detached from plates by gentle 
scraping in 1ml PBS-EDTA (0.5mM). The resulting suspensions were transferred into 
1.5ml eppendorf and a sample removed for lysis and western blot analysis. The rest of 
the cells were harvested by spinning at 1000rpm for 5min at 4°C. Pellets were 
resuspended in 250μl 1% (w/v) sodium dodecyl sulphate (SDS) containing 15mM N-
ethylmaleimide (NEM) and protease inhibitors and boiled for 5min on a heating block. 
Following cooling on ice, an equal volume of ice-cold covalent buffer (50mM Tris (pH 
8.0), 150mM NaCl, 1% Triton, 0.5% sodium deoxycholate, 15 mM NEM and protease 
inhibitors) was added, lysate was mixed and spun at top speed at 4°C for 20min. The 
pellet was removed and lysates quantified using the BCA method as previously 
described. Samples were then subjected to immunoprecipitation with indicated 
antibodies as described previously, except that Protein-G sepharose beads were 






2.2.14 Western blotting 
Equivalent concentrations of lysates were denatured by addition of SDS loading buffer 
and boiling for 5min on a heating block. However when blotting for PS1 or PS2, the 
boiling step was omitted as boiling PS1 or PS2 disrupts the epitope-antibody 
recognition site. Similarly, washed Protein G beads were boiled in SDS loading buffer 
and boiled for 5min on a heating block. Samples were resolved on 10% (w/v) or 12% 
(w/v) SDS-PAGE gels, transferred to nitrocellulose membrane (Schleicher and Schuell 
Bioscience). Following transfer, membranes were blocked for 1h at room temperature 
in 5% (w/v) marvel milk/PBS-Tween 0.1% (v/v). Primary antibodies were diluted as 
outlined in Appendix 5, either in 5% (w/v) milk or 3% BSA in TBS-Tween 0.1% (v/v) and 
incubated shaking at 4°C overnight. Membranes were washed three times in TBS-
Tween for 10min each and incubated in diluted secondary antibody for 1h at room 
temperature. Following washing, proteins were detected with the Licor Odyssey 
Infrared Imaging System for Licor antibodies; ECL illumination kit was used for HRP 
conjugated antibodies. 
2.2.15 ELISA for sTNFR1 
HEK293T cells were transfected by calcium phosphate precipitation with indicated 
constructs. Thirty-six hours after transfection, cell culture medium was collected for 
ELISA analysis and cells were subjected to western blotting. An ELISA kit (Invitrogen) 
for sTNFR1 was purchased from Invitrogen. ELISA analyses were carried out according 
to the manufacturer’s protocol. 
2.2.16 Flow Cytometry 
Cells growing in the tissue culture plates were washed twice with ice cold PBS before 
detaching with PBS/10μM EDTA solution. Cells were re-suspended in 5ml of PBS with 





cells were re-suspended in 100µl of primary antibody diluted with PBSA, and incubated 
for 1h on ice.  Cells were washed with 1ml of PBSA followed by centrifugation at 
1000rpm, 4˚C for 5min. 100µl of secondary antibody diluted with PBSA was added, and 
incubated 30min on ice in dark. Cells were washed twice with 1ml of PBSA, and 
centrifuged at 1000rpm, 4˚C for 5min. Cells were then re suspended in 200-500µl of 
1% paraformaldehyde (PFA) for analysis.  
2.2.17 Immunostaining for cultured cells 
For immunostaining, cells were cultured in 6-well plates on coverslips coated with 
poly-l-lysine, under specific growth conditions.  
Extracellular antigen staining 
For extracellular antigens, cells were treated with 100µl of primary antibody diluted 
with PBSA, and incubated for 1h on ice.  After washing twice with 1ml of PBSA, 100µl 
of secondary antibody diluted with PBSA was added. Cells were incubated for 30min 
on ice, and washed twice with 1ml of PBSA. Nuclei were counterstained with 1:1000 
diluted DAPI/PBS for 20min at room temperature, in dark. Coverslips were mounted 
on glass slides using prolong gold antifade (Invitrogen). The images were recorded by 
confocal microscope (Olympus Fluoview confocal microscope system) and analysed 
using Olympus Fluoview 6 software 
Intracellular antigen staining 
For cytoplasmic antigens, PFA fixed cells were permeabilized with 0.2% Triton X-100 
supplemented with 0.5% BSA with or without 5% normal goat serum for 30min at 4°C. 
100µl of primary antibody diluted with supplemented 0.2% Triton X-100 was added to 
the cells, and incubated for 2h on ice.  Cells were washed with 1ml of 0.2% Triton X-





supplemented 0.2% Triton X-100, on ice in dark. Cells were washed twice with 1ml of 
supplemented 0.2% Triton X-10. Nuclei were counterstained with 1:1000 diluted 
DAPI/PBS for 20min at room temperature in dark. Mounting and imaging of the 
samples was performed as described in extracellular antigen staining section. 
Nuclear antigen staining 
For nuclear antigens, cells were permeabilized with 100% methanol at -20°C for 10min, 
followed by blocking in 0.2% Triton X-100 supplemented with 0.5% BSA with or 
without 5% normal goat serum for 30min at 4°C. 100µl of primary antibodies diluted 
with supplemented 0.2% Triton X-100 was added, and incubated for 2h on ice. Cells 
were washed with 1ml of supplemented 0.2% Triton X-100, followed by incubation 
with 100µl secondary antibodies diluted with supplemented 0.2% Triton X-100, for 
60min on ice in dark. Cells were washed twice with 1ml supplemented 0.2% Triton X-
100. Nuclei were counterstained with 1:1000 diluted DAPI/PBS for 20min at room 
temperature in dark. Mounting and imaging of the samples was performed as 
described in extracellular antigen staining section. 
2.2.18 Subcellular fractionation 
After the indicated treatments, cells were washed with ice cold PBS and scraped in 1ml 
of PBS. The cells were pellet at 1000rpm at 4˚C for 5min. Cell pellet was lysed in 1ml of 
buffer I and homogenized by passage through a 16.5 gauge needle. Nuclei were spun 
down at 3000rpm for 10min. The resulting supernatant obtained containing plasma 
membrane and cytoplasmic fraction. It was either subject to sucrose gradient 
fractionation to isolate early and late endosome or isolate cytosolic, nucleic and 





Sucrose gradient fractionation 
The supernatant obtained above was laid at the bottom of an ultracentrifuge tube. To 
form a discontinuous sucrose gradient, lysis buffer containing 0.25M (900μl), 0.5M 
(500μl), 0.8M (300μl), 1.16M (1500μl), 1.3M (1500μl), and 2M (300μl) sucrose were 
sequentially laid over the homogenate. The samples were ultracentrifuged at 100,000g 
in a Beckman table top ultracentrifuge swinging rotor SW55 at 4°C for 14-16h. Fifteen 
0.3ml fractions were collected from top to bottom of the gradient sample. Equal 
volumes (48µl) of each fraction and 12μl of 5X sample buffer were subjected to 
western blot analysis. These immunoblot was then probed with antibodies for each 
organelle marker- plasma membrane (Na+/K+ ATPase), cytosol (β-tubulin/GAPDH), 
early endosome (EEA1), late endosome (LAMP1), trans-golgi network (TGN-38), 
nucleus (Histone 2b) and endoplasmic reticulum (PDI). The fractions for early 













Cytosolic, nucleic and plasma membrane fractionation 
After the indicated treatments, cells were washed with ice cold PBS and lysed in buffer 
I and homogenized by passage through a 16.5 gauge needle. Nuclei were spun down at 
3000rpm for 10min, and the resulting supernatant was then microfuged at 40,000rpm 
for 60min at 4°C. The supernatant was removed (cytosol), and buffer containing 1% 
Triton X-100 was added to the pellet (membrane). Nuclear proteins were extracted in 
buffer II.  
 
 





2.2.19 Statistical Analysis 
Quantitative data are shown as mean ± SEM from three independent experiments 
unless indicated otherwise. Statistical analysis was performed using GraphPad PRISM 
5.0 (GraphPad Software, La Jollla, CA). A value of p<0.05 was considered statistically 







Subcellular localization of the ectodomain 
shedding and γ-secretase-mediated 







The γ-secretase protease complexes and associated regulated intramembrane 
proteolysis play an important role in controlling receptor-mediated intracellular 
signalling events, which have a central role in AD, cancer progression and immune 
surveillance. Previously our group reported that IL-1R1 undergoes PMA-induced 
metalloprotease-mediated ectodomain shedding followed by γ-secretase-mediated 
regulated intramembrane proteolysis. Furthermore we showed that defective γ-
secretase activity alters IL-1β-mediated IL-6 production (Elzinga et al., 2009). 
Additionally, using ADAM10 and ADAM17 specific inhibitors, and embryonic fibroblasts 
from ADAM10-/- and ADAM17-/- knockout mouse, we demonstrated that ADAM17 
mediates the ectodomain cleavage event of IL-1R1 (unpublished). 
ADAM17 was initially characterized as the TNFα converting enzyme (TACE) and has 
over 70 substrates (Dreymueller et al., 2012; Moss et al., 1997). ADAM17-/- mice die 
shortly after birth with open eyelids and defects in epithelial maturation of multiple 
organs, along with several skin and hair abnormalities (Peschon, 1998). A number of 
ADAM17 substrates are anti- or pro- inflammatory receptors including: TNFR1, TNFR2, 
IL1-R2, CD40, and CD163 (Edwards et al., 2008; Weber et al., 2012). Various groups 
studying the ADAMs have been targeting ADAM17, along with other ADAM family 
members, using pharmacological inhibitors and gene knock-out approaches to 
attenuate inflammatory responses in animal models (Dreymueller et al., 2012). The 
biggest limitation of this approach has been the promiscuity of ADAMs with respect to 
their substrates, where a single ADAM can target multiple proteins (Crowe et al., 1995; 
Mullberg et al., 1995; Bennett TA et al., 1996; Coodly, 1996; Moss et al., 1997; 
Buxbaum, 1998), as well as a single protein can be targeted by multiple ADAMs 
(Dreymueller et al., 2012). Thus, it is important to study the specific subcellular 
localization of these cleavage events and the basis of their substrate specificities to 





IL-1R1 belongs to the IL-1R superfamily members defined by their common 
homologous cytoplasmic TIR domain and the repeated extracellular Ig domains. Upon 
IL-1β binding, IL-1R1 associates with IL-1RAcP, which leads to the recruitment of the 
adaptor proteins and the activation of downstream signalling cascades (Subramaniam 
et al., 2004). Although many studies have been carried out to understand the functions 
of IL-1R1 signalling complexes and the exact role played by the adaptor proteins, the 
subcellular occurrence and recruitment of these adaptor proteins remains elusive. 
Amongst the IL-1R1 adaptor proteins, TRAF6 has been shown to indirectly regulate a 
number of IL-1 superfamily members. For instance, TRAF6 is recruited to the IL-1 
receptor complex, via its interaction with MyD88 or IRAK leading to NF-кB activation. 
Its role is also highlighted by the studies carried out in TRAF6-/- mice which are 
defective in IL-1-mediated signalling (Lomaga et al., 1999). 
A role for TRAF6 in regulated intramembrane proteolysis of IL-1R1 is also highlighted as 
TRAF6-mediated ubiquitination positively modulates regulated intramembrane 
proteolysis of IL-1R1 (Twomey et al., 2009). The role played by TRAF6 in IL-1R1 
signalling is well characterized, however the role played by TRAF6-mediated 
ubiquitination of IL-1R1 is not known. In this regard, the involvement of TRAF6 in 
mediating the ubiquitination of IL-1R1 and its regulated intramembrane proteolysis, 
co-relates the post-translational modification of IL-1R1 with the adaptor proteins 
involved in the signalling cascade. This is supported by the observation that IL-1R1 
undergoes monoubiquitination upon IL-1β stimulation, promoting its internalization 
which is subsequently poly-ubiquitinated and interacts with two ubiquitin-binding 
proteins, Tollip and Tom1, which modulate sorting of IL-1R1 from late endosome to 
lysosome for degradation (Brissoni et al., 2006). Thus, indicating the role of IL-1R1 
ubiquitination in mediating trafficking and signalling events. We hypothesize that 
TRAF6-mediated ubiquitination could play an important role in co-relating trafficking, 





Ectodomain shedding and regulated intramembrane proteolysis is tightly regulated 
cleavage events. Recent studies reflect their importance on trafficking and degradation 
of substrates thus regulating the signalling cascades. However nothing is known about 
the subcellular location for ectodomain shedding and regulated intramembrane 
proteolysis of IL-1R1 or its regulation.  
The aims of the research presented in this chapter are- 
1. To determine the subcellular location of ectodomain shedding and γ-secretase-
mediated cleavage of IL-1R1. 
2. To study the role played by TRAF6-mediated ubiquitination of IL-1R1 in regulated 
intramembrane proteolysis. 
3. To determine the fate of the IL-1R1 ICD generated following γ-secretase 
cleavage. 
4. Given that, IL-1R1, IL-1R2, and IL-6 are all characterized substrates for γ-
secretase-mediated regulated intramembrane proteolysis, we determined whether or 






3.2.1 IL-R1 is a substrate for γ-secretase-mediated proteolysis  
To examine the expression of IL-1R1 and verify that it undergoes PMA-induced 
ectodomain shedding and subsequent γ-secretase-mediated cleavage, the broad 
spectrum pharmacological inhibitor of γ-secretase, was used. It is a non-competitive, 
non-transition state analogue inhibitor which overlaps with the active site of γ-
secretase (Kornilova et al., 2003). HEK293T cells were transiently transfected with IL-1-
R1 and forty hours post-transfection cells were pre-treated with DAPT (10μm/ml; 8h) 
or DMSO as a vehicle control in serum-free media. Cells were subsequently treated 
with PMA (200ng/ml; 2h), alone or in combination with DAPT. The cleavage profile of 
IL-1R1 was examined by immunoblotting with C-terminus specific anti-IL-1R1 antibody 
(IL-1R1 C20). Immunoblot analysis revealed that IL-1R1 undergoes constitutive and 
PMA-induced proteolytic cleavage as evident from the detection of two proteolytic 
fragments, which based on previous data (Elzinga et al., 2009) correspond to IL-1R1 
CTF and IL-1R1 ICD (Figure 3.1 lane 1 & 2). The γ-secretase inhibitor, DAPT, completely 
suppresses the formation of IL-1R1 ICD, (Figure 3.1 lane 3 & 4), suggesting that it is 
indeed the product of γ-secretase-mediated cleavage of IL1-R1 CTF, a parallel 
increased accumulation of IL-1R1 CTF is also observed. Thus, confirming the expression 
of the exogenous IL-1R1 and its responsiveness to PMA and γ-secretase protease 







Figure 3.1 IL-R1 is a substrate γ-secretase-mediated cleavage  
Immunoblot of cell lysates from HEK293T cells transiently transfected with IL-1R1. Cells 
were pre-treated with the γ-secretase inhibitor DAPT (10mM/ml; 8h) alone or in 
combination with PMA (200ng/ml; 2h) as indicated in the figure. C-terminus specific 
anti-IL-1R1 C20 antibody was used to assess cleavage profile of the receptor. The data 





3.2.2 Ectodomain shedding is a pre-requisite for γ-secretase-mediated generation of 
IL-1R1 ICD 
All the known γ-secretase substrates have been shown to undergo ectodomain 
shedding as a pre-requisite to γ-secretase-mediated cleavage (Haapasaloa et al., 2012). 
Next, using a TACE specific hydroxamate based metalloprotease inhibitor, TAPI, we 
studied the importance of IL-1R1 ectodomain shedding in its γ-secretase-mediated 
cleavage.  
HEK293T cells were transiently transfected with IL-1R1 and forty hours post-
transfection cells were pre-treated with TAPI, (50μM/ml; 2h) in serum-free media, and 
subsequently treated with PMA (200ng/ml; 2h) to induce ectodomain shedding. 
Immunoblot analysis of IL-1R1 cleavage profile in untreated and PMA-treated cells 
revealed that TAPI inhibits both constitutive and PMA-induced ectodomain shedding 
and formation of the IL-1R1 CTF (Figure 3.2 compare lane 1, 2 with lane 3, 4 
respectively), and a simultaneous reduction in the generation of IL-1R1 ICD is also 
observed (Figure 3.2 lane 3). This data suggests that ectodomain shedding is a pre-







Figure 3.2 IL-1R1 ectodomain shedding is a pre-requisite for γ-secretase-mediated 
cleavage  
Immunoblot of cell lysates from HEK293T cells transiently transfected with IL-1R1 and 
pre-treated with the broad spectrum metalloprotease inhibitor TAPI (50μM/ml; 2h), 
alone or in combination with PMA (200ng/ml; 2h) as indicated. C-terminus specific 
anti-IL-1R1 C20 antibody was used to assess cleavage profile of the receptor. The data 






3.2.3 IL-1R1 internalization is required for IL-1β and PMA-induced ectodomain 
shedding 
Having shown that ectodomain shedding precedes cleavage by γ-secretase protease 
complex, we next wanted to determine the subcellular location for this cleavage event. 
Following ligand binding, IL-1R1 undergoes clathrin-mediated internalization, which is 
critical for IL-1 induced gene expression (Hansen et al., 2013). Thus, using both 
pharmacological and genetic approaches, IL-1R1 internalization was inhibited to 
determine whether ectodomain shedding of IL-1R1 occurs on the cell surface or post-
receptor-internalization. Dynamin is a small GTPase required for the delivery of 
proteins from the clathrin- and caveolin-coated vesicles formed at the plasma 
membrane to early endosomes (Hinshaw., 2002). In this context, dynasore a 
noncompetitive inhibitor of dynamin GTPase activity that blocks dynamin-dependent 
endocytosis (Macia et al., 2006) and dynamin K44A mutant (Dyn-DN) with low affinity 
for guanylnucleotides and defective in receptor internalization (E. Lee et al., 2001) 
were used in our studies.  
3.2.3.1 Pharmacological inhibition of internalization 
HEK293T cells were transiently transfected with IL-1R1 and forty hours post-
transfection, cells were pre-treated with dynasore (50μM/ml; 2h) or DMSO as a vehicle 
control in serum-free media followed by IL-1β (50ng/ml; 1h or 2h) treatment. 
Immunoblot analysis revealed both constitutive and IL-1β induced increase in IL-1R1 
CTF formation (Figure 3.3 lane 2 & 4), which is inhibited in the presence of dynasore 
(Figure 3.3 lane 3 & 5). To verify that dynasore is indeed inhibiting IL-1R1 
internalization, RAW264.7 cells were analyzed for IL-1β induced internalization of IL-
1R1. RAW264.7 cells were grown on coverslips up till 70% confluency following which 





serum-free media. Subsequently cells were stimulated with IL-1β (30ng/ml; 1h or 3h) 
and stained for either cell surface IL-1R1 or total IL-1R1. 
For analysis of cell surface levels of IL-1R1, cells grown on coverslips were stained with 
an N-terminus specific anti-IL-1R1 antibody (IL-1R1 N20), followed by staining with the 
anti-rabbit-Alexa Fluor-488; DAPI was used to stain the nucleus. The coverslips were 
then mounted on a glass slide and analysed using confocal microscopy. To determine 
the levels of total IL-1R1 in cells, cells grown on coverslips were first fixed with 4% PFA 
and then permeabilized using 0.1% Triton X-100 in 3% BSA for 2h. Cells were then 
stained using an N-terminus specific anti-IL-1R1 antibody, followed by staining with 
anti-Alexa Fluor-488. Samples were imaged using Olympus Fluoview confocal 
microscope and analysed using Fluoview FV 1000 software. While the cells treated 
with IL-1β show decreased levels of cell surface staining for IL-1R1, dynasore treated 
cells upon stimulation with IL-1β show no decrease in the cell surface levels of IL-1R1 
Figure 3.4.  
This data demonstrates that inhibiting IL-1R1 internalization negatively affected TACE-
mediated ectodomain shedding of IL-1R1, indicating that IL-1R1 internalization 






Figure 3.3 Inhibiting internalization inhibits ectodomain shedding of IL-1R1 
Immunoblots of cell lysates from HEK293T cells transiently transfected with IL-1R1 and 
treated as indicated. C-terminus specific anti-IL-1R1 C20 antibody was used to assess 








Figure 3.4 Ectodomain shedding is a pre-requisite to γ-secretase-mediated cleavage 
of IL-1R1   
RAW264.7 cells were treated with dynasore alone or dynasore and IL-1β for indicated 
time. Cells were then stained for cell surface IL-1R1 or after permeabilization for total 
IL-1R1 with anti-IL-1R1 N-terminus antibody. Samples were imaged using Olympus 
fluoview confocal microscope and analysed using Fluoview FV 1000 software. Green: 





3.2.3.2 Dynamin K44A mutant reduces PMA-induced ectodomain shedding of 
IL-1R1 
HEK293T cells were transiently transfected with IL-1R1 and co-transfected with either 
empty vector or dynamin K44A mutant (Dyn-DN), forty hours post-transfection cells 
were treated with PMA (200ng/ml) to induce ectodomain shedding of IL-1R1. 
Immunoblot analysis revealed that while constitutive and PMA-induced formation of 
IL-1R1 CTF and ICD are seen in cells transfected with IL-1R1 (Figure 3.5 a lane 1 & 2), 
co-expression of Dyn-DN inhibited PMA-induced IL-1R1 CTF formation but did not 
affect constitutive ectodomain shedding of IL-1R1 and generation of IL-1R1 CTF (Figure 
3.5 compare lane 3 &4). To validate the functionality of the Dyn-DN as an inhibitor of 
IL-1R1 internalization, cell surface levels of IL-1R1 in untreated and PMA treated cells 
were analysed. HEK293T cells were grown on coverslips and transfected with IL-1R1 
and co-transfected with either empty vector or Dyn-DN, and forty hours post-
transfection cells were either left untreated or stimulated with PMA (200ng/ml; 2h). 
Cells were then stained with anti-IL-1R1 N20 antibody followed by anti-rabbit Alexa 
Fluor-488 antibody; DAPI was used to stain the nucleus. Samples were imaged using 
Olympus Fluoview confocal microscope and analysed using Fluoview FV 1000 software. 
Cells treated with PMA show punctate red staining for IL-1R1 in the cytoplasm, 
suggesting internalization of the receptor as indicated with the arrows (Figure 3.5 left 
panels). In contrast, in cells expressing Dyn-DN, IL-1R1 staining was observed primarily 
at the cell surface in both untreated and PMA-treated cells, demonstrating that Dyn-
DN blocked the internalization of IL-1R1 as indicated with the arrows (Figure 3.5 right 
panels). This data demonstrates that Dyn-DN inhibits PMA-induced ectodomain 







Figure 3.5 Dynamin K44A mutant reduces PMA-induced IL-1R1 ectodomain shedding 
(a) Immunoblots of cell lysates from HEK293T cells transiently transfected with IL-1R1 
and either empty vector or Dyn-DN. At forty hours post-transfection cells were treated 
with PMA (200ng/ml; 2h) or DMSO as a vehice control in serum-free media. (b) Cells 
co-expressing IL-1R1 and empty vector or dynamin DN, were grown on coverslips. At 
forty hours post-transfection cells were treated with PMA and stained with anti-IL-1R1 
antibody followed by anti-rabbit Alexa Fluor-488. Samples were analysed using 
Olympus fluoview confocal microscope and fluoview FV1000 software. Red: IL-1R1; 






3.2.4 IL-1R1 ectodomain shedding occurs in the endosomes 
To complement the data obtained from inhibiting clathrin-mediated receptor 
internalization, the subcellular location of TACE-mediated ectodomain shedding was 
examined using cells over-expressing Rab5 proteins. Rab proteins belong to a 
superfamily of small molecular weight GTPases known to be associated with 
membrane trafficking. Rab5 protein mediates the fusion of endocytic vesicles and 
trafficking to the early endosomes (Stenmark et al., 2001). Using wild-type (WT), 
dominant active (DA) and dominant negative (DN) Rab5 mutants, the role of 
internalization and trafficking was studied for the ectodomain shedding of IL-1R1.  
HEK293T cells were transfected with IL-1R1 and co-transfected with Rab5 WT, Rab5 DN 
or Rab5 DA constructs; forty hours post-transfection cells were treated with PMA 
(200ng/ml; 2h) in serum-free media to promote ectodomain shedding and formation 
of IL-1R1 CTF and ICD. Immunoblot analysis revealed that expression of Rab5 DN, 
inhibited PMA-induced formation of IL-1R1 CTF and IL-1R1 ICD (Figure 3.6 Figure 3.a 
compare lane 3 & 4). On the other hand expression of Rab5 DA led to increased 
formation of IL-1R1 CTF and IL-1R1 ICD(Figure 3.6 a compare lane 1 & 2 with lane 5 & 
6). This data shows that, Rab5 DN inhibits PMA-induced IL-1R1 CTF formation while the 
Rab5 DA, enhances the PMA-induced formation of both IL-1R1 CTF and ICD.   
Simultaneous immunoflourescence analysis was done to check the efficacy of the Rab5 
DN and Rab5 DA mutants employed in the study. HEK293T cells were grown on 
coverslips and transfected with IL-1R1 and co-transfected with Rab5 WT, Rab5 DN, or 
Rab5 DA as indicated in Figure 3.6 b; forty hours post-transfection cells were treated 
with PMA (200ng/ml; 2h) in serum-free media. Cells were then fixed, permeabilized 
and stained using N-terminus specific anti-IL-1R1 antibody. The immunofluorescence 
analysis revealed that Rab5 DN prevented PMA-induced trafficking of IL-1R1 to the 





in the sorting endosomes and a simultaneous increase in the accumulation of the 
unfused endocytic vesicle (Figure 3.6). This is indicated by increased formation of 
circular vesicles and increased co-staining of IL-1R1 and Rab5 positive vesicles seen in 
yellow after PMA treatment with no change in cell surface level of IL-1R1 (indicated 
with the arrows). Co-localization of IL-1R1 and endocytic vesicles was either decreased 
or absent in cells co-transfected with Rab5 WT or Rab5 DA respectively (indicated with 
the arrows) (Figure 3.6b). This data shows that Rab5 DN prevents trafficking of IL-1R1 
from sorting endosomes to early endosomes, thus inhibiting PMA-induced ectodomain 









Figure 3.6 IL-1R1 ectodomain shedding occurs in the endosomes  
(a) Immunoblot of cell lysates from HEK293T cells transiently transfected with IL-1R1 
and either Rab5 WT, Rab5 DN or Rab5 DA. At forty hours post-transfection cells were 
treated with PMA (200ng/ml; 2h) in serum-free media. Anti-IL-1R1 C20 antibody was 
used to assess cleavage profile of the receptor. (b) Cells grown on coverslips and co-
expressing IL-1R1 and either empty vector or Rab5 WT, Rab5 DN or Rab5 DA, were 
stimulated with PMA and stained with anti-IL-1R1 antibody and stained using Alexa 
Fluor 594. Samples were analysed using Olympus fluoview confocal microscope and 
fluoview FV1000 software. Red: IL-1R1; Green: Rab5 positive vesicles; Yellow: Co-







3.2.5 Mapping the IL-1R1 internalization site 
Next, to further characterize the role played by IL-1R1 ectodomain shedding, canonical 
internalization motifs known to mediate clathrin-dependent receptor internalization 
were mapped. In this context, four highly conserved tyrosine-based sorting signals 
*YXXφ+ were found in IL-1R1 extracellular and the cytoplasmic domain(Figure 3.7). The 
tyrosine residues in the motif are known to be responsible for receptor endocytosis. 
Two of these motifs were in the extracellular domain, while the other two were 
present in the ICD. Previous studies have shown that IL-1R1 lacking the cytoplasmic 
domain still binds to IL-1β and undergoes internalization, thus showing that the ICD of 
IL-1R1 is dispensable for its internalization. Therefore, residues W262 and Y278 in the 
IL-1R1 extracellular domain were mutated to alanine and the mutants were 






Figure 3.7 Mapping the internalization motif for IL-1R1 
(a) Alignment of receptors with known internalization motifs and IL-1R1. (b) Schematic 
representation of the four IL-1R1 amino acids which are tentative residues involved in 





3.2.6 IL-1R1 W262A mutant is defective in ectodomain shedding 
HEK293T cells were transfected with wild-type IL-1R1, IL-1R1 W262A or IL-1R1 Y278A 
mutants and forty hours post-transfection cells were treated with PMA (200ng/ml; 2 h) 
and processed for western blot analysis. In cells expressing wild-type IL-1R1 or IL-1R1 
Y278A mutant, IL-1R1 underwent both constitutive and PMA-induced regulated 
intramembrane proteolysis, as determined by clear detection of IL-1R1 CTF and ICD 
(Figure 3.8a). In contrast, IL-1R1 W262A mutant was defective in both constitutive and 
PMA-induced regulated intramembrane proteolysis and abolished formation of both 
IL-1R1 CTF and IL-1R1 ICD (Figure 3.8 a lane 3 and 4). To validate that the IL-1R1 
W262A mutant was defective in receptor internalization, cell surface levels of IL-1R1 
W262A in untreated and PMA treated cells was analysed. HEK293T cells were grown 
on coverslips and transfected with either wild-type IL-1R1 or IL-1R1 W262A mutant, 
and forty hours post-transfection cells were either left untreated or stimulated with 
PMA (200ng/ml; 2h). Cells were then stained with anti-IL-1R1 N20 antibody followed 
by anti-rabbit Alexa Fluor-488 antibody; DAPI was used to stain the nucleus. Samples 
were imaged using Olympus Fluoview confocal microscope and analysed using 
Fluoview FV 1000 software. Cells treated with PMA show punctate red staining for IL-
1R1 in the cytoplasm, suggesting internalization of the receptor (Figure 3.8 b left 
panels). However, in cells expressing IL-1R1 W262A mutant, IL-1R1 staining was only 
observed at the cell surface in untreated and PMA-treated cells, suggesting that IL-1R1 
W262A mutant is defective in internalization (Figure 3.8b right panels). 
 Due to differences between the expression levels of wild-type IL-1R1 and IL-1R1 
W262A mutant the immunofluorescence results were not distinctly clear, though it 
was still evident that the IL-1R1 W262A mutant localized on the cell surface post PMA 
treatment. Collectively, this data demonstrates that the W262 residue is required for 






Figure 3.8 IL-1R1 W262A is defective in ectodomain shedding 
(a) Immunoblot analysis of whole cell lysates from HEK293T cells transiently 
transfected with wild-type IL-1R1, IL-1R1 W262A and IL-1R1 Y278A. Blots were 
analysed using C-terminus specific anti-IL-1R1 antibody. (b) Cells expressing wild-type 
IL-1R1 and IL-1R1 W262A were grown on coverslips. At forty hours post-transfection 
cells were treated with PMA and stained with anti-IL-1R1 antibody followed by anti-
rabbit Alexa Fluor-488. The data represents increased detection of IL1R1 within in the 
cytosol in PMA treated IL1R1 expressing cells, which is decreased in IL1R1 W262A 
expressing cells. Samples were analysed using Olympus fluoview confocal microscope 
and fluoview FV1000 software.  Green: IL-1R1; Blue: DAPI The data is representative of 






3.2.7 IL-1R1 ICD undergoes proteasomal degradation 
The results so far demonstrates that preventing the trafficking of IL-1R1 to late 
endosomes, leads to increased formation of the IL-1R1 ICD. However, inhibiting 
trafficking to late endosome, in turn inhibits subsequent trafficking to the lysosome. 
Thus, it still remains unclear if increased IL-1R1 ICD formation is attributed to the 
subsequent defect in trafficking of IL-1R1 from late endosome to lysosome, which in 
turn inhibits its degradation. Thus, specific inhibitors for both lysosomal and 
proteasomal degradation were employed in this study. HEK293T cells were transfected 
with IL-1R1, and forty hours post-transfection, cells were pre-treated with epoximicin: 
a proteasomal inhibitor (10μM/ml; 2h) and concanamicin: a lysosomal inhibitor 
(50μM/ml; 2h) in serum-free media, following which the cells were treated with PMA 
(200ng/ml; 2h). Increased accumulation of IL-1R1 CTF and ICD in epoximicin treated 
cells was seen ((Figure 3.9 lanes 3 & 4), in contrast concanamicin treatment led to 
increased accumulation of the IL-1R1 full length and IL-1R1 CTF ((Figure 3.9 lanes 5 & 






Figure 3.9 IL-1R1 CTF is regulated by both lysosomal and proteasomal degradation 
pathway; IL-1R1 ICD undergoes proteasomal degradation 
Immunoblot of cell lysates from HEK293T cells transiently transfected with IL-1R1 and 
pre-treated with either epoximicin (10μM) or concanamicin A (50μM) for 2 hours. 
Following pre-treatment the cells were treated with PMA (200ng/ml; 2h). C-terminus 
specific anti-IL-1R1 C20 antibody was used to assess cleavage profile of the receptor. 






 3.2.8  TRAF6-mediated ubiquitination of IL-1R1  
3.2.8.1 TRAF6-mediated IL-1R1 ubiquitination occurs post-internalization 
Previously our group showed that IL-1R1 is a substrate for TRAF6-mediated 
ubiquitination and also that the E3 ligase activity of TRAF6 enhances regulated 
intramembrane proteolysis of IL-1R1 (Twomey et al., 2009). Interestingly, TRAF6 is 
recruited to the IL-1R1 signalling complex in the early endosome (Li et al., 2006), and is 
required for association of IL-1R1 signalling complex with IRAK1 and also for the 
recruitment of TAK1 complex by facilitating K63-linked polyubiquitination on the 
substrates or itself (Cao et al., 1996; Deng et al., 2000; Ninomiya-tsuji et al., 1999). The 
data obtained so far demonstrates that IL-1R1 ectodomain shedding also occurs on the 
early endosome. Based on these observations, we studied the mechanism through 
which TRAF6-mediated ubiquitination of IL-1R1 enhances its regulated intramembrane 
proteolysis by firstly determining the type of ubiquitination mediated by TRAF6 and 
additionally looking at whether TRAF6-mediated ubiquitination of IL-1R1 occurs on the 
cell surface or the endosome i.e., prior to- or post- IL-1R1 ectodomain shedding.  
HEK293T cells were transiently transfected with IL-1R1, TRAF6 and co-transfected with 
HA tagged Ubiquitin (HA-Ub) to study the effect of TRAF6 on IL-1R1 ubiquitination and 
regulated intramembrane proteolysis. To further characterize the type of 
ubiquitination mediated by TRAF6, cells were alternatively co-transfected with HA-
tagged ubiquitin with lysine residue numbered 63 mutated to arginine (HA-Ub K63R) 
not capable of undergoing lysine 63 linked polyubiquitination. Additionally to 
determine the subcellular occurrence of TRAF6-mediated ubiquitination of IL-1R1, Dyn 
DN which prevents internalization of IL-1R1 was also included in this study. Cells were 





lysed and immunoblotted with respective antibodies to confirm the expression of 
constructs and equivalency of loading.  
After confirming the equivalent expression of the various plasmids, cells were lysed 
under stringent SDS-denaturing conditions. IL-1R1 was immunoprecipitated with a C-
terminus specific anti-IL-1R1 antibody followed by western blotting with anti-HA or 
anti-IL-1R1 antibody to detect ubiquitinated-IL-1R1 and IL-1R1 respectively. As 
expected, TRAF6 enhanced regulated intramembrane proteolysis of IL-1R1 
demonstrated by increased levels of IL-1R1 CTF and ICD ((Figure 3.10 lane 3 lower 
panel). Also, this data demonstrates that IL-1R1 undergoes TRAF6-mediated K63-linked 
ubiquitination post-internalization, since there was no difference in the ubiquitination 
pattern of the full length IL-1R1 in presence of internalization inhibitor mutant Dyn-DN 
and the K63R mutant ((Figure 3.10 lane 4 & 7). Collectively this data demonstrates 














Figure 3.10 TRAF6-mediated ubiquitination of IL-1R1 occurs post-internalization 
HEK293T cells were transfected with wild-type IL-1R1 and co-transfected with HA-Ub 
or HA-Ub K63R and TRAF6 and Dyn K44A. Forty hours post-transfection cells were 
harvested under stringent SDS denaturing condition and then subjected to 
immunoprecipitation for IL-1R1 and Western blot for HA-Ub. Ubiquitinated IL-1R1 full-






3.2.8.2 IL-1R1 K360/378/383R mutant is defective in TRAF6-induced IL-1R1 
ectodomain shedding 
In an independent study carried out in our group, TRAF6-mediated ubiquitination of IL-
1R1 was shown to occur between amino acids 357 and 390 in the cytosolic domain of 
IL-1R1 (unpublished). There are four lysine residues in IL-1R1 juxtamembrane domain-
K356, K360, K378 and K383 (Figure 3.11). These residues were mutated making IL-1R1 
K360/378R, K357/360/378R and K360/378/380R double or triple lysine mutants. We 
analysed these mutants for any defect in TRAF6-mediated ubiquitination. HEK293T 
cells were transiently transfected with IL-1R1 wild-type, IL-1R1 K360/378R, IL-1R1 
K357/360/378R or IL-1R1 K360/378/380R, and co-transfected with HA-Ub and either 
empty vector or TRAF6. At forty hours post-transfection cells were lysed and 
immunoblotted with respective antibodies to confirm the expression of constructs and 
equivalency of loading (Figure 3.11b).  After confirming the equivalent expression of 
the various plasmids, cells were lysed under stringent SDS-denaturing conditions. IL-
1R1 was immunoprecipitated with a C-terminus specific anti-IL-1R1 antibody followed 
by western blotting with anti-HA or anti-IL-1R1 antibody to detect ubiquitinated-IL-1R1 
and IL-1R1 respectively. In cells expressing wild-type IL-1R1, IL-1R1 K360/378R or IL-
1R1 K357/360/378R mutant, both constitutive and TRAF6-mediated ubiquitination 
(Figure 3.11 upper panels) and regulated intramembrane proteolysis of IL-1R1 was 
evident, as IL-1R1 CTF and ICD were clearly detected (Figure 3.11 lower panels). In 
contrast, in cells expressing IL-1R1 K360/378/380R mutant, co-expression of TRAF6 
failed to increase IL-1R1 CTF ubiquitination (Figure 3.11 upper panels) and regulated 
intramembrane proteolysis of IL-1R1, and no increase in IL-1R1 CTF was detected 






Figure 3.11 IL-1R1 K360/378/383R mutant is defective in TRAF6-induced ectodomain 
shedding 
(a) Schematic representation of juxtamembrane IL-1R1 lysine residues mutated to 
arginine. (b) Immunoblot analysis of HEK293T cells transfected with wild-type IL-1R1, 
IL-1R1 lysine mutants and co-transfected with TRAF6. Forty hours post-transfection 
cells were harvested under stringent SDS denaturing condition and then subjected to 
immunoprecipitation for IL-1R1 and Western blot for HA-Ub. Ubiquitinated IL-1R1 full-






3.2.8.3 IL-1R1 K360/378/383R mutant is not defective in internalization 
Next we assessed the effect of mutagenesis of these three lysine residues on the cell 
surface localization and its PMA-induced internalization of IL-1R1. HEK293T cells were 
transfected with empty vector, wild type IL-1R1 or IL-1R1 K360/378/380R mutant; 
forty hours post-transfection, cells were treated with PMA (200ng/ml; 2h), lysed and 
analysed by western blot. Immunoblot analysis revealed that while wild-type IL-1R1 
showed both constitutive and PMA-induced accumulation of IL-1R1 CTF and ICD 
formation (Figure 3.12 a lane 1 & 2). In contrast, the IL-1R1 K360/378/383R mutant 
showed decreased levels of constitutively cleaved and PMA-induced formation of IL-
1R1 CTF (Figure 3.12 a compare lane 1 & 2 with lane 3 & 4). Interestingly, IL-1R1 ICD 
was still being formed upon PMA-stimulation (Figure 3.12 a lane 4). 
In parallel cells were grown on coverslips, transfected and treated as above. Post-
treatment cells were fixed and probed with anti-IL-1R1 antibody for cell surface 
staining. PMA treatment induced internalization of the receptor in both wild-type IL-
1R1 and IL-1R1 K360/378/383R mutant, as seen by increased number of vesicles 
indicated by punctate staining within the cell (Figure 3.12 b), clearly indicating that the 
IL-1R1 K3R mutant was not defective in internalization. The cell surface levels of wild-
type IL-1R1 and IL-1R1 K360/378/383R mutant were also studied using flow cytometry. 
HEK293T cells expressing IL-1R1 or IL-1R1 K360/378/383R mutant and treated with 
PMA (200ng/ml; 2h) were detached and incubated with anti-IL-1R1 antibody for 45 
minutes on ice. Following which the cells were incubated with secondary Alexa-Fluor-
488 antibody for 30 minutes. Levels of cell surface IL-1R1 were measured by flow 
cytometry. HEK293T cells over-expressing IL-1R1 and IL-1R1 K360/378/380R mutant 






Figure 3.12 IL-1R1 K360/378/383R mutant is not defective in internalization 
(a) Immunoblot analysis of IL-1R1 and IL-1R1 K360/378/383R mutant treated with 
PMA. (b) Immunoflourescence analysis HEK293T cells expressing IL-1R1 and IL-1R1 
K360/378/383R mutant and stimulated with PMA-to induce internalization and 
ectodomain shedding of IL-1R1. Cells were stained with anti-IL-1R1 antibody followed 
by ALexa Fluor 594. Samples were analysed using Olympus fluoview confocal 
microscope and fluoview FV1000 software. Red: IL-1R1; Blue: DAPI. (c) Cells expressing 
IL-1R1 and IL-1R1 K360/378/383R mutant were detached under nonpermeabilized 
condition and incubated with primary anti-IL-1R1 antibody for 45 minutes and 
secondary green fluorescent antibody for 30 minutes. After washings, levels of 
membrane IL-1R1 were measured by flow cytometry and are shown as histogram 





3.2.9 IL-1R1 ICD translocates to the nucleus 
Certain γ-secretase cleavage products have been shown to produce biologically active 
receptor-derived ICDs, such as those observed for the Notch and p75NTR, which 
migrate to the nucleus and regulate gene expression (Fortini, 2002; Ilagan, 2004; Koo, 
2004; Kopan, 2003). Thus, as the next step we studied the possible nuclear 
translocation of IL-1R1 ICD.  
3.2.9.1 Immunoflourescence analysis to study nuclear translocation of IL-1R1 
ICD 
HEK293T cells were transfected with IL-1R1 and forty hours post-transfection cells 
were treated with IL-1β (30ng/ml; 2h, 5h) and processed for immunofluorescence 
using C-terminus and N-terminus specific anti-IL-1R1 antibody, followed by Alexa Fluor 
488. IL-1β induced the formation of IL-1R1 CTF and IL-1R1 ICD with time (Figure 3.13 
a). In contrast, no nuclear staining for IL-R1 was seen in untreated cells or cells treated 
with IL-1β and stained with C-terminus specific anti-IL-1R1 antibody ((Figure 3.13 b). 
The ligand bound IL-1R1 is known to translocate to the nucleus (Curtis et al., 1990). 
Hence, cells were also stained with N-terminus specific anti-IL-1R1 antibody. The cells 
did not show nuclear staining for IL-1R1 (Figure 3.113 c). This data demonstrates the 
protocol or the cell system being used is not suitable. Thus, nuclear fractionation was 
carried out to check for the translocation of IL-1R1 ICD to the nucleus using PS wild-






Figure 3.13 Immunoflourescence analysis to study nuclear translocation of IL-1R1 ICD 
(a) HEK293T cells transfected with IL-1R1 and forty hours post-transfection stimulated 
with IL-1β (30ng/ml) for indicated times. Immunoblot analysis revealed ligand induced 
ectodomain shedding and formation of IL-1R1 CTF and ICD. (b) Simultaneously cells 
were stained with N-terminal and C-terminal specific anti-IL-1R1 antibodies, to 
determine nucleic staining for the IL1R1. Samples were imaged using Olympus 
fluoview confocal microscope and fluoview FV1000 software. Green: IL-1R1; Blue: DAPI 





3.2.9.2 PS1 is required for the γ-secretase-mediated formation of IL-1R1 ICD 
and its translocation to the nucleus 
PS proteins are required for γ-secretase activity. Thus, wild-type PS (PSWT), PS1 knock-
out (PS1KO), PS2 knock-out (PS2KO) and PS double-knock-out (PSDKO) MEFs were 
used to check for the translocation of IL-1R1 ICD to nucleus. PSWT MEFs over-
expressing IL-1R1 were pre-treated with DAPT (10μM/ml; 8h) and stimulated with 
PMA (200ng/ml; 2h) subsequently the cells were processed for western blot analysis 
and nucleic fractionation. γ-secretase-mediated cleavage of IL-1R1 and subsequent IL-
1R1 ICD formation was observed in PSWT and PS2KO MEFs ((Figure 3.14 a & 3.14c). In 
contrast PS1KO MEFs were defective in γ-secretase-mediated cleavage of IL-1R1 
(Figure 3.14 b). This data demonstrates that PS1 is required for γ-secretase-mediated 
cleavage of IL-1R1 and formation of IL-1R1 ICD formation. Simultaneously, these cells 
were processed for nucleic fractionation and analysed using western blots. Following 
PMA (200ng/ml; 2h) increased localization of IL-1R1 ICD in the nucleic fraction was 
observed (Figure 3.14d). Additionally, in PSWT and PS2KO MEFs, but neither in PS1KO 
nor in PSDKO MEFs, IL-1R1 ICD translocated to the nucleus (Figure 3.14 e lane 3 to 6). 
The observed IL-1R1 ICD in the nucleic fraction was inhibited on pre-treatment with 
DAPT (10μM/ml; 8h) (Figure 3.14f). Collectively the data demonstrates that PS1 is 
required for the γ-secretase-mediated formation of the IL-1R1 ICD, and that the IL-1R1 












Figure 3.14 IL-1R1 ICD translocates to the nucleus 
(a/b/c) Immunoblot analysis of PSWT, PS1KO and PS2KO MEFs, over-expressing IL-1R1. 
Forty hours post-transfection, cells were pre-treated with DAPT (20μM/ml; 8h) and 
treated with PMA (200ng/ml; 2h). (d) Subcellular fractionation of IL-1R1 in MEF PS WT 
cells untreated or treated with PMA, showing increased co-localization of IL-1R1 ICD 
with the nucleic fractionation upon PMA treatment. (e) Nucleic and cytosolic fraction 
of IL-1R1 transfected PSWT, PSDKO, PS1KO and PS2KO MEFs. (f) Nucleic fraction of IL-
1R1 in MEF PSWT, PSDKO, PS1KO and PS2KO cells treated with PMA or PMA and DAPT. 
Anti-PARP (nucleic marker) and anti-tubulin (cytosolic marker) antibodies were used to 
check for the purity of the fraction. C-terminus specific anti-IL-1R1 antibody was used 















3.2.10 IL-1R1 ICD has four nuclear localization signal sequences 
A nuclear localization signal (NLS) is a short stretch of amino acid which mediates the 
transport of proteins into the nucleus.  Positively charged residues are abundant in NLS 
sequences and mutating these residues has been reported to disrupt the nuclear 
import of proteins. The Nuclear Localization Predictor program available online was 
used along with alignment programs to predict the presence of NLS sequences within 
the ICD of IL-1R1. Figure 3.15 shows the alignment of IL-1R1 ICD across species and 
highlights the presence of several highly conserved putative NLS sequences. To 
investigate the importance of these residues in translocation of IL-1R1 ICD into the 
nucleus, the highly positively charged lysine residues within these NLS sequences were 
mutated to arginine. These lysine residues were also specifically targeted based on the 
previous mutational studies done on IL-1R1, listed in the Table 1.6. The residues 
K445/446, K527, K527/532, and K548 were mutated and further characterized to study 






Figure 3.15 Alignment of IL-1R1 ICD across a number of species 
Schematic representation of the four IL-1R1 point mutants constructed in our attempt 






3.2.11 Mutating residues within the IL-1R1 NLS sequences does not alter the 
translocation of IL-1R1 ICD into the nucleus 
HEK293T cells were transfected with either the wild-type IL-1R1, IL-1R1 K445/446R, IL-
1R1 K527R, IL-1R1 K527/532R or IL-1R1 K548R mutants  and forty hours post-
transfection pre-treated with DAPT (20μM/ml; 8h) and subsequently with PMA 
(200ng/ml; 2h). All these mutants- IL-1R1 K445/446R, IL-1R1 K527R, IL-1R1 K527/532R  
responded to PMA and DAPT treatment similar to cells expressing wild-type IL-1R1, 
with clear detection of CTF and ICD fragments (Figure 3.16). These constructs were 
also examined for altered subcellular localization compared to the wild-type IL-1R1. 
HEK293T cells were plated on coverslips and transfected with the wild-type IL-1R1 and 
the four NLS sequence mutants and co-transfected with either Rab5 or Rab7 to stain 
for the early and late endosomes respectively. Cells were fixed and permeabilized and 
labelled with C-terminus specific anti-IL-1R1 antibody, followed by Alexa Fluor-594; 
and DAPI to stain the nucleus. The subcellular localization of IL-1R1 K445/446R and IL-
1R1 K548R mutants remained unchanged, however, the IL-1R1 527R and IL-1R1 
527/532R mutants showed increased co-localization with the late endosomes (Figure 
3.17). These mutants were also analyzed for nuclear translocation of the ICD using 
fractionation. Immunoblot analysis of the nucleic fractions revealed that IL-1R1 
K445/446R and K527/532R mutants did not show any defective nuclear localization of 
ICD, in contrast there was decreased ICD detected in the nuclear fraction in cells 
expressing K527R mutant.  However, no IL-1R1 K548R ICD was seen in nuclear fraction 








Figure 3.16 Response of IL1-R1 NLS sequence mutants to PMA and DAPT 
HEK293T cells were transfected with the indicated constructs and forty hours post-
transfection, pre-treated with DAPT, followed by treatment with PMA. Cell lysates 
were analysed using immunoblots. C-terminus specific anti-IL-1R1 antibody was used 
to assess the cleavage profile of the receptor. (a) IL-1R1 K445/446R (b) IL-1R1 K527R 








Figure 3.17 Subcellular localization and trafficking of IL-1R1 NLS sequence mutants 
HEK 293T cells growing on coverslips were transfected with wild-type IL-1R1, IL-1R1 
K445/446R, IL-1R1 K527R, IL-1R1 527/532R and IL-1R1 548R, and co-transfected with 
early endosome marker (Rab5) and late endosome marker (Rab7). Cells were then 
fixed, permeablized and stained using C-terminus specific anti-IL-1R1 antibody. 
Increased co-localization of IL-1R1 K527R and IL-1R1 K527/532R was seen with the late 
endosomes, while other mutants showed no trafficking defect. (Red: IL-1R1; Green: 










Figure 3.18 Nucleic translocation of wild-type IL-1R1 and IL-1R1 NLS sequence 
mutants 
Nucleic fraction of wild-type IL-1R1 and IL-1R1 NLS sequence mutants transfected 
HEK293T cells treated with PMA alone or in combination with DAPT. Anti-PARP 
(nucleic marker) and anti-tubulin (cytosolic marker) antibodies were used to check for 
the purity of the fraction. C-terminus specific anti-IL-1R1 antibody was used to assess 







3.2.12 TLR4 is a substrate for γ-secretase mediate regulated intramembrane 
proteolysis 
Identification of members of the IL-1/TLR superfamily, for instance IL-1R1, IL-1R2, and 
IL-6R as substrates for γ-secretase-mediated regulated intramembrane proteolysis 
(Chalaris et al., 2010; Elzinga et al., 2009; Kuhn et al., 2007), prompted us to investigate 
whether or not other members of the family, particularly TLR4 was a potential γ-
secretase substrate. 
HEK293T cells were transfected with the C-terminus HA-epitope-tagged TLR4 
construct, and forty-eight hours post-transfection cells were pre-treated with DAPT 
(20μM/ml; 8h) or DMSO as a vehicle control in serum-free media and subsequently 
with PMA (200ng/ml; 2h). Cells were harvested and lysed using RIPA lysis buffer. 
Immunoblot analysis showed that PMA-induced formation of two detectable 
fragments that corresponded in size to a putative TLR CTF and ICD fragment (Figure 
3.19 lane 1 & 4). Importantly formation of the putative TLR4 ICD fragment was 
significantly decreased in the presence of DAPT (Figure 3.19a lane 2 & 3). 
Densitometry analysis of the TLR4 ICD showed significant decrease in the TLR4 ICD 







Figure 3.19 TLR4 is a γ-secretase substrate 
(a) HEK293T cells transiently expressing TLR4 HA, forty-eight hours post-transfection 
were pre-treated with DAPT (20μM/ml; 8h) followed by treatment with PMA 
(200ng/ml; 2h). Immunoblots were probed with anti-HA tag antibody. (b) 
Densitometry analysis of TLR4 ICD normalised to total β-actin for all experimental 
conditions. The amount of TLR4 ICD is expressed as TLR4 ICD immunoreactivity + 





3.2.13 TLR4Fas-TM construct does not undergo γ-secretase-mediated 
proteolysis 
The p75NTR is a well characterized γ-secretase substrate, while the Fas receptor is not 
a substrate for γ-secretase-mediated cleavage. Kong and co-workers employed a novel 
experimental approach to identify which domains of p75NTR were required for γ-
secretase cleavage. In this study they generated a p75NTR chimeric receptor in which 
they exchanged the transmembrane domain of p75NTR with transmembrane domain 
of the Fas receptor, and in doing so created a non-cleavable p75NTR (Kong et al., 
1999). We employed the same approach and replaced the transmembrane domain of 
TLR4 with the transmembrane domain of the Fas receptor, to generate a chimeric 
TLR4Fas-TM construct. To determine if TLR4Fas-TM chimeric receptor was indeed 
resistant to γ-secretase-mediated cleavage, HEK293T cells were transiently transfected 
with TLR4Fas-TM chimeric receptor and stimulated with PMA (200ng/ml; 2h) and 
analysed using western blot to check for the formation of the γ-secretase-cleavage 
dependent TLR4 ICD. Immunoblot analysis revealed that upon PMA treatment wild-
type TLR4 undergoes ectodomain shedding as seen by increased generation of TLR4 
CTF and ICD (Figure 3.20 lane 1 & 2), in contrast the TLR4Fas-TM construct did 
undergo PMA-mediated ectodomain shedding as evident from increased detection of 
TLR4 CTF, but it was defective in γ-secretase-mediated cleavage and subsequent 






Figure 3.20 TLR4Fas-TM construct does not undergo γ-secretase-mediated proteolysis 
HEK293T cell transiently expressing wild-type TLR4 and TLR4 FasTm receptor, forty-
eight hours post-transfection were treated with PMA (200ng/ml; 2h), lysed and probed 
with anti-HA tag antibody to assess the cleavage profile of TLR4. The data is 








3.3.1 IL-1R1 endocytosis is required for ectodomain shedding of IL-1R1 
IL-1R1 plays an important role in innate immunity and inflammatory responses. On 
binding to IL-1β, IL-1R1 forms a complex with the IL-1RAcP and initiates two different 
signalling pathways: cell surface-TAK1-dependent and cytosolic-TAK1-independent 
(Subramaniam et al., 2004). In an independent study we found that IL-1R1 undergoes 
ADAM17-mediated ectodomain shedding (unpublished). Gaining more knowledge 
about the spatiotemporal localization of ADAM17-mediated cleavage of IL-1R1 will 
help us to understand the importance and subsequent signalling pathways that it 
affects. In this context, using a pharmacological inhibitor: dynasore, and a dominant 
negative mutant of dynamin, Dyn-DN, we demonstrated that IL-1R1 undergoes 
ectodomain shedding on the early endosomes (Figure 3.3, 3.4 and 3.5). This was 
further confirmed using the dominant active Rab5 DA and dominant active Rab5 DN 
mutants, whereby we showed that Rab5 DN prevented formation of early endosomes 
and inhibited the formation of IL-1R1 CTF. In contrast, Rab5 DA enhanced the fusion of 
endocytic vesicles and formation of the early endosomes, thus leading to increased IL-
1R1 CTF and subsequently formation of the IL-1R1 ICD (Figure 3.6). 
Inhibiting receptor internalization using a pharmacological inhibitor or dominant 
negative mutants raises the possibility of an indirect effect of inhibiting the membrane 
trafficking in the cell system. Thus, we also mapped a highly conserved internalization 
motif in IL-1R1, mutagenesis of which inhibited constitutive and PMA-induced 
ectodomain shedding of IL-1R1 (Figure 3.7). The IL-1R1 W262A mutant did not express 
to the same levels as the wild-type IL-1R1. Despite of low expression levels it was 
significantly clear that IL-1R1 W262A mutant was defective in ectodomain shedding 
and CTF formation (Figure 3.8). Our demonstration that unlike many other receptors 





endosome highlights that it may play an important role in the IL-1R1-mediated 
endosomal signalling pathways. This is of particular interest since most released 
ectodomains in addition to regulating the normal turnover of the receptor also retain 
their biological activities and it is feasible that before being secreted into the 
extracellular milieu sIL1-R1 participates in mediating signalling events. Additionally, on 
the basis of a study carried out by Heguy and co-workers showing that ligand bound C-
terminal domain truncated IL-1R1 migrates to the nucleus (Heguy et al., 1991), it is 
possible for sIL-1R1 to translocate to the nucleus and participate in gene regulation. 
3.3.2 TRAF6 E3 ligase enhances constitutive and PMA-induced ectodomain shedding 
In the current study we have clearly shown that IL-1R1 ectodomain shedding occurs on 
the early endosomes and that IL-1R1 ICD undergoes proteasomal degradation (Figure 
3.9). In a recent study carried out by Hansen and co-workers, inhibition of dynamin-
dependent endocytosis was shown to deregulate IL-1β induced signalling. They 
suggested a novel pathway requiring IL-1R1 endocytosis for IL-1β-induced NF-кB-
dependent gene expression downstream of nuclear translocation and DNA binding of 
NF-κB (Hansen et al., 2013). Previously our group had proposed a molecular 
mechanism whereby TRAF6 promotes ubiquitination and regulated intramembrane 
proteolysis of IL-1R1 through its ubiquitin ligase activity. In brief, TRAF6 was shown to 
preferentially induce ubiquitination of IL-1R1. Furthermore, TRAF6 ubiquitin ligase 
activity and ubiquitination of IL-1R1 were positively correlated with IL-1R1 ectodomain 
shedding and γ-secretase-mediated cleavage (Twomey et al., 2009).  
We have subsequently shown that the TRAF6 ubiquitination sites are restricted to the 
juxtamembrane residues 360, 378, 383 and IL-1R1 triple lysine mutant (IL-1R1 
K360/378/383R) is defective in TRAF6-mediated polyubiquitination of IL-1R1 CTF 
(Figure 3.11) and is further defective in constitutive and PMA-induced ectodomain 





the receptor. This is suggestive of a role for TRAF6-mediated ubiquitination of IL-1R1 in 
mediating ectodomain shedding and γ-secretase-mediated cleavage.  
3.3.3 IL-1R1 ICD translocates to the nucleus 
As previously discussed γ-secretase-mediated cleavage of several substrates plays an 
important role in regulating their signalling events. It either functions to clear the CTF 
from the membrane, thereby terminate the signalling events. Also, for substrates like, 
APP, p75NTR and Notch the ICD generated translocates to the nucleus and drives 
transcription of various genes. Previously, IL-1β/IL-1R1 complex has been shown to 
translocate to the nucleus. However, deletion of the C-terminus domain of IL-1R1 did 
not affect its nuclear translocation. The role played by the IL-1β/IL-1R1 complex within 
the nucleus has been studied but remains unclear. Thus, the possibility that IL-1R1 ICD 
translocates to the nucleus was explored.  
The limitation of this study was lack of IL-1R1 ICD specific antibody. Attempts to map 
the γ-secretase cleavage site within the transmembrane domain of IL-1R1 failed. Two 
different approaches were used. Firstly point mutants of the highly conserved site 
within the transmembrane domain were made, which failed to create a non-cleavable 
IL-1R1 receptor. Hogl and co-workers used mass spectroscopy in order to determine 
the cleavage sites of APLP by ADAM10, BACE1 and γ-secretase,  (Hogl et al., 2011). 
Using the same approach, an attempt was made to map the γ-secretase cleavage site 
for IL-1R1. However, due to low expression of the IL-1R1 ICD, it was not successful. 
Having failed to map the cleavage site, GFP-tagged IL-1R1 construct was made. 
However, the GFP-tag was cleaved from the IL-1R1 and degraded. Therefore, no 
immunofluorescence studies were carried out in HEK293T cells over-expressing the 





Using PS WT MEFs, subcellular fractionation studies revealed that IL-1R1 ICD 
translocates to the nucleus (Figure 3.14). Sequence alignments, and using NLS 
sequence predictor tools, four NLS sequences were found in the ICD of IL-1R1 (Figure 
3.15).  These NLS sequences contained residues which had been previously studied 
and shown to either drastically affect trafficking or expression of IL-1R1. Hence, these 
residues were not targeted for mutagenesis in this study. For the other residues, NLS 
predictor program was used and residues-445, 446, 527, 532 and 548 were chosen and 
mutated to arginine. The residue 527, when mutated affected the trafficking of IL-1R1 
as seen by increased co-localization with the early endosome (Figure 3.17). The 
mutation of the lysine residue 445/446 to arginine did not affect translocation of IL-
1R1 ICD, in contrast reduced levels of ICD were observed in nucleic fraction of cells 
over-expressing IL-1R1 K527/532R mutant (Figure 3.18). However, this could be an 
indirect effect of defective trafficking of this mutant. On the other hand in cells 
expressing IL-1R1 K548R mutant no ICD was observed in nucleic fraction. We suggest 
that a more quantitative approach is required to validate this result and determine the 
role played by IL-1R1 ICD in the nucleus.  Parkhurst and co-workers studied the nuclear 
translocation of p75NTR ICD using nuclear translocation assay and biochemical 
fractionation (Parkhurst et al., 2010).  This group fused C-terminus domain of p75NR 
ICD with the LexA DNA-binding domain-Gal4 transactivation domain (LG), which was 
transfected in the cells. The LG sequence is capable of activating a GFP reporter gene 
controlled by eight LexA operator sequences. Nuclear translocation is required to 
transactivate the LexA operator sites of the reporter gene. Using a similar approach 






3.3.4 TLR4 is a substrate for γ-secretase-mediated endosomal regulated 
intramembrane proteolysis 
In this study, TLR4 was shown to undergo constitutive and PMA-induced ectodomain 
shedding followed by γ-secretase-mediated regulated intramembrane proteolysis. 
Identification of TLR4 as a γ-secretase substrate reflected a novel role of PS in 
regulating LPS-induced immune responsiveness. This was investigated in detail by our 
group and surprisingly γ-secretase-independent role of PS2 was seen in LPS-induced 
cytokine and interferon production both in-vitro and in-vivo (refer to manuscript). 
Similar to IL-1R1, members of the TLR superfamily regulate the ligand induced 
signalling events via compartmentalization. TLR4-mediated signalling events have been 
shown to be spatially segregated, where TLR4 recruits TRIF and MyD88 on the cell 
surface, followed by endosomal recruitment of TRAM and TRIF (Guillot et al., 2004; 
Kagan et al., 2008). The molecular mechanisms underlying this spatial segregation 
remain elusive. Experiments performed to determine the subcellular localization for γ-
secretase-mediated cleavage of TLR4 could provide insight into the role played by this 
cleavage in spatially segregated TLR4-mediated signalling events. Preliminary 
experiments were carried out to screen C-terminus specific TLR4 antibody suitable for 
immunoflourescence. C-terminus specific TLR-4 antibody (sc-8694-R) revealed that 
dominant negative Rab5 construct defective in fusion of vesicles and formation of 
early endosomes prevented trafficking of TLR4 (Figure 3.21). This could help 
investigate the subcellular localization for TLR4 cleavage and further study the nuclear 






Figure 3.21 γ-secretase-mediated cleavage of TLR4 occurs after exit from the early 
endosome 
Immunoflourescence analysis of corresponding cells grown on coverslips, expressing 
TLR4 and co-transfected with GFP-tagged Rab5 WT or Rab5 DN constructs. Cells were 
stimulated with PMA (200ng/ml; 2h), fixed, permeabilized and stained with C-terminus 
specific anti-TLR4 antibody. Samples were imaged using Olympus fluoview confocal 









TNFR1 is a substrate for γ-secretase-







The γ-secretase enzyme complex was initially characterized by its involvement in Aβ 
peptide generation and subsequently found to mediate cleavage of the Notch 
receptor, an essential proteolytic event in the propagation of Notch signalling 
(Strooper et al., 1999; Fortini, 2002; Hub et al., 2001; Kopan, 2003) . To date, over 90 
distinct γ-secretase substrates have been identified indicating that γ-secretase has a 
generic role in the processing of membrane proteins (Haapasaloa, 2012). From 
culminating research, it is now evident that the γ-secretase protease functions to 
target many of its substrates for degradation; for example, the cleavage of CD43 by γ-
secretase terminates CD43-initiated signalling events facilitating its clearance from the 
plasma membrane (Andersson et al., 2005). For other substrates, cleavage by γ-
secretase leads to the generation of biologically active receptor-derived ICDs, such as 
those observed for the Notch, and p75NTR, which migrate to the nucleus and regulate 
gene expression (Fortini, 2002; Ilagan, 2004; Koo, 2004; Kopan, 2003).  
The PS proteins are the catalytic component of this multiprotein γ-secretase complex 
(Hass et al., 2009; Wilson et al., 2002). Genetic inactivation of PS1 alone or both PS1 
and PS2 results in a marked reduction, or complete loss of this γ-secretase activity 
(Strooper et al., 1998; Herreman et al., 2000; Wolfe et al., 1999). Various groups have 
demonstrated that expression of FAD-linked PS variants are either directly cytotoxic or 
enhance susceptibility to apoptosis (Deng et al., 1996; Parent, 2004; Wolozin et al., 
1998). Consistent with this, PS null mice display many abnormalities, including gross 
deformities of the axial skeleton and massive neuronal loss (Donoviel et al., 1999). 
These have been credited to increased susceptibility to apoptosis owing to which these 
animals die shortly after birth (Hartmann et al., 1999). This phenotype has always been 
attributed to defective Notch signalling following inhibition of γ-secretase activity 
(Curry et al., 2005; Rosati et al., 2013). However, the involvement of specific cell death 





Work in our group had previously demonstrated a role for PS1 in TNF-mediated 
intracellular signalling (unpublished data). Among the members of the TNF 
superfamily, TNFR1 is most widely studied due to its ability to sequentially activate an 
NF-кB-mediated cell survival pathway and also signal for cell death by activating 
caspases (Schneider-Brachert et al., 2004). The predominance of TNFR1 signalling is 
also reflected by its ubiquitous expression in most cell types. Three ligands are 
selectively responsible for the activation of TNFR1; the membrane bound TNFα, 
soluble TNFα, and the soluble lymphotoxin-α (LT-α)/TNF-β.  
In 2006, Fluhrer et al. reported that the TNFR1 ligand, TNFα, undergoes regulated 
intramembrane proteolysis via the action of the iCLIP family member, signal peptide 
peptidase like protein, SPPL2b (Fluhrer et al., 2006). SPPL2b releases the ICD of TNFα 
into the cytosol and the carboxy-terminal region is secreted into the extracellular 
milieu similar to γ-secretase processing. Furthermore, the TNF receptor superfamily 
member, p75NTR is a very well characterized substrate for γ-secretase  (Frade et al., 
2010; Skeldal et al., 2011), enabling the generation of the p75NTR ICD which 
translocates to the nucleus and is reported to regulate gene transcription (Kanning et 
al., 2003). 
TNFR1 fits the profile of the majority of known γ-secretase substrates, being a type-1 
transmembrane receptor, with an extracellular N-terminal and an intracellular C-
terminal domain, it is subjected to TACE-mediated ectodomain shedding, a 
characteristic feature of γ-secretase substrates (Black et al., 1997; Peschon, 1998). 
These characteristics suggest that it is feasible for the membrane-bound TNFR1 CTF 






The aim of this chapter is twofold- 
1. Determine whether or not TNFR1 is a γ-secretase substrate. 
2. Characterize the subcellular location of TNFR1 proteolysis and determine the 






4.2.1 Expression of exogenous TNFR1 
Activation of TNFR1 by TNFα initiates several distinct intracellular signalling pathways 
that can either lead to activation of the MAPKs and the transcription factor NF-кB, or 
the induction of apoptosis (Verstrepen et al., 2008). Exogenous expression of TNFR1 is 
known to induce apoptotic cell death, thereby making in vitro cell culture studies 
difficult. In order to prevent cell death on over-expression of TNFR1, we used a TNFR1 
mutant, TNFR1 L380A, which has a point mutation in the DD and like the DD 
inactivating lprcg mutation in Fas, prevents the induction of apoptosis following ectopic 
expression in cells (Boone et al., 2000). In this study the TNFR1 L380A mutant is 
referred to as TNFR1 to distinguish it from other TNFR1 mutants employed in the study 
unless otherwise specified. 
To examine the expression of TNFR1 and verify that it undergoes ectodomain 
shedding, HEK293T cells were transiently transfected with TNFR1 and thirty-four hours 
post-transfection, cells were treated with PMA (200ng/ml; 2h) in serum-free media to 
promote TACE-mediated ectodomain shedding. The expression and cleavage profile of 
TNFR1 was analysed by immunoblotting, using anti-TNFR1 C25 antibody raised against 
the C-terminal epitope 431-455. TNFR1 expressed to comparable levels in all 
experimental conditions (Figure 4.1a). The generation of a constitutive and PMA-
induced TNFR1 CTF was readily detected in cell lysates. In cultures stimulated with 
PMA, increased formation of an additional band of ~32-kDa was clearly detected. This 
band most likely corresponds to the TNFR1 ICD formed by γ-secretase-mediated 
cleavage of TNFR1 (Figure 4.1a). 
To confirm PMA-induced ectodomain shedding of TNFR1, conditioned media from the 





stimulation induced significant ectodomain shedding and generation of sTNFR1 (Figure 
4.1b). Similarly, flow cytometry analysis of cell surface TNFR1 revealed a decrease in 
TNFR1 cell surface levels following PMA treatment (Figure 4.1c/d). Thus, the 
expression of the exogenous TNFR1 and its responsiveness towards PMA was 






Figure 4.1 Expression and localization of TNFR1 
(a) Whole cell lysates were immunoblotted with a C-terminus specific anti-TNFR1 
antibody to confirm expression of exogenous TNFR1 and to allow assessment of its 
cleavage pattern following treatment with PMA. (b) Analysis of conditioned media for 
sTNFR1 from cell cultures treated with PMA, using sTNFR1 specific ELISA (Invitrogen). 
Data are expressed as picogram of sTNFR1 per milligram of total protein + standard 
error of the mean, representative of three independent experiments versus TNFR1 
control. Asterisks indicate significance to the control- DMSO. (c) Cell surface levels of 
TNFR1 measured by flow cytometry, performed with AccuriC6, and analysed using 
Accuri FlowJo software. (d) Relative cell surface levels of TNFR1 in untreated and PMA 
treated cells, and statistical analysis was performed using unpaired Student’s t-test. *, 
p<.05; **, p<.01; ***, p<0.001. Asterisks indicate significance to the control-DMSO. All 





4.2.2 Identification of TNFR1 as a γ-secretase substrate 
Two different approaches were used to identify TNFR1 as a potential γ-secretase 
substrate. First, DAPT, a pharmacological inhibitor of γ-secretase, was used. Second, 
we used a genetic approach employing wild type (WT) and PS double-knock-out (PS 
DKO) murine embryonic fibroblasts (MEFs), which possess no γ-secretase catalytic 
activity due to the absence of both PS1 and PS2 (Herreman et al., 2000). 
4.2.2.1 Pharmacological inhibition of γ-secretase activity 
HEK293T cells were transiently transfected with TNFR1 construct and twenty-eight 
hours post-transfection cells were pre-treated with DAPT (10μm/ml; 8h) or DMSO as a 
vehicle control in serum-free media. Cells were subsequently stimulated with PMA 
(200ng/ml; 2h) or recombinant human TNFα (hTNFα) (30ng/ml; 2h), alone or in 
combination with DAPT (Figure 4.2). The γ-secretase substrate IL-1R1 was included as 
a positive control in this experiment (Elzinga et al., 2009). 
The cleavage profiles of TNFR1 and IL-1R1 were examined by immunoblotting with 
their respective C-terminus antibody (TNFR1 C25 and IL-1R1 C20). Immunoblot analysis 
revealed that TNFR1 underwent constitutive and PMA-induced proteolytic cleavage as 
evident from the detection of proteolytic fragments, which based on molecular 
weights were predicted to correspond to TNFR1 CTF, generated following TNFR1 
ectodomain shedding and ~32-kDa TNFR1 ICD (Figure 4.2a lane 1 & 2). Pre-treatment 
of cell cultures with the γ-secretase inhibitor, DAPT, completely suppressed the 
formation of this ~32-kDa TNFR1 ICD (Figure 4.2a lane 4), suggesting that it was indeed 
the product of γ-secretase-mediated cleavage of TNFR1 CTF. In cells treated with both 
PMA and DAPT no TNFR1 ICD fragment was detected (Figure 4.2a lane 3), however a 
parallel increased accumulation of the TNFR1 CTF was observed. This responsiveness 





substrates (Haapasaloa et al., 2012), indicating a precursor product relationship, 
whereby inhibition γ-secretase cleavage of TNFR1 CTF abolished TNFR1 ICD formation 
while increasing TNFR1 CTF levels. Densitometry analysis of TNFR1 CTF levels also 
confirmed that it responded to DAPT as seen by increased immunoreactivity of the 
TNFR1 CTF (Figure 4.2b). Next we examined whether generation of TNFR1 CTF and ICD 
were stimulated by TNFR1 ligand TNFα (Figure 4.2c). Stimulation of HEK293T cells 
expressing TNFR1 with TNFα led to increased accumulation of TNFR1 ICD, and pre-
treatment with DAPT inhibited constitutive and TNFα-stimulated TNF-R1 ICD fragment 
formation (Figure 4.2c lane 3 & 4). The responsiveness to PMA and DAPT treatment 
was confirmed when we analyzed the cleavage of IL-1R1, a known γ-secretase 
substrate (Figure 4.2d). Together this pharmacological data demonstrates that TNFR1 






Figure 4.2 Ectodomain shedding-derived TNFR1 CTF is a substrate for γ-secretase 
(a), (c) Immunoblot of cell lysates from HEK293T cells transiently transfected with 
TNFR1 and treated as indicated. C-terminus specific anti-TNFR1 antibody was used to 
assess cleavage profile of the receptor. (b) Densitometry analysis of TNFR1 CTF 
normalised to total β-actin for all experimental conditions. The amount of TNFR1 CTF is 
expressed as TNFR1 CTF immunoreactivity + standard error of the mean, 
representative of four independent experiments. Significance was calculated using 
two-way ANOVA, indicated with lines between the two compared groups. Asterisks 
without line indicate significance to the control- DMSO. (d) Immunoblot of cell lysates 
from HEK293T cells transiently transfected with IL1-R1, and treated with the same 
pharmacological modulators as TNFR1. C-terminus specific anti-IL-1R1 antibody was 






4.2.2.2 PS-deficiency prevents γ-secretase-mediated proteolysis of TNFR1   
PS proteins are necessary and required for γ-secretase activity. We next analyzed the 
cleavage of TNFR1 in wild-type (WT) and PS double-knock-out (PSDKO) murine 
embryonic fibroblasts (MEFs), which are deficient in PS-dependent γ-secretase activity. 
Immunoblot analysis of TNFR1 cleavage in untreated and PMA-stimulated cells 
revealed that wild-type MEFs over-expressing TNFR1 undergo constitutive and PMA-
stimulated TNFR1 ICD formation (Figure 4.3 lane 1 & 2). In contrast, and as predicted, 
in PSDKO MEFs, the constitutive and PMA-stimulated generation of TNFR1 ICD was 
abolished, and a simultaneous accumulation of the CTF fragment was observed, 






Figure 4.3 PS deficiency prevents γ-secretase-mediated regulated intramembrane 
proteolysis of TNFR1  
Immunoblot of PS WT and PSDKO MEFs transiently expressing TNFR1 and probed with 
C-terminus specific anti-TNFR1 antibody, to allow assessment of its cleavage pattern 






4.2.3 PS1-dependent γ-secretase activity is required for cleavage of TNFR1 CTF 
After confirming TNFR1 to be a novel γ-secretase substrate, we next used a genetic 
model of γ-secretase inactivation to determine whether it is cleaved by a PS1-
containing or PS2-containing γ-secretase complex. The γ-secretase enzyme activity is 
attributed to two highly conserved aspartate residues in the transmembrane domain6 
and 7 of PS1 (PS1D257 and PS2D385) and PS2 (PS2D263 and PS2D366) (M S Wolfe et 
al., 1999). We analysed the cleavage of TNFR1 in HEK293T cells expressing TNFR1 and 
co-expressing either wild-type (WT) or dominant negative-PS1 (PS1D257A/D385A) mutant 
and wild-type (WT) or dominant negative-PS2 (PS2D263A/D366A) mutant. Immunoblot 
analysis of TNFR1 cleavage in cells treated with PMA revealed that cells expressing PS1 
WT had no effect on γ-secretase mediated cleavage of TNFR1 (Figure 4.4a lane 2 & 4), 
but expression of the PS1D257A/D385A mutant inhibited formation of the TNFR1 ICD and 
caused an accumulation of TNFR1 CTF (Figure 4.4a lane 2 & 6). In contrast, in HEK293T 
cells expressing TNFR1 and co-transfected with PS2 WT or PS2D263A/D366A mutant, 
expression of PS2D263A/D366A mutant had no effect on either the constitutive or PMA-
induced generation of TNFR1 ICD (Figure 4.4b lane 5 & 6). This data suggests that like 
many other substrates (B De Strooper et al., 1998, 1999; Elzinga et al., 2009), TNFR1 is 
a substrate for PS1-dependent γ-secretase cleavage and is not cleaved by PS2 






Figure 4.4 γ-secretase inactive PS1D257A/D385A inhibits γ-secretase-dependent regulated 
intramembrane proteolysis of TNFR1 
(a) Immunoblot of HEK293T cells transiently transfected with TNFR1 and co-
transfected with either PS1 WT or PS1D257A/D385A mutant. (b) Immunoblots of HEK293T 
cells transiently transfected with TNFR1 and co-transfected with either PS2 WT or 
PS2D263A/D366A mutant. At thirty four hours post-transfection cells were treated with 
PMA (200ng/ml; 2h) to promote ectodomain shedding and subsequent γ-secretase-
mediated cleavage. C-terminus specific anti-TNFR1 antibody was used to assess the 






 4.2.4 Ectodomain shedding is a pre-requisite for γ-secretase cleavage of TNFR1  
It is reported that all type I transmembrane receptors which are subjected to γ-
secretase-mediated cleavage, initially undergo ectodomain shedding in the 
extracellular domain as a pre-requisite to γ-secretase-mediated cleavage (Haapasaloa 
et al., 2012). Next, using a TACE specific hydroxmate based metalloprotease inhibitor-
TAPI; the importance of TACE-mediated ectodomain shedding of TNFR1 in γ-secretase-
mediated cleavage was studied. 
HEK293T cells were transiently transfected with TNFR1 and thirty-four hours post-
transfection, cells were pre-treated with TAPI (10μM/ml; 2 h) in serum-free media, and 
subsequently treated with PMA (200ng/ml; 2h) to induce ectodomain shedding of 
TNFR1. Release of soluble TNFR1 (sTNFR1) ectodomain was clearly detectable in 
conditioned media of cells expressing TNFR1 as measured by ELISA (Invitrogen). TNFR1 
underwent constitutive and PMA-induced ectodomain shedding, and PMA treatment 
led to a significant increase in the generation sTNFR1, which was inhibited by TAPI 
(Figure 4.5a). Immunoblot analysis of the same cultures with an anti-TNFR1 C25 
antibody revealed that treatment with PMA also led to an increase in the generation of 
TNFR1 CTF and TNFR1 ICD (Figure 4.5b); suggesting ectodomain shedding is a 






Figure 4.5 TAPI prevents ectodomain shedding and subsequent γ-secretase-mediated 
cleavage of TNFR1 
(a) Analysis of sTNFR1 using conditioned media from cell plates treated with PMA to 
induce ectodomain shedding in presence or absence of TAPI and analysed using 
sTNFR1 specific ELISA (Invitrogen). Data expressed as picogram of sTNFR1 per 
milligram of total protein + standard error of the mean, representative of three 
independent experiments versus TNFR1 control. Significance was calculated using two-
way ANOVA, indicated with lines between the two groups. Asterisks without line 
indicate significance to the control-DMSO. (b) Immunoblot analysis of corresponding 
cell lysates probed with C-terminus specific anti-TNFR1 antibody (c) Densitometry 
analysis of TNFR1 ICD normalised to total β-actin for all experimental conditions. The 
amount of TNFR1 ICD is expressed as TNFR1 ICD immunoreactivity + standard error of 
the mean, representative of three independent experiments. The data is 





4.2.5 Inhibiting TNFR1 CTF internalization disrupts its γ-secretase-mediated cleavage 
Once TNFR1 was identified as a new γ-secretase substrate, the subcellular occurrence 
of this cleavage event was studied. TNFR1 undergoes clathrin-mediated internalization 
(Schneider-Brachert et al., 2004; Stefan Schütze et al., 2008) Three different 
approaches were used to determine the effect of inhibiting clathrin-mediated 
internalization on γ-secretase-mediated cleavage of TNFR1. 
4.2.5.1 Pharmacological inhibition of internalization 
HEK293T cells were transiently transfected with TNFR1 and thirty-four hours post-
transfection cells were pre-treated with dynasore (50μM/ml; 2h), a pharmacological 
inhibitor of clathrin-mediated endocytosis, or DMSO as a vehicle control in serum-free 
media followed by PMA (200ng/ml; 2h) treatment. ELISA analysis revealed that sTNFR1 
was readily detected in conditioned media of cells treated with PMA, and a significant 
increase in sTNFR1 levels was seen following inhibition of TNFR1 internalization on 
treatment with dynasore (Figure 4.6b). Immunoblot analysis of corresponding cell 
lysates confirmed PMA-induced TNFR1 CTF and TNFR1 ICD generation and that 
treatment with dynasore, decreased formation of the TNFR1 ICD (Figure 4.6a lane 3). 
It is known that following TNFα binding, signalling from TNFR1 leads to the activation 
of both NF-кB and the JNK pathways, where the TNFR1-mediated activation of NF-кB is 
initiated at the plasma membrane, while activation of JNK is initiated following TNFR1 
internalization (Schütze et al., 1999). To verify dynasore was indeed inhibiting TNFR1 
internalization and affecting TNFR1 signalling events, wild-type MEFs were pre-treated 
with dynasore (50μM/ml; 2h) and stimulated with recombinant murine TNFα (mTNFα) 
for increasing times. Immunoblot analysis revealed that dynasore had no effect on 
TNFα-induced phosphorylation and degradation of the NF-кB inhibitor, IкBα. However, 





observed (Figure 4.6c). This demonstrates the functionality of dynasore in our 
experimental system as an inhibitor of TNFR1 internalization and TNFα-mediated 







Figure 4.6 Dynasore prevents γ-secretase-mediated cleavage of TNFR1 
(a) Immunoblot analysis of HEK293T cell lysates, transiently expressing TNFR1 and 
treated as indicated. C-terminus specific anti-TNFR1 antibody was used to assess the 
cleavage profile of TNFR1. (b) Analysis of sTNFR1 from conditioned media from cell 
plates treated with PMA to induce ectodomain shedding in presence or absence of 
dynasore and analysed using sTNFR1 specific ELISA (Invitrogen). Data expressed as 
picogram of sTNFR1 per milligram of total protein + standard error of the mean, 
representative of three independent experiments versus TNFR1 control. (NSD) (c) 
Immunoblot analysis of cell lysates from MEF PS WT cells treated with DMSO as 
control or Dynasore and stimulated with murine TNFα for indicated time point. The 





4.2.5.2 Dynamin K44A mutant inhibits γ-secretase-mediated cleavage of TNFR1 
Next a genetic approach was employed using wild-type dynamin (Dyn WT) or dynamin 
K44A mutant (Dyn-DN) which prevents clathrin-dependent internalization. HEK293T 
cells were transfected with TNFR1 and co-transfected with either Dyn WT or Dyn-DN. 
Immunoblot analysis revealed that while co-expression of Dyn WT had no effect on 
TNFR1 CTF or TNFR1 ICD formation, the co-expression of Dyn-DN had no effect on 
PMA-induced TNFR1 CTF formation but significantly reduced PMA-stimulated 
generation of TNFR1 ICD (Figure 4.7a lane 4). Simultaneous analysis of conditioned 
media from cells expressing either Dyn WT or Dyn-DN confirmed that inhibition of 
TNFR1 internalization had no effect on constitutive or PMA-induced ectodomain 
shedding and generation of sTNFR1 (Figure 4.7b).  The functionality of the Dyn-DN as 
an inhibitor of TNFR1 internalization and signalling was confirmed by immunoblot 
analysis of TNFR1 CTF level in cytosolic fractions of HEK293T cells expressing TNFR1 
and co-transfected with either Dyn WT or Dyn-DN. The cytosolic levels of TNFR1 CTF 
were found to increase on PMA treatment in the cytosolic fractions of the cells 
expressing Dyn WT but failed to do so in cells expressing Dyn-DN (Figure 4.7c compare 
lane 2 and 6).  This indicates that while ectodomain shedding of TNFR1 occurs on the 
plasma membrane, internalization of the TNFR1 CTF is required for subsequent 
cleavage by γ-secretase. Again, as for our studies employing dynamin, to verify that 
Dyn-DN was inhibiting TNFR1 internalisation and affecting TNFR1 signalling events, 
wild-type MEFs co-expressing either Dyn WT or Dyn-DN were stimulated with mTNFα 
(Figure 4.7d). Immunoblot analysis revealed that Dyn WT had no effect on TNFα-
induced phosphorylation and degradation of the NF-кB inhibitor IкBα. However, in 
cells expressing Dyn-DN reduced JNK activation was observed (Figure 4.7d). This 
validates our experimental system, and provides further evidence that inhibition of 






Figure 4.7 Over-expression of Dyn-DN prevents γ-secretase-mediated cleavage of 
TNFR1 
(a) Immunoblot analysis of HEK293T cell lysates, transiently expressing TNFR1 and Dyn 
WT or Dyn-DN and stimulated with PMA. (b) Analysis of sTNFR1 from conditioned 
media from cell cultures treated with PMA to induce ectodomain shedding and 
analysed using sTNFR1 specific ELISA (Invitrogen). Data expressed as picogram of 
sTNFR1 per milligram of total protein + standard error of the mean, representative of 
three independent experiments versus TNFR1 control. (NSD) (c) Cytosolic fractions of 
HEK293T cells treated with PMA for increasing time and analysed for TNFR1 CTF.  (d) 
Immunoblot analysis of cell lysates from MEF PS WT cells transiently transfected with 
Dyn WT or Dyn-DN, and stimulated with mTNFα for indicated times. The data is 






4.2.5.3 TNFR1 internalization domain mutant does not undergo γ-secretase-
mediated cleavage 
Schneider-Brachert et al. identified a motif within the C-terminus domain of TNFR1 
that mediated TNFR1 internalization known as the TNFR1 internalization domain or 
TRID. Deletion of this region failed to induce receptor endocytosis, subsequent 
formation of complex II and induction of apoptosis-inducing pathways. The authors 
also identified a highly conserved motif within TRID region, known to be involved in 
clathrin-mediated internalization of a number of cell surface receptors-YXXW 
sequence, comprised of tyrosine (Y) and tryptophan (W) enclosing any two amino 
acids. Mutations in this sequence caused TNFR1 to remain at the cell surface, 
essentially preventing internalization (Schneider-Brachert et al., 2004).  
TNFR1 TRID mutant at W239A, was made and employed in the study to determine the 
subcellular occurrence of the γ-secretase-mediated TNFR1 cleavage (Figure 4.8a). 
HEK293T cells were transfected with either TNFR1 or TNFR1 W239A and thirty-four 
hours post-transfection, cells were treated with PMA (200ng/ml; 2h) and lysed to 
assess the effect of internalization on γ-secretase-mediated cleavage. In cells 
expressing wild-type TNFR1, PMA-induced an increase in generation of TNFR1 CTF and 
TNFR1 ICD, however in cells expressing TNFR1 W239A mutant, formation of TNFR1 ICD 
was completely inhibited. Thus, inhibiting TNFR1 internalization clearly inhibited γ-
secretase-mediated cleavage of the receptor (Figure 4.8b lane 4). Analysis of sTNFR1 
levels in conditioned media from the same cell cultures confirmed that PMA-induced 
ectodomain shedding was not perturbed in cells expressing TNFR1 W239A (Figure 
4.8c). However, increased levels of sTNFR1 were detected in cells over-expressing 
TNFR1 W239A which was attributed to increased localization of the receptor at plasma 
membrane. To validate TNFR1 W239A did not undergo internalization in the cell 





TNFR1 CTF following PMA-induced ectodomain shedding. TNFR1 W239A CTF was not 
detected to the same levels as in cells expressing TNFR1 WT, indicating that TNFR1 
W239A did not undergo internalization (Figure 4.8d).  Again, TNFα-mediated signalling 
and activation of both NF-кB and JNK pathway was also examined. Wild-type MEFs 
expressing TNFR1 WT or TNFR1 W239A mutant were stimulated with mTNFα for the 
indicated times. Again, inhibition of TNFR1 receptor internalisation had no effect on 
TNFα-induced NF-кB activation however; upon expression of TNFR1 W239A mutant 
reduced JNK activation was observed (Figure 4.8e). Collectively, this data 
demonstrates that ectodomain shedding of TNFR1 is a prerequisite for γ-secretase-
mediated cleavage of TNFR1 and that γ-secretase-mediated cleavage of TNFR1 occurs 

















Figure 4.8 TNFR1 W239A mutant does not undergo γ-secretase-mediated cleavage 
(a) Immunoblot analysis of HEK293T cells transiently transfected with TNFR1 and 
TNFR1 W239A treated with PMA (200ng/ml; 2h). (b) Analysis of sTNFR1 from 
conditioned media from cell cultures treated with PMA to induce ectodomain 
shedding and analysed using sTNFR1 specific ELISA (Invitrogen). Data expressed as 
picogram of sTNFR1 per milligram of total protein + standard error of the mean, 
representative of three independent experiments versus TNFR1 control. (NSD) (c) 
Cytosolic fractions of HEK293T cells treated for increasing time with PMA and analysed 
for TNFR1 CTF.  (d) Immunoblot analysis of cell lysates from MEF PS WT cells 
transfected with either TNFR1 WT or TNFR1 W239A and stimulated with mTNFα for 





 4.2.6 TNFR1 is cleaved by γ-secretase in early endosomes  
To complement data obtained from inhibiting receptor internalization, we next 
examined the subcellular location of γ-secretase-mediated cleavage of TNFR1 was 
further examined using cells expressing Rab dominant negative (DN) mutants. Rab5 
and Rab7 proteins belong to a superfamily of small molecular weight GTPases known 
to be associated with early and late endosomes, respectively. The Rab5 protein plays 
an important regulatory role in early endocytosis and trafficking to the early 
endosomes, while Rab7 plays a key role downstream of Rab5, in regulating membrane 
transport leading from early to late endosomes (Stenmark & Olkkonen, 2001). 
4.2.6.1 Rab5-DN inhibits γ-secretase-mediated cleavage of TNFR1 
HEK293T cells expressing TNFR1 were co-transfected with either Rab5 WT or Rab5-DN 
constructs. At thirty-four hours post-transfection cells were treated with PMA 
(200ng/ml; 1h) to promote ectodomain shedding and subsequent formation of TNFR1 
ICD. Immunoblot analysis revealed that preventing trafficking of TNFR1 to the early 
endosome using Rab5-DN inhibited γ-secretase-mediated cleavage of the TNFR1 CTF, 
leading to decreased TNFR1 ICD formation (Figure 4.9a lane 3 & 4). On the other hand, 
Rab5 WT did not affect γ-secretase-mediated cleavage of TNFR1 and the TNFR1 ICD 
formation (Figure 4.9a lane 1 & 2). Next, subcellular fractionation was performed to 
check for the efficacy of the Rab5 constructs. In cells expressing Rab5 WT, TNFR1 
receptor co-localized with the early endosomes, but decreased co-localization of 
TNFR1 and the early endosomal marker-EEA1 was observed in cells over-expressing 
Rab5-DN (Figure 4.9b). This data demonstrates that preventing the trafficking of 






4.2.6.2 Rab7-DN leads to an accumulation of TNFR1 CTF in early endosome, and 
increases generation of TNFR1 ICD  
HEK293T cells expressing TNFR1 were co-transfected with either Rab7 WT or Rab7-DN 
constructs. At thirty-four hours post-transfection cells were treated with PMA 
(200ng/ml; 90min) to promote ectodomain shedding and subsequent formation of 
TNFR1 ICD. Immunoblot analysis revealed that preventing trafficking of TNFR1 from 
the early endosome to late endosome using Rab7-DN enhanced TNFR1 ICD formation 
(Figure 4.10b lane 3 & 4). On the other hand Rab7 WT construct did not significantly 
affect γ-secretase-mediated cleavage of TNFR1 and the TNFR1 ICD formation (Figure 
4.10b lane 1 & 2). Subcellular fractionation was performed to check for the efficacy of 
the Rab7 constructs. Immunoblot analysis of cytosolic fractions revealed that in cells 
expressing Rab7 WT, TNFR1 CTF co-localized in the fractions enriched with the early 
endosomes. In contrast, co-localization of both TNFR1 CTF and TNFR1 ICD with 
fractions positive for the early endosomal marker-EEA1 was observed in cells over-
expressing Rab7-DN (Figure 4.10c). Thus demonstrating that the inhibition of TNFR1 
trafficking from the early endosome increases γ-secreatse-mediated cleavage of 
TNFR1. Collectively, this data demonstrates that TNFR1 undergoes γ-secretase-






Figure 4.9 Preventing early endosome fusion reduces γ-secretase-mediated cleavage 
of TNFR1 
(a) Immunoblot analysis of HEK293T cells expressing TNFR1 and co-transfected with 
either Rab5 WT or Rab5 DN construct and treated with PMA to induce ectodomain 
shedding (b) HEK293T cells transiently expressing TNFR1 and co-transfected with 
Rab5WT and Rab5 DN; treated with PMA and analysed for full length TNFR1 co-
localizing with the early endosomal fraction.  C-terminus specific anti-TNFR1 antibody 








Figure 4.10 γ-secretase-mediated cleavage of TNFR1 occurs in the early endosome 
(a) Immunoblot analysis of HEK293T cells expressing TNFR1 and co-transfected with 
either Rab7 WT or Rab7 DN construct and treated with PMA to induce ectodomain 
shedding (b) Densitometry analysis of TNFR1 ICD normalised to total β-actin for all 
experimental conditions. The amount of TNFR1 ICD is expressed as TNFR1 ICD 
immunoreactivity + standard error of the mean, representative of three independent 
experiments. (c) HEK293T cells transiently expressing TNFR1 and co-transfected with 
Rab7 WT and Rab7 DN; treated with PMA and analysed for full length TNFR1 co-
localizing with the early endosomal fraction.  C-terminus specific anti-TNFR1 antibody 
was used to assess cleavage profile of TNFR1. The data is representative of three 






4.3.1 Identifying TNFR1 as a novel γ-secretase substrate 
The PS proteins are involved in regulating the responsiveness of neuronal cells to 
apoptosis (Bulat et al., 2009). As previously described, PS proteins are the catalytic 
components of γ-secretase enzyme complex with over 91 substrates. However, cell 
death receptors as potential substrates for γ-secretase mediated cleavage have not 
been studied. We screened the TNFR superfamily members: TNFR1, TNF-R2, DR3 and 
DR4 as potential substrates. Similar to p75NTR, IL-1R1 and Notch (Elzinga et al., 2009; 
Levine et al., 1996; Weskamp et al., 2004); TNFR1, TNF-R2, DR3 and DR4 are type 1 
transmembrane proteins, therefore fitting the criteria of previously identified γ-
secretase substrates. Furthermore, TNFR1 and TNF-R2 undergo ectodomain shedding, 
which is considered to be a pre-requisite for subsequent γ-secretase-mediated 
cleavage. In this context, TNFR1 was found to be cleaved by γ-secretase enzyme 
complex. 
PMA treatment of cells expressing TNFR1 led to the formation of a fragment of ~38-
kDa and a smaller fragment of ~32-kDa. This was consistent with the cleavage profile 
of previously established γ-secretase substrates such as IL-1R1, Notch, p75, APP, Mucin 
etc. (Haapasaloa et al., 2012). This observation prompted us to investigate whether the 
TNFR-1 underwent γ-secretase-mediated cleavage following ectodomain shedding. We 
employed both pharmacological and genetic approaches. Consistent with previous 
studies (Becker-Herman et al., 2005; Böhm et al., 2006; Elzinga et al., 2009), DAPT 
alone or in combination with PMA inhibited the formation of TNFR1 ICD with a 
simultaneous accumulation of the CTF (Figure 4.2a). Furthermore ligand induced ICD 
formation was also inhibited by DAPT (Figure 4.2c). PS proteins are required for γ-
secretase activity. Thus, MEF PSDKO cells devoid of γ-secretase activity were used.  





(Figure 4.3). Thus we showed that TNFR1 undergoes PS-dependent γ-secretase-
mediated cleavage. 
Considering the distinct roles played by the two PS proteins in apoptosis, the finding 
that TNFR1 cleavage was a γ-secretase substrate was very intriguing. For instance, 
previous studies have demonstrated that loss or down-regulation of PS1 expression is 
associated with a loss of neuronal differentiation and increased apoptotic cell death 
(Roperch et al., 1999; Weihl et al., 1999; Maraver et al., 2007). Thus, indicating a pro-
apoptotic role of PS1 protein. In contrast the wild-type and FAD-linked PS2 has been 
shown to trigger apoptosis and down-regulate PS1 expression through p53-dependent 
mechanisms (Smith et al., 2002). Collectively, these findings point towards the role 
played by PS proteins in regulating apoptosis. The γ-secretase enzyme complex 
consists of four different subunits: NCT, Aph-1a or Aph-1b, Pen-2, PS1 or PS2 and 
depending upon the subunit involved, four different γ-secretase complexes can co-
exist. Once PS-dependent γ-secretase-mediated cleavage of TNFR1 was confirmed, the 
next question that arose was whether PS1 or PS2-mediated this cleavage event. To 
answer this question, γ-secretase inactive PS1 and PS2 mutants were used. TNFR1 was 
co-expressed with either PS1 WT or γ-secretase inactive PS1D257/385A (Figure 4.4a). The 
use of catalytically inactive PS1 did raise the possibility that PS1D257/385A over-
expression led to increased binding of PS1 WT or mutant, containing γ-secretase 
enzyme complex to TNFR1 CTF, making it unavailable to PS2 containing γ-secretase 
complex. Hence, to rule out competitive inhibition we also used PS2 WT and 
PS2D263/366A to determine the effect of lack PS2-dependent γ-secretase activity (Figure 
4.4b). The results clearly showed that TNFR1 γ-cleavage was dependent upon the PS1-





4.3.2 Subcellular location for shedding and γ-secretase cleavage of TNFR1 
Ectodomain shedding is a characteristic of most known γ-secretase substrates. To 
determine whether ectodomain shedding of TNFR1 and γ-secretase-mediated cleavage 
of CTF were sequential events; a pharmacological inhibitor of TACE-mediated cleavage-
TAPI was used. Inhibiting ectodomain shedding of TNFR1 resulted in decreased ICD 
formation, clearly indicating that ectodomain shedding of TNFR1 was a pre-requisite to 
γ-secretase-mediated cleavage of TNFR1 CTF (Figure 4.5). 
The TNF super-family of ligand and their receptors initiate an array of signalling 
pathways, leading to diverse cellular responses such as cell survival or death. TNFα- 
signalling is preferentially mediated through TNFR1. Following ligand binding, TNFR1 
recruits the adaptor protein TRADD via the homotypic DD interactions. TRADD then 
recruits TRAF2, RIP1 and other associated proteins-UBC13, cIAP1/2 (Zarnegar et al., 
2008). The complex thus formed at the cell surface is referred to as the Complex I 
which signals for the NF-кB activation. The TNFR1 complex I then undergoes 
internalization and gets dissociated. This event leads to the formation of endosomal 
complex II, thereby initiating the pro-apoptotic signalling. The compartmentalization of 
TNFR1 mediated signalling acts as a switch between the anti- and pro-apoptotic 
signals. Thus, we next tried to gain a better understanding of the role γ-secretase-
mediated cleavage of TNFR1 might play in signalling pathway from Complex I and 
Complex II. Furthermore, due to the apparent discrepancy between the subcellular 
localization of PS proteins and cleavage of the known γ-secretase substrates an open 
question that arose was the subcellular site for the occurrence of γ-secretase-
mediated cleavage of TNFR1 CTF. 
To address this question- pharmacological and genetic approaches were used. TNFR1 
is known to undergo clathrin mediated internalization (Mosselmans et al., 1988; 





internalization, dynasore, capable of inhibiting clathrin mediated internalization was 
used. Dynasore treatment led to increased retention of the receptor at the cell surface 
with a simultaneous increase in levels of sTNFR1 and decreased ICD formation (Figure 
4.6). Lack of a TNFR1 C-terminus antibody for immunofluorescence restricted the 
study to validate the functionality of the inhibitor. Since, inhibiting TNFR1 
internalization has been shown to have no affect on TNFα-induced NF-кB activation 
but delay the JNK activation, we studied TNFα-induced NF-кB and JNK activation 
(Schütze et al., 2008). Consistent with the study, inhibiting clathrin mediated TNFR1 
internalization had no effect on TNFα-induced NF-кB activation but delayed the JNK 
activation (Figure 4.6c). 
Dynamin-DN, defective in clathrin mediated internalization was also used. Co-
expression of dynamin-DN with TNFR1 led to increased ectodomain shedding of the 
receptor and decreased levels of TNFR1 ICD. Simultaneously, defective TNFα-induced 
JNK activation was observed in dynamin-DN expressing cells with no affect on NF-кB 
signalling. Cytosolic fractions were isolated and levels of TNFR1 CTF internalized from 
the cell surface after PMA treatment were determined. Decreased CTF levels were 
detected in cells co-expressing TNFR1 and dynamin-DN cells (Figure 4.7).  
One could argue that inhibiting clathrin mediated internalization affected the 
trafficking of the receptor; however it also altered the functionality of the γ-secretase 
enzyme by altering it’s trafficking and assembly. To rule out this possibility, TNFR1 
internalization mutant was made. Schneider-Brachert et al. identified a highly 
conserved motif YXXW within TNFR1 internalization domain (TRID) region. The W 
residue was mutated in the receptor and TNFR1 W239A construct was used. TNFR1 
W239A expressing cells showed no ICD formation after PMA treatment. Similar to 
dynasore treated and dynamin-DN expressing cells, increased ectodomain shedding 
was observed for TNFR1 W239A. Cytosolic fractions of TNFR1 W239A showed no 





showed that inhibiting TNFR1 internalization disrupted γ-secretase-mediated cleavage 
of TNFR1.  
TNFR1 is most extensively studied receptor of the TNF superfamily owing to its dual 
functionality. As previously mentioned it is capable of sequentially inducing both anti- 
and pro-apoptotic signals, signalling from cell surface and endosome respectively. This 
was intriguing, considering the γ-cleavage event occurred post internalization. In the 
next study, Rab5 and Rab7 constructs capable of specifically inhibiting the membrane 
trafficking of the receptor from cell surface to early endosome and to the late 
endosome were used. Rab5-DN prevented fusion of endocytic vesicles to form early 
endosome. Over-expression of Rab5-DN in HEK293T cells reduced TNFR1 ICD 
formation. To determine the efficacy of the mutant early endosomes were isolated by 
sucrose gradient fraction. Fractions enriched in early endosomes were analysed for 
TNFR1. Decreased levels of TNFR1 were detected in cells co-expressing Rab5-DN 
mutant (Figure 4.9).  In parallel Rab7-DN construct which prevents trafficking of the 
receptor from early to late endosome was also used. Co-expression of TNFR1 with 
Rab7-DN led to accumulation of TNFR1 CTF in the early endosome as shown by sucrose 
gradient fractionation and isolation of early endosomal fraction. Simultaneously 
increased ICD was detected in these early endosomes, due to γ-secretase-mediated 
cleavage of the receptor. Whole cell lysates were analysed for TNFR1 cleavage and 
significant increase in ICD was detected (Figure 4.10).  The data showed that γ-
secretase-mediated cleavage of TNFR1 CTF occurred on the early endosomes. 
4.3.2 Conclusion and future direction 
In this study, TNFR1 is shown for the first time to undergo PS1-dependent γ-secretase-
mediated cleavage. Additionally, ectodomain shedding of TNFR1 and its γ-secretase-
mediated cleavage are shown to be two sequential cleavage events, where γ-





the early endosomes. The data extends the regulation of TNFR1 signalling and its 
compartmentalization to a next step, where γ-secretase enzyme complex might play 
an important role. Based on the data, the importance of PS1-dependent γ-secretase-










Role of γ-secretase-mediated cleavage in 







Independent research groups have demonstrated by yeast-two-hybrid or co-
immunoprecipitation approaches that PS proteins interact with a diverse array of 
proteins  (Chen et al., 2002). In some cases, while the biological significance of the 
association with PS proteins is not apparently obvious, these proteins can be 
subdivided into functional groups including those involved in γ-secretase protein 
complex, Wnt signalling, cell-cell adhesion, vesicular transport, calcium signalling and 
apoptosis.  
Our group previously reported and characterized of a highly conserved TRAF6 
consensus-binding site within the hydrophilic loop domain of PS-1 (Elzinga et al., 2009), 
additionally TRAF6-mediated ubiquitination of IL-R1 was shown to enhance its 
regulated intramembrane proteolysis which in turn was mediated by PS1-dependent γ-
secretase-mediated activity (Twomey et al., 2009). In another study we have 
demonstrated that PS1 interacts with TRAF2 (unpublished). TRAF2 also interacts with 
other TNF receptor superfamily members CD30 and CD40 via a major TRAF2-binding 
consensus sequence, (P/S/A/T)x(Q/E)E (Ye et al., 1999), or is recruited to TNFR1 
through its association with the TRADD adaptor protein (Hsu et al., 1996). Therefore, 
the finding that TNFR1 also undergoes PS1-dependent γ-secretase-mediated cleavage 
prompted us to examine whether similar to TRAF6 and IL-1R1, TRAF2-induces 
ubiquitination of TNFR1 and plays a role in regulating the intramembrane proteolysis 
of TNFR1.  
TRAF2 is also an important adaptor protein in TNFα-mediated TNFR1 signalling 
pathway (Devin et al., 2000; Hsu et al., 1996). Upon TNFα stimulation, TNFR1 complex I 
is formed at the cell surface which is important for cell survival and inflammatory 
signalling (Schneider-Brachert et al., 2004; Schütze et al., 2008; Tchikov et al., 2011). 





TNFR1 complex II, which triggers cell death. Recent reports have shown that the 
adaptor proteins recruited within this TNFR1 complex I i.e., RIP1, TRADD and TRAF2-
regulate the formation of complex II and its output (Hsu et al., 1996; Kim et al., 2000). 
In addition to these three adaptor proteins; A20, an ubiquitin-editing enzyme, cIAP1, 
an ubiquitylating enzyme, LUBAC, a linear ubiquitylating enzyme complex, and TAK1 
are also a part of complex I which negatively regulate the formation of complex II 
(Gyrd-Hansen et al., 2010; Haas et al., 2009; Walczak, 2011). There is also a second 
level of regulation by the activity of cylindromatosis (CYLD), a deubiquitylating enzyme 
which controls the transition from TNFR1 complex I to the cytosolic death-inducing 
TNFR1 complex II (Brummelkamp et al., 2003). Additionally, the composition of 
complex II determines the cell death outcome: apoptosis or necrosis. While TNFR1 
signalling complex II containing TRADD associated with FADD, c-FLIP and caspase-8 
induces apoptosis and suppresses the induction of necrosis; the association of RIP1 
with FADD, c-FLIP and caspase-8 leads to the induction of necrosis (Reviewed in Figure 
12). 
In this context, the finding that PS1-dependent γ-secretase-mediated cleavage of 
TNFR1 occurred post-internalization prompted us to explore the role played by PS1-
dependent cleavage event in controlling the cell survival and cell death signals. The PS 
proteins are co-regulatory and have antagonistic functions. This is supported by 
several studies, for instance p53 inhibits expression of PS1, subsequently resulting in 
apoptosis and tumor suppression (Roperch et al., 1998), additionally over-expression 
of PS2, independent of its γ-secretase activity is also known to trigger p53-dependent 
apoptosis and simultaneously down regulate the expression of PS1 (Smith et al., 2002). 
Based on this information, we hypothesized a role for γ-secretase-mediated cleavage 






The aims of the research presented in this chapter are 
1. To study TRAF2-mediated ubiquitination of TNFR1 and its effect on regulated 
intramembrane proteolysis of TNFR1. 
2. To determine the role played by PS proteins in TNFα-mediated signalling 
pathways. 







5.2.1 TNFR1 ICD undergoes proteasomal degradation 
After determining the subcellular location for γ-secretase-mediated cleavage of TNFR1, 
the fate of TNFR1 ICD was studied using epoxomicin, a lysosomal and concanamicin A, 
a proteasomal degradation inhibitor. HEK293T cells over-expressing TNFR1 were 
treated with either expoxomicin (10μM/ml; 2h) or concanamicin A (50μM/ml; 2h). 
Cells were harvested, lysed and the lysates were immunoblotted with C-terminus 
specific anti-TNFR1 antibody. Treatment with epoximicin increased detection of the 
TNFR1 ICD, where as TNFR1 full length and TNFR1 CTF accumulated in presence of 
concanamicin A. This data shows that TNFR1 ICD undergoes proteasomal degradation 
(Figure 5.1a lane 1 & 2), while full length TNFR1 and TNFR1 CTF are degraded via a 
lysosomal pathway (Figure 5.1a lane 1 & 3).  
This finding was further validated using a Ubiquitin mutant in which all lysine residues 
were mutated (Ub Kφ), and is therefore defective in the formation of polyubiquitin 
chains. HEK293T cells were transfected with TNFR1 and co-transfected with wild-type 
ubiquitin (Ub WT) or Ub Kφ mutant and thirty-four hours post-transfection, cells were 
treated with PMA (200ng/ml; 2h). Immunoblot analysis of cell lysates revealed that 
PMA-induced the formation of TNFR1 CTF and ICD in Ub WT transfected cells (Figure 
5.1b lane 1 & 2) while increased accumulation of TNFR1 ICD was observed in 
untreated and PMA-treated cells transfected with Ub Kφ (Figure 5.1b lane 3 & 4). This 
data demonstrated that while polyubiquitination is not necessary for the formation of 







Figure 5.1 TNFR1 ICD undergoes proteasomal degradation 
(a) Immunoblot analysis of HEK293T cells transiently expressing TNFR1 and treated 
with proteasomal inhibitor-epoxomicin (10μM) and lysosomal (50μM) inhibitor-
concanamcin for 2h. (b) HEK293T cells co-expressing TNFR1 and Ubiquitin WT or 
Ubiquitin Kφ; treated with PMA (200ng/ml; 2h) and immunobloted using C-terminus 
specific anti-TNFR1 antibody to assess the cleavage profile of the receptor. The data is 





5.2.2 TRAF2 E3 ligase regulates constitutive and PMA-induced TNFR1 ICD formation 
The above data shows that polyubiquitination is required for TNFR1 ICD degradation. 
Previous studies by our group showed TRAF6-mediated ubiquitination of IL-1R1 and 
subsequent enhanced regulated intramembrane proteolysis (Twomey et al., 2009). In 
this context the possibility of TRAF2 playing a role in ubiquitination of TNFR1 was 
explored. TRAF2 interacts with two members of the TNF receptor superfamily, CD30 
and CD40, via a major TRAF2-binding consensus sequence, (P/S/A/T)x(Q/E)E (Ye et al., 
1999). Additionally, upon TNFα binding TNFR1 recruits TRADD via the homotypic DD 
interactions, following which the N-terminal domain of TRADD interacts with TRAF2 
(Hsu et al., 1996). Considering the redundancy amongst the TRAF family members, 
TRAF6 WT and TRAF6 DN lacking the E3 ligase activity was also included in this study. 
HEK293T cells transiently expressing TNFR1 and Ub Kφ were co-transfected with TRAF2 
WT or TRAF2 DN and TRAF6 WT or TRAF6 DN; and thirty-four hours post-transfection, 
cells were treated with PMA (200ng/ml; 2h). Immunoblot analysis revealed that the 
cells co-transfected with TRAF2 WT undergo constitutive and PMA-induced TNFR1 CTF 
and ICD formation (Figure 5.2a lane 1 & 2), while the cells co-expressing TRAF2 DN 
show reduced constitutive and PMA-induced TNFR1 ICD formation subsequent to 
ectodomain shedding (Figure 5.2a lane 3 & 4). In contrast, and consistent with a non-
essential role for TRAF6 in TNFR1 signalling, co-expression of TRAF6 WT or TRAF6 DN, 
does not affect TNFR1 ICD formation (Figure 5.2b lane 3 & 4). Though not conclusive, 
this data demonstrates that E3 ligase activity of TRAF2 might participate in the 






Figure 5.2 Dominant negative TRAF2 E3 ligase reduces constitutive and PMA-induced  
TNFR1 ICD formation 
Immunoblot analysis of HEK293T cells transfected with expression vectors as indicated 
in the figure, thirty hours post-transfection cells were treated with PMA (200ng/ml; 
2h), lysed and the blots were probed with C-terminus specific anti-TNFR1 antibody to 






5.2.3 TNFR1 undergoes TRAF2-mediated polyubiquitination 
Having shown that TRAF2-E3 ligase activity played a role in modulating TNFR1 ICD 
formation, the next question was whether TNFR1 undergoes TRAF2-mediated 
ubiquitination. To address this, HEK293T cells were transfected with TNFR1 and HA-Ub 
and then co-transfected with FLAG-TRAF2 WT or FLAG-TRAF2 DN as indicated (Figure 
5.3a) and thirty-four hours post-transfection cells were lysed and immunoblotted with 
C-terminus specific anti-TNFR1 antibody and anti-FLAG antibody to confirm the 
expression of constructs and equivalency of loading (Figure 5.3a, lower panels). 
Similarly to distinguish whether TRAF2-induced mono- or polyubiquitination of TNFR1, 
we used HA-Ub Kφ mutant and checked for equivalent expression of the constructs 
(Figure 5.3b).  
After confirming the equivalent expression of the various plasmids, cells were lysed 
under stringent SDS-denaturing conditions. TNFR1 was immunoprecipitated with a C-
terminus specific anti-TNFR1 antibody followed by western blotting with anti-HA or 
anti-TNFR1 antibody to detect ubiquitinated-TNFR1 or TNFR1 respectively.  
Immunoblot analysis revealed that in HA-Ub WT expressing cells, in the presence of 
TRAF2, TNFR1 undergoes ubiquitination (Figure 5.3 a, upper panels lane 1 & 2) while 
in the presence of TRAF2 DN, ubiquitination of TNFR1 is significantly reduced (Figure 
5.3 a, upper panels lane 3 & 4), in contrast in cells expressing HA-Ub Kφ, no difference 
is seen in cells expressing TRAF2 WT or TRAF2 DN, with or without PMA-treatment. 







Figure 5.3 TNFR1 undergoes TRAF2-mediated polyubiquitination 
(a) HEK293T cells were transiently expressing TNFR1 and HA-Ub were co-transfected 
with TRAF2WT or TRAF2 DN. (b) HEK293T cells were transiently expressing TNFR1 and 
HA-Ub Kφ were co-transfected with TRAF2WT or TRAF2 DN. Forty hours post-
transfection cells were harvested under stringent SDS denaturing condition and then 
subjected to immunoprecipitation for TNFR1 and Western blot for HA-Ub. 
Ubiquitinated TNFR1 was detected with anti-HA antibody. Blot was also stripped and 
reprobed with an anti-TNFR1 antibody as a control. Lower panel shows the expression 
levels of the TNFR1, TRAF2 WT and TRAF2 DN in the HEK293T cell lystaes used for 







5.2.4 Inhibiting γ-secretase-mediated cleavage of TNFR1 does not affect the TNFα-
mediated signalling pathway 
An important event in TNFα-mediated TNFR1 signalling is the activation of MAPK (JNK, 
p38 and ERK1/2), and canonical NF-κB transcription factor from the cell surface 
(Verstrepen et al., 2008). To determine whether or not inhibition of γ-secretase activity 
and cleavage of TNFR1 had any effect on the activation of MAPK and NF-κB, we next 
examined the transient activation of JNK1/2 and NF-κB, in PS WT MEFs that were 
either untreated or treated with DAPT, and in PSDKO MEFs that are deficient in γ-
secretase activity.  
PS WT MEFs were serum starved overnight and pre-treated with DAPT (10μM/ml; 8h), 
following which cells were stimulated with TNFα (10ng/ml), for increasing time (Figure 
5.4a). Alternately, PS WT and PS DKO MEFs cells were serum starved overnight and 
stimulated with TNFα (10ng/ml) for increasing time (Figure 5.4b). Western blot 
analysis was carried out to determine the effect of inhibiting γ-secretase activity on the 
activation of TNFα-induced signalling pathways. Immunoblot analysis revealed that 
inhibition of γ-secretase activity by using either γ-secretase inhibitor DAPT or PSDKO 
MEFs, does not affect the activation of JNK1/2 and NF-κB. This data shows that 
activation of TNFα-mediated signalling is independent of its cleavage by γ-secretase 






Figure 5.4 Inhibiting γ-secretase-mediated activity does not affect the TNFR1 
mediated signalling pathway 
(a) MEF from PS wild type and PS double knock-out mice, were serum starved 
overnight and pre-treated with γ-secretase inhibitor, DAPT (10μM; 8h). Following pre-
treatment cells were treated with murine TNFα for increasing time as indicated. Cells 
were lysed and probed for the indicated antibodies.  (b) MEF from PS wild type mice, 
were serum starved overnight and treated with murine TNFα for increasing time as 
indicated. Cells were lysed and probed for the indicated antibodies. The data is 





5.2.5 PS2 affects JNK activation in MEFs in TNFR1 signalling pathway 
The above data shows that inhibiting γ-secretase activity does not affect TNFα-
mediated signalling pathways, and our previous data shows that TNFR1 undergoes 
PS1-dependent γ-secretase-mediated cleavage. To explore the possible involvement of 
PS2 in TNFR1 siganlling, we used PS1 single knock-out (PS1KO) and PS2 single knock-
out (PS2KO) mouse embryonic fibroblasts (MEFs) to study any defects in TNFα-
mediated signalling pathways. PS1KO and PS2KO MEFs were serum starved overnight, 
following which cells were stimulated with TNFα (10ng/ml), for increasing time. 
Western blot analysis was carried out to determine the effect of loss of PS1 or PS2 on 
TNFα-mediated signalling pathway. Immunoblot analysis revealed that while the PSWT 
and PS1KO MEFs showed comparable TNFα-induced activation of JNK1/2 and NF-кB 
(Figure 5.5 lane 1 to 10), the loss of PS2 was selectively associated with loss of TNFα-
induced JNK1/2 activation PS1KO MEFs are not defective in either the activation of 
JNK1/2 or NF-кB (Figure 5.5 lane 11 to 15).  Collectively this data shows that TNFα-








Figure 5.5 PS2 KO MEF cells are defective in activation of JNK1/2 
MEF from PS1 and PS2 single knock-out mice, were serum starved overnight and 
treated with murine TNFα for increasing time as indicated. Cells were lysed and probed 







5.2.6 Affect of loss of PS on TNFα-induced apoptosis  
Following TNFα stimulation, TNFR1 gets internalized and recruits death adaptor 
proteins to initiate apoptotic signal in the cells, where the activation of JNK has been 
shown to affect TNF induced apoptosis (Silke, 2011). To examine whether loss of γ-
secretase activity is also involved in the apoptosis pathway, we treated PS wild-type 
cells with TNFα and cycloheximide with or without DAPT (10μM/ml; 8h) for indicated 
times (Figure 5.7a). Alternatively, PS wild-type and double knockout cells were also 
employed in this study (Figure 5.7b).  Cells were lysed and immunoblotted for cleaved 
PARP. Analysis revealed that the loss of γ-secretase activity enhanced TNFα-induced 
PARP cleavage significantly suggesting that pharmacological inhibition of γ-secretase 
increases susceptibility to apoptosis. However, no significant increase in TNFα-induced 






Figure 5.6 Loss of γ-secretase activity increases susceptibility to apoptosis 
(a) PS wild-type MEFs were either left untreated or pre-treated with DAPT (10μM/ml; 
8h), following which they were treated with TNFα and cycloheximide for indicated 
time points. (b) PS wild-type and PS double knockout MEFs were TNFα and 
cycloheximide for indicated time points. Cells were lysed and immunoblotted using 





5.2.7 Interaction between PS1 and TNFR1 signalling adaptor proteins 
So far our data shows that TNFR1 undergoes PS1-dependent γ-secretase-mediated 
cleavage and in contrast loss of PS2 and not PS1 affects TNF-α mediated activation of 
JNK. Interestingly, PS proteins are known to interact with a diverse array of proteins 
and PS1 and PS2 have been shown to co-regulate each others’ expression through p53-
dependent mechanisms, which also play an important role in triggering apoptosis 
(Roperch et al., 1998; Smith et al., 2002b). We have also shown that PS1 and PS2 
assocate with several adapter proteins (TRAF6, TRAF2, IRAK2) involved in IL-1/TLR and 
TNF/NGF signalling pathways. In this context, we explored the possibility of an 
interaction between PS1 and RIP1 which is recruited to TNFR1 in Complex I following 
TNFα-stimulation. HEK293T cells were transiently transfected with PS1 and co-
transfected with RIP1 and thirty hours post-transfection cells were lysed and 
immunoblotted with anti-PS1, anti-RIP1 and anti-β actin antibody to confirm the 
expression of constructs and equivalency of loading. After confirming the equivalent 
expression of the various plasmids, cells were lysed under non-denaturing conditions. 
PS1 was immunoprecipitated with an anti-PS1 antibody followed by western blotting 
with anti-RIP antibody to detect RIP1 co-immunoprecipitated with PS1 (Figure 5.7a). 
Simultaneously RIP1 was also immunoprecipitated with anti-RIP1 antibody followed by 
western blotting with anti-PS1 antibody to detect PS1 co-immunoprecipitated with 
RIP1 (Figure 5.7a). Using a similar experimental set up interaction between PS1 and 
TRADD was also studied. PS1 was immunoprecipitated with an anti-PS1 antibody 
followed by western blotting with anti-TRADD antibody to detect TRADD co-
immunoprecipitated with PS1 (Figure 5.7b). Simultaneously TRADD was also 
immunoprecipitated with anti-TRADD antibody followed by western blotting with anti-
PS1 antibody to detect PS1 co-immunoprecipitated with TRADD. The data revealed 
that PS1 interacts with RIP1, while PS1 and TRADD interaction was not observed using 






Figure 5.7 PS1 interacts with RIP1 
HEK293T cells were transiently transfected with the indicated expression constructs. 
After 30 hours post-transfection cell lysates were immunoprecipitated with the 
indicated antibodies. Co-immunoprecipitated proteins were detected with an anti-PS1 
or anti-RIP1 or anti-TRADD antibodies. Immunoblot analysis of transfected cell lystaes 
with the indicated antibodies confirmed expression of all constructs. The data is 






5.3.1 TRAF2 ubiquitinates TNFR1 
In the study presented in chapter 4, we showed that TNFR1 undergoes γ-secretase-
mediated proteolysis within the early endosomes. Additionally most known γ-
secretase cleavage products have been shown to undergo proteasomal degradation 
including  Notch ICD, Mucin ICD, p75NTR ICD (Julian et al., 2011; Kanning et al., 2003; 
Urra et al., 2007). In this context, using lysosomal and proteasomal inhibitors we found 
that TNFR1 ICD to undergo proteasomal degradation, while in contrast TNFR1 full 
length receptor and TNFR1 CTF were degraded via a lysosomal pathway (Figure 5.1a). 
Proteasomal degradation has been associated with ubiquitination of targeted proteins. 
Additionally, Chin and Horwitz linked monoubiquitination of the TNFR1 to its 
degradation after endocytosis (Chin et al., 2005, 2006). Hence, the importance of 
monoubiquitination of the TNFR1 in either formation or degradation of the TNFR1 ICD 
was assessed. Using wild-type Ubiquitin (Ub WT) or the HA-tagged Ubiquitin all lysine 
mutant (Ub Kφ) which is defective in forming poly-ubiquitin chains and only undergoes 
monoubiquitination we propose that polyubiquitination is required for degradation of 
ICD and monoubiquitination is sufficient for γ-secretase-dependent formation of 
TNFR1 ICD (Figure 5.1b). 
TRAF2 is an important adaptor protein in the TNFR1 signalling pathway. Upon TNFα-
stimulation TRAF2 is recruited via the amino-terminal domain of adapter protein 
TRADD, and activates a variety of downstream signalling cascades. Additionally, TRAF2 
is the E3 ligase responsible for K63-linked polyubiquitination of RIP1, thus playing an 
important role in activating the IKK complex (Devin et al., 2000). We have previously 
demonstrated a role for TRAF6 in ubiquitination and regulated intramembrane 





we found that TRAF2 lacking its E3 ligase activity shows reduces constitutive and PMA-
induced TNFR1 ICD formation, compared to the wild-type TRAF2 expressing cells 
(Figure 5.2). Additionally, TRAF2-induces ubiquitination of TNFR1, thus pointing 
towards a co-relationship between TRAF2-induced ubiquitination of TNFR1 and its 
regulated intramembrane proteolysis (Figure 5.3).  
These results highlight that while polyubiquitination is required for degradation of 
TNFR1 ICD, TRAF2-mediated polyubiquitination could play a role in formation of TNFR1 
ICD. Thus, it is important to study the type of polyubiquitination required for these two 
process. For instance, it is feasible that K48-linked polyubiquitination is required for 
the degradation of TNFR1 ICD, while TRAF2-induced K63-linked polyubiquitination is 
important for its formation. Using Ub mutants with all lysine residues mutated to 
arginine except residue 48 (Ub K48) or with just the lysine 48 residue mutated to 
arginine (Ub K48R) the type of polyubiquitination can be studied. 
5.3.2 Loss of PS2 affects TNFα-mediated JNK1/2 activation 
We showed TNFR1 to undergo PS1-dependent γ-secretase-mediated cleavage, which 
prompted us to investigate the role of γ-secretase-mediated cleavage in TNFα-
mediated signalling pathway. The experiments carried out in PS WT, PS1KO, PS2KO 
and PSDKO cells revealed no effect of loss of γ-secretase activity on TNFα-induced 
signalling (Figure 5.5). On the contrary, PS2 deficiency was seen to affect TNFα-
induced JNK activation. In our attempt to further characterize the γ-secretase-
independent role of PS2 on TNFα-mediated signalling, our group carried out studies in 
vivo and detected low level of chemokine CXCL1 in serum of PS2KO animals in 
response to TNF-α. These observations suggest that PS2 has a novel function in 





5.3.3 Interaction between PS1 and RIP 
Our data shows PS1-dependent γ-secretase-mediated cleavage of TNFR1, while loss of 
PS2 and not PS1 was found to affect TNFα-mediated signalling pathways. Since, PS1 
interacts with TRAF2; we also investigated whether or not PS1 interacts with other 
TNFR1 signalling adaptor proteins. We used HEK293T cells over-expressing the PS1, 
RIP1 and TRADD constructs. Using reverse co-immunoprecipitation studies we found 
PS1 to interact with RIP1, while PS1 did not interact with TRADD in reverse co-
immunoprecipitation set up. The use of an over-expression system does limit our 
study, and experiments need to be carried out in cells endogenously expressing these 
proteins. Furthermore, TNFα-dependency or regulation of the interaction between 
these proteins should also be examined. It is feasible that the two PS proteins have 
distinct roles in TNFR1 signalling pathway. Where, PS1-dependent γ-secretase-
mediated cleavage of TNFR1 could function to terminate the signal from complex I, 
dissociating it and subsequently leading to the formation of complex II. Further 
experiments studying the interaction of PS proteins and various adaptor proteins, 
could provide us with a better understanding about the role played by these 












6.1 Overall summary  
After their discovery through genetic linkage of families with autosomal dominant 
forms of FAD, PS proteins have emerged as the catalytic components of γ-secretase 
protease complexes and are associated with all forms of AD (Lessard et al., 2010; 
Spasic et al., 2008; Yan et al., 2010). Additionally since the characterization of APP as 
the first γ-secretase substrate, over 90 new substrates have been identified and 
characterized, with a wide variety of roles that can be subdivided into functional 
groups including those involved in cell-cell adhesion, vesicular transport, calcium 
signalling and apoptosis (Haapasaloa et al., 2012). The growing list of γ-secretase 
substrates has highlighted the biological importance of the PS protein and has added a 
new perspective to the current concepts regarding the receptor-mediated signalling 
events.  
The conventional view of receptor-mediated signalling holds that the plasma 
membrane receptors upon binding of their ligands relay signals across membranes 
following which the activation of intracellular enzymes or changes in second 
messengers facilitate the propagation of these signals. Alternatively, following ligand 
binding, most receptors either undergo ectodomain shedding or internalization, 
thereby negatively regulating or terminating the ligand-receptor generated signal 
(Hayashida et al., 2010). Once internalized a receptor can be either degraded or 
recycled back to the plasma membrane. The emergence of regulated intramembrane 
proteolysis as a distinct mechanism for the regulation of receptor-mediated signalling 
events now challenges the current concepts regarding receptor-mediated signalling 
and its regulation, where 1) by removing the membrane bound CTFs responsible for 
signalling, γ-secretase-mediated cleavage possibly inhibits or initiates key signalling 
events, 2) processing of proteins by the γ-secretase enzyme complex act to enhance or 
inhibit its interaction with the cytosolic adaptor proteins, hence directing the output of 





cases is a transcriptionally active ICD, which regulates gene transcription (Haapasaloa 
et al., 2012)  Section 1.4. Additionally, the study of the various PS KO mouse models 
and transgenic animals has highlighted the role of PS/γ-secretase in the immune 
system (Jayadev et al., 2010; Maraver et al., 2007; Tournoy et al., 2004; Yagi et al., 
2008; Zhu et al., 2011b). Relevant to the current study it is noteworthy that the IL-
1R/TLR and TNF receptor superfamily play important roles in innate immunity, 
inflammatory and growth-factor responses Section 1.6. IL-1R1 and TLR4 are type-1 
transmembrane proteins and have no intrinsic enzymatic activity thus they need to 
recruit multimeric complexes with accessory proteins like IL-1RAcP for IL-1R1 or MD2 
and CD14 for TLR4 and cytosolic adapter molecules such as the TRAFs, IRAKs and RIP1 
in order to initiate cellular responses (Verstrepen et al., 2008). What is unique about 
these three receptors is that they all undergo spatially segregated, ligand-induced 
signalling events initiating from both the cell surface and the endosomes (Brissoni et 
al., 2006; Kagan et al., 2008; Li et al., 2006; Schneider-Brachert et al., 2004). The aim of 
this work was to characterize TNFR1 and TLR4 as potential substrates for regulated 
intramembrane proteolysis and determine the subcellular occurrence of these 
cleavage events. Further to this, we also studied whether these receptors undergo 
PS1- or PS2- dependent γ-secretase-mediated cleavage.  
Our results point towards a new mechanism for the induction and regulation of 
signalling events mediated by these receptors. In the  current study, in addition to 
previously described IL-1R1 (Elzinga et al., 2009), we identified TNFR1 and TLR4 as 
novel γ-secretase substrates, where ectodomain shedding of these receptors was pre-
requisite for further cleavage by γ-secretase enzyme complex. Along with TNFR1 
ectodomain shedding, IL-1R1 and TLR4 were found to undergo constitutive and 
ligand/PMA-induced secretion of the soluble ectodomain in the extracellular milieu. 
Similar to CD74  (Becker-Herman et al., 2005), ectodomain shedding of IL-1R1 occurs in 





milieu. This is of particular interest since most released ectodomains in addition to 
regulating the normal turnover of the receptor also retain their biological activities and 
compete for binding to receptor ligands. It is also feasible that before being secreted 
sIL1-R1 directly mediates intracellular signalling events. A study carried out by Heguy 
and co-workers has shown that in addition to full length ligand bound IL-1R1, ligand 
bound C-terminal domain truncated IL-1R1 migrates to the nucleus (Heguy et al., 
1991). In this context, our finding that IL-1R1 ICD undergoes nuclear translocation, 
which is dependent upon the NLS sequence 4, is indeed very interesting, and points 
towards a new mechanism of regulation of IL-1β-induced signalling. Owing to the 
highly homologous C-terminus domains of IL-1R1 and TLR4 it will be interesting to 
investigate whether or not TLR4 ICD also translocates to the nucleus.  
These observations are encouraging and supportive of future studies to determine the 
role played by trafficking and spatially segregated cleavage events in mediating various 
signalling events, and in turn the role played by PS proteins dependent or independent 
of their γ-secretase activity in mediating these trafficking events. Based on our results, 
on completion of our studies we propose the models in Figure 6.1 and Figure 6.2. On 
basis of data available from literature and results obtained in the current study, it is 
important to determine the role played by metalloproteinases and γ-secretase-
mediated processing of these receptors. Increased levels of both, soluble ectodomains 
and ligands for these receptors have been observed in several diseases including 







Figure 6.1 Proposed model for the spatial regulation of IL-1R1 signalling and 
occurrence of ectodomain shedding and subsequent γ-secretase cleavage. 
IL-1 stimulation leads to the recruitment of IL-1RAcP forming the IL-1/IL-1R1/IL-1RAcP 
complex. This complex undergoes clathrin-mediated internalization and is either 
translocated to the nucleus or traffics into the endosomes, where it undergoes 
cleavage in the extracellular domain by metalloproteinase, ADAM17, generating a 
soluble IL-1R1 which is then secreted into the media and has also been reported to 
undergo nuclear translocation. Ectodomain shedding of IL-1R1 is a pre-requisite 
cleavage event for subsequent PS1 dependent γ-secretase mediated cleavage. The IL-
1R1 ICD thus formed undergoes either proteasomal degradation or translocates to the 
nucleus. During this proteolytic processing pathway, IL-1R1 also recruits TRAF6 on the 
endosomes, where it undergoes K63-linked polyubiquitination which in turn enhances 
the regulated intramembrane proteolysis of IL-1R1 by ADAM17 and subsequently by γ-






Figure 6.2 Proposed model for TNFR1 and subcellular localization of receptor 
ectodomain shedding and γ-secretase-mediated cleavage 
TNFα-stimulation leads to trimerization of the TNFR1, which is then cleaved in its 
extracellular domain by ADAMs (ADAM10/17) to generate sTNFR1, secreted in the 
extracellular milieu. Simultaneously TRADD, RIP and TRAF2 are recruited to TNFR1 on 
the cell surface, forming Complex I, which signals for cell survival pathways. We 
propose that PS1 at this stage interacts with RIP1 and TRAF2-possibly as a part of the γ-
secretase enzyme complex. This TNFR1 bound Complex I undergoes clathrin-mediated 
internalization followed by γ-secretase-mediated cleavage. Based on preliminary data 
we propose that γ-secretase-mediated cleavage of TNFR1 regulates the spatial 





6.2 Future Perspectives 
6.2.1.  Characterizing the role played by TRAF-induced ubiquitination of IL-1R1 
and TNFR1  
TRAFs act as the major signal transducers of TNFR and the IL-1/TLR superfamily and 
their role in both adaptive and innate immunity has also been highlighted (Y. Wang et 
al., 2010; Xie et al., 2008). In the current study we demonstrated TRAF6-induced 
ubiquitination and cleavage of IL-1R1. Furthermore, it has been shown that inhibition 
of IL-1R1 endocytosis prevents its interaction with TRAF6 (Q. Li et al., 2006). Thus we 
hypothesized that IL-1R1 would be ubiquitinated by TRAF6 either in the endosome or 
post-endosomal compartments. To investigate this theory, IL-1R1 was co-transfected 
with TRAF6 and dominant negative dynamin construct, which is defective in clathrin-
mediated internalization. The effect of dynamin dominant negative construct was 
observed on the TRAF6-induced regulated intramembrane proteolysis and 
ubiquitination of IL-1R1 and was found to inhibit internalization of IL-1R1 to endosome 
preventing both TRAF6-induced regulated intramembrane proteolysis and 
ubiquitination of IL-1R1. Further to this, other experiments carried out in our group 
using dominant-negative Rab constructs such as Rab4 required for trafficking of protein 
through fast recycling pathway, Rab11 for the slow recycling pathway and Rab7 for 
trafficking to the lysosome showed an increase in TRAF6-induced cleavage and 
ubiquitination of IL-1R1. Thus, demonstrating that TRAF6-mediated ubiquitination of IL-
1R1 occurs in the endosomes. Further to this we also observed that TNFR1 undergoes 
TRAF2-induced ubiquitination.  
An important factor to consider here is that ubiquitination of target proteins is a 
regulatory event in receptor endocytosis and endosomal trafficking (Mukhopadhyay et 
al., 2007). In this regard, the finding that the subcellular trafficking of IL-1R1 and TNFR1 





towards a role of TRAFs in mediating trafficking of  IL-1R1 and TNFR1. Thus there is a 
need to characterize these interactions, and determine how γ-secretase-mediated 
cleavage of these receptors is regulated by TRAF-mediated ubiquitination which could 
further provide an insight into the mechanism behind the regulation of receptor-
mediated signaling pathways. This could be carried out by studying the cell surface 
localization of IL-1R1, and its internalization and trafficking in wild-type TRAF6 and 
TRAF6 knockout cells. This could also be carried out in PSKO, PS1KO and PS2KO cells to 
further determine role of PS proteins independent of their γ-secretase activity.  
Additionally, IL-1R1 signaling is spatially segregated and majorly mediated at the 
endosomal compartments. It is thus, feasible that TRAF6-mediated ubiquitination of IL-
1R1 functions to positively recruit the signalling adaptor molecules and formation of IL-
1R1 signalling complexes. This is supported by the observation that, TRAF6-induced 
ubiquitination of IL-17 receptor is important for IL-17 associated signaling (Hartupee et 
al., 2009). Therefore, studying the interactions between IL-1R1 and its adaptor 
molecules, and even PS proteins and members of the IL-1R1 signalling pathway could 
provide an insight into the role played by TRAF6 in IL-1R1 signalling pathway. 
Similar to TRAF6-induced ubiquitination of IL-1R1, we observed TRAF2-induced 
ubiquitination of TNFR1 which was diminished in the presence of dominant negative 
TRAF2 lacking E3 ligase activity. TRAF2 was originally identified by its association with 
TNFR2 (Rothe et al., 1994), and TRAF2 has been reported to play an important role in 
anti-apoptotic signalling, JNK activation and perinatal survival (Devin et al., 2000; S. Y. 
Lee et al., 1997; Yeh et al., 1997). As the next step it is important to determine the 
specificity of TRAF2-induced ubiquitination of TNFR1 to assure that it is unique to 
TRAF2 and whether the effect is redundant among TRAF family members.  Due to low 
expression levels of endogenous TNFR1 cleavage fragments, the experiments to study 
the effect of TRAF2 on ubiquitination of TNFR1 require to be carried out in an over-





family to validate that the effect seen on co-expression of TRAF2 is specific. In this 
regard, Parkin, an E3 ubiquitin ligase which possesses two RING finger domains and 
can mediate monoubiquitination, and both K48- and K63-linked polyubiquitination 
could be used.  Similar to IL-1R1, we also checked whether the lack of TRAF2 E3 ligase 
activity had any effect on TNFR1 ICD formation. Due to reduced expression of TNFR1 in 
cells co-transfected with TRAF2 DN our result was not conclusive. Hence, it is 
important to carry out similar experiments in wild-type TRAF2 and TRAF2 knockout 
cells. ELISA for sTNFR1 in these cells would further validate whether TRAF2 is required 
for ectodomain shedding and just affects γ-secretase-mediated cleavage of TNFR1.   
6.2.2 Nuclear localization of IL-1R1 ICD 
Cleavage of IL-1R1 by regulated intramembrane proteolysis is important for several 
reasons. Firstly, the cleavage in the extracellular domain by ADAM17, leads to the 
secretion of sIL-1R1 in the extracellular milieu. sIL-1R1 has been previously suggested 
to regulate IL-1R1-mediated signalling pathways by sequestering IL-1β, or terminating 
the signal from IL-1R1. However, the observation that IL-1R1 undergoes ectodomain 
shedding in the endosome challenges the current concept and indicates that sIL-1R1 
could play a more important role than just regulating IL-1R1-mediated signalling 
pathways. Secondly, defective signalling in cells expressing C-terminal truncated IL-1R1 
has been shown (Heguy et al., 1991). Thus highlighting the importance of γ-secretase 
cleavage generated IL-1R1 ICD. This could be attributed to the interaction between the 
IL-1R1 ICD and various adaptor molecules involved in mediating the IL-1β induced 
signalling. In this context, in addition to previously reported migration of ligand-bound 
IL-1R1 to the nucleus, in the current study we demonstrated that IL-1R1 ICD 
translocates to the nucleus. The IL-1R1 ICD has four NLS sequences, and mutating the 






To further study the role of IL-1R1 ICD and its translocation to the nucleus, it is 
important to map the γ-secretase cleavage site. In an attempt to map the cleavage site 
our group employed the approach as used by Lichtenthaler and group to map APLP2 
cleavage site by ADAM10, BACE1 and γ-secretase enzyme complex (Hogl et al., 2011). 
N- and C-terminus tagged IL-1R1 constructs was generated, over-expressed in a cell 
system. On ligand/PMA stimulation the IL-1R1 ICD generated was immunoprecipitated 
using the antibody against the C-terminus tag. However, due to low expression levels 
of IL-1R1 ICD this technique was not successful. Alternatively, a site directed 
mutagenesis approach mutating alternate residues within the transmembrane domain 
of IL-1R1 could be used. Once the site is mapped, it could be used to generate a non-
cleavable, constitutively cleaved and IL-1R1 ICD constructs. Using these constructs and 
monitoring the effect of these constructs on IL-1β induced signalling the role played by 
the translocation of IL-1R1 ICD to the nucleus can be more extensively studied. IL-1R1 
ICD construct could be further employed to generate IL-1R1 ICD specific antibody to 
perform chromatin immunoprecipitation (ChIP) and detect its association with the 
promoter of the several genes. Additionally microarray analysis could be used in order 
to identify DNA binding sites of the IL-1R1-ICD.  
In addition to IL-1R1 ICD reported here, over time ICDs for several γ-secretase 
substrates have been shown to migrate to the nucleus and regulate gene transcription 
(Table 1.2). The cytosolic domain of IL-1R1 and TLR4 are highly homologous, an 
alignment of TLR family members and their intracellular cytosolic domain with IL-1R1 is 
depicted in Figure 6.3. The alignment results indicate conservation amongst the 
residues of NLS sequence 1 and 4 of IL-1R1 ICD with TLR family members. In particular 
TLR3 and TLR4 show consensus within the NLS sequence 1, though not highly 
conserved, it would be interesting to study whether TLR4 ICD translocates to the 






NLS conservation - IL1R and TLR    
 
                                  NLS1         
IL1R 1 TM-ICD   (98) GEDIVEVINENVKK-SRRLIIILVRETS 
 TLR 3 TM-ICD   (92) GVFELEAIVNSIKR-SRKIIFVITHHLL 
 TLR 1 TM-ICD   (97) GKSIVENIITCIEK-SYKSIFVLSPNFV 
 TLR 6 TM-ICD   (97) GKSIVENIINCIEK-SYKSIFVLSPNFV 
TLR 10 TM-ICD   (99) GKSISENIVSFIEK-SYKSIFVLSPNFV 
 TLR 2 TM-ICD   (94) GKWIIDNIIDSIEK-SHKTVFVLSENFV 
 TLR 4 TM-ICD   (84) GVAIAANIIHEGFHKSRKVIVVVSQHFI 
 TLR 7 TM-ICD   (97) GQPVLENLSQSIQL-SKKTVFVMTDKYA 
 TLR 8 TM-ICD   (98) GLAIIDNLMQSINQ-SKKTVFVLTKKYA 
 TLR 9 TM-ICD   (98) GKTLFENLWASVYG-SRKTLFVLAHTDR 
 TLR 5 TM-ICD   (98) GENRIANIQDAIWN-SRKIVCLVSRHFL 
 




                            NLS4      NLS3  NLS2 
IL1R 1 TM-ICD  (188) PQSAKTRFWKNVRYHMPVQRRSPSSKHQLLSPA 
 TLR 3 TM-ICD  (182) ----IGAFRHKLQVALGSKNSVH---------- 
 TLR 1 TM-ICD  (186) ----RGLFWANLRAAINIKLTEQAKK------- 
 TLR 6 TM-ICD  (186) ----RGLFWANIRAAFNMKLTLVTENNDVKS-- 
TLR 10 TM-ICD  (188) ----CGLFWANLRAAINVNVLATREMYELQTFT 
 TLR 2 TM-ICD  (183) ----REGFWVNLRAAIKS--------------- 
 TLR 4 TM-ICD  (173) ----RHIFWRRLRKALLDGKSWNPEGTVGTGCN 
 TLR 7 TM-ICD  (183) ----HPYFWQCLKNALATDNHVAYSQVFKETV- 
 TLR 8 TM-ICD  (184) ----EGLFWQTLRNVVLTENDSRYNNMYVDSIK 
 TLR 9 TM-ICD  (184) ----QRSFWAQLGMALTRDNHHFYNRNFCQGPT 
 TLR 5 TM-ICD  (186) ----VGWFLHKLSQQILKKEKEKKKDNNIPLQT 
 
    Consensus  (204)      G FW NLR AI                  
 
 
                     108    NLS1    126 
IL1R 1 TM-ICD  (104) VINENVKKSRRLIIILVRE 
 TLR 3 TM-ICD   (98) AIVNSIKRSR-KIIFVITH 
 TLR 4 TM-ICD   (90) NIIHEGFHKSRKVIVVVSQ 




Figure 6.3 Alignment of cytosolic domain of TLR family members and IL-1R1 ICD 
Sequence alignment of IL-1R1 ICD and the putative ICD of several TLR family members, 





6.2.3 PS proteins and their interactions with the IL-1R1, TLR4 and TNFR1 adaptor 
molecules  
We identified PS2 as an important determinant of TLR4, IL-1R1 and TNFR1 signalling 
pathways thus, demonstrating a role of PS2 in innate immune responses. However, we 
did not see similar effects in cell system deficient in both the PS proteins. This is partly 
supported by the observation that PS1-/+ PS2-/+ mice remain healthy indicating a critical 
border below which the drop of PS gene dosage and function faces serious risks 
(Tournoy et al., 2004). However, it has been not been determined whether this γ-
secretase independent signalling deficit is due to loss of PS2 interaction with adaptor 
molecules involved in the signalling pathways, or due to an indirect effect of loss of 
PS2 expression, for instance wild-type and FAD-linked PS2 down-regulates PS1 
expression through p53-dependent mechanism (H. O. Smith et al., 2002), and thus it is 
feasible that loss of PS2 expression in our cell system enhances the PS1 protein 
expression and PS1 gain of function. Hence, the phenotype observed in cell/animal 
models lacking PS2 could be a result of PS1 gain in function. 
Previous studies by our group have been focused on the PS1 protein and its interaction 
with various adaptor molecules involved in the IL-1R1 and TLR4 signalling pathways. 
We have shown that PS1 interacts with TRAF6 and IRAK1 (Elzinga et al., 2009).  
Preliminary experiments also revealed that PS proteins do not interact with either Mal 
or p62 and therefore have preference for interaction with some of the signalling 
components over others. In the current study, we further showed an interaction 
between PS1 and RIP1, an adaptor molecule involved in TNFR1-mediated signalling 
pathway. Additionally it would be of interest to determine whether binding of PS1 to 
RIP1 is either direct or mediated by another protein and whether this interaction is a 
ligand dependent event. To further characterize the role played by the interaction 
between PS1 and RIP1, PS1 mutants or competitive binding peptides could be used to 





Reciprocally, the sites on RIP1 at which PS1 interacts should be mapped, mutated and 
used to investigate the implications of RIP1 binding to PS1. It has become evident that 
different adaptor proteins are temporarily recruited to the IL-1R1, TNFR1 and TLR4 
signalling pathways; furthermore the spatial segregation of the signalling pathways 
activated has been well characterized. Thus, it is important to further study the 
subcellular compartments at which these interactions occur. Our preliminary data 
suggests that preventing γ-secretase-mediated cleavage of TNFR1 using DAPT, a γ-
secretase inhibitor decreases the recruitment of RIP1, while enhancing TRADD 
interaction with TNFR1 (Figure 6.4b). We propose that this could play a role in TNFR1-
mediated apoptotic signalling pathways (Figure 6.4a). However, it still remains to be 
determined whether PS1 interacts with RIP1 independently or as a part of γ-secretase 
enzyme complex. Therefore immunoprecipitation experiments to study the 
interactions between RIP1 and other components of γ-secretase enzyme complex such 







Figure 6.4 Spatial segregation and recruitment of RIP1/TRADD to TNFR1 complex I  
(a) Proposed model controlling the spatial segregation of TNFR1-mediated signalling by 
complex I and complex II. (b) HEK293T cells were transfected with TNFR1 and co-
transfected with RIP1 and TRADD. Thirty hours post-transfection cells were pre-tretaed 
with DAPT (10μM/ml; 8h) followed by treatment with PMA (200ng/ml). Cells were 
lysed and immunoblotted using C-terminus specific anti-TNFR1, anti-RIP1, anti-TRADD 
and anti-actin antibody.  (c) Cells were lysed under non-denaturing conditions and co-
immunoprecipitated using C-terminus specific anti- TNFR1 antibody. Following which 
they were probed with either anti-RIP1 or anti-TRADD antibody.  The data is 





6.2.4. Determining the role of TNF-R1, IL-1R1- and TLR4-ICD 
Using a series of γ-secretase inhibitors and PS deficient cells and mice, work in our 
laboratory showed that IL-1β-, TNF-α and LPS-mediated signalling was independent of 
γ-secretase activity. On the contrary, data presented in the current research work is 
indicative of the importance of PTM and spatial regulation of these γ-secretase-
mediated cleavage events, which is further highlighted by the translocation of IL-1R1 
ICD to nucleus and presence of NLS sequences within the TLR4 ICD. PS proteins have 
been implicated in several other processes independent of their γ-secretase-mediated 
activity. Thus, it is important to further investigate the role of these cleaved fragments. 
Cleavage-resistant chimeric IL-1R1, and TNFR1 similar to the TLR4FasTM construct 
(Figure 3.20) will be an important tool to test the role of TNF-R1, IL-1R1 and TLR4 
proteolysis in immune responses and examine whether or not proteolysis of TNF-R1, IL-
1R1 and TLR4 and generation of receptor-derived ICDs enhance TNF-α, IL-1β- or LPS 
signalling or acts as a dominant inhibitor of cell responsiveness. The activation status of 
MAPK, NF-κB and IRF-3 by western blot analysis, luciferase reporter assays and 
cytokine production could be assessed. Furthermore, it will also be important to 
determine whether or not the cleavage fragments of these receptors show enhanced 
processing or accumulate in certain disease conditions such as in AD patients or 
autoimmune disorders like autoimmune lymphoproliferative syndrome (ALPS) and SLE. 
To date, blocking IL-1 signaling is the most effective therapy in many auto-
inflammatory disorders such as familial cold autoinflammatory syndrome, Muckle-
Wells syndrome, chronic infantile neurologic cutaneous and articular syndrome, and 
TNF-receptor associated periodic syndrome. Thus, it will be important to study role 







Since the discovery of AD, various theories have been proposed for the onset of this 
disease ranging from 1) exacerbation of aging, 2) degeneration of anatomical pathways, 
including the cholinergic and cortico-cortical pathways, 3) an environmental factor such as 
exposure to aluminium, head injury, or malnutrition, 4) genetic factors including mutations 
of APP and PSEN genes and allelic variation in Apo E, 5) mitochondrial dysfunction, 6) a 
compromised blood brain barrier, (7) immune system dysfunction, and (8) infectious 
agents (Armstrong, 2013). What remains common in the background is the γ-secretase 
enzyme complex which regulates the processing and turnover of a range of proteins which 
are implicated in these pathways. For instance, altered γ-secretase activity and specificity 
with aging is considered as a possible mechanism for AD (Placanica et al., 2009). The 
cholinergic hypothesis of AD states that changes in expression of NGF, its precursor 
proNGF, the high and low NGF receptors, trkA and p75NTR, respectively which are γ-
secretase substrates, may all contribute to the cholinergic dysfunction similarly, altered 
APP processing by γ-secretase contributes to the amyloid cascade hypothesis (Hardy et al., 
1992; Schliebs et al., 2011). All these observations not only highlight the importance of γ-
secretase enzyme in AD, but point out a generic role of this enzyme. The genetic factors 
contributing to AD include mutations in PSEN genes, which are the catalytic components of 
γ-secretase, and mutations within PSEN alter its activity. Thus, can it be said that AD is a 
result of altered γ-secretase enzyme activity which can be attributed to environmental 
factors, aging or genetic predisposition due to mutations within its catalytic components 
resulting in altered processing of its substrates like APP, p75NTR, IL-1R1, IL-1R2 
contributing to AD symptoms? 
In the current research study we focused on innate immune receptors and in addition to 
previously determined IL-1R1, characterized TLR4 and TNFR1 as novel γ-secretase 





enzyme activity, there was plenty of evidence to link these three receptors and γ-secretase 
enzyme complex. Increased levels of sIL-1R2 (IL-1R2 is a γ-secretase substrate and IL-1R1 
decoy receptor) in cerebrospinal fluid of AD patients, increased IL-1β expression by glial 
cells associated with amyloid plaques, increased levels of IL-1β in blood and plasma of AD 
patients; increased TNFα in cerebrospinal fluids, upregulation of TNFR1 expression in AD 
brain, and deletion of TNFR1 resulting in decreased amyloid plaques formation and 
inflammation; upregulation of TLR4 mRNA in APP transgenic mice and increased TLR4 in 
AD brain, with further evidence of defective TLR4-mediated signalling in PS-deficient B 
cells Section 1.6. Based on this evidence it was not surprising to find out that along with 
previously identified 91 γ-secretase substrates, these receptors were also in the list. 
However, further characterization of these receptors led to a few very interesting findings 
and challenged the current concepts regarding receptor-mediated signalling events and 
immune signalling. 
Firstly, in addition to previously reported TNFR1, we found IL-1R1 and TLR4 to undergo 
ectodomain shedding. Though initially the ectodomain shedding was regarded as a means 
of terminating ligand initiated signalling, in past few years this concept has been 
challenged, where the soluble ectodomains still retain their biological activity. 
Furthermore, the finding that IL-1R1 undergoes this cleavage in the endosome coupled 
with the demonstration that ligand bound C-terminal truncated IL-1R1 translocates to the 
nucleus points towards a role for soluble receptor ectodomains beyond the termination of 
signals. Further studies are needed to better understand the roles played by these soluble 
ectodomains. Another important concept that emerges from our findings is a probable 
role of γ-secretase cleavage in mediating the spatial segregation of receptor complexes. 
These three receptors undergo spatially segregated complex formations and the signals 
initiated. Thus the finding that the subcellular location for ectodomain shedding and γ-
secretase-mediated cleavage of these substrates varies points towards a role of γ-cleavage 





further supported by translocation of IL-1R1 ICD to nucleus and presence of NLS sequence 
within the TLR4 ICD.  
When our group investigated the role of γ-secretase cleavage on signalling events 
mediated by IL-1R1, TLR4 and TNFR1, to our surprise they were independent of γ-secretase 
activity but dependent upon PS2, supporting previous findings suggesting roles of PS 
proteins independent γ-secretase (Reviewed in Section 1.3) and highlighting molecular 
and functional relationships between PS proteins and innate immune signalling pathways. 
However, this does not refute the importance of ectodomain shedding and γ-secretase-
mediated cleavage of these receptors but points towards a distinct biological function. 
More work is needed to further study the importance of regulated intramembrane 
proteolysis independent of loss of PS2 function. In this context the preliminary data 
pointing towards the spatial segregation of TNFR1 complex I and complex II and its 
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